{"b9ea1e77b148042f415af2f18525be2d941e5a79": [["In March 2020, the World Health Organization declared COVID-19 a global pandemic.", [["COVID", "TEST", 54, 59]]], ["In response to COVID-19, many countries have applied strict social distancing measures and a lockdown policy.", [["COVID", "TEST", 15, 20], ["strict social distancing measures", "TREATMENT", 53, 86], ["a lockdown policy", "TREATMENT", 91, 108]]], ["The pandemic has had a serious impact on schools, students and teachers.", [["serious", "OBSERVATION_MODIFIER", 23, 30]]], ["Students and teachers have not been allowed to visit schools and universities physically and most institutions have transformed to an online teaching and learning approach.", [["learning approach", "TREATMENT", 154, 171]]]], "a37f59b5860777f503e462fcb853c2824e287084": [["IntroductionMany people with epilepsy can obtain seizure control when under the care of a general practitioner, but others require more specialized care from a neurologist or epileptologist [1] .", [["epilepsy", "DISEASE", 29, 37], ["seizure", "DISEASE", 49, 56], ["people", "ORGANISM", 17, 23], ["people", "SPECIES", 17, 23], ["epilepsy", "PROBLEM", 29, 37], ["seizure control", "TREATMENT", 49, 64]]], ["In 2017, the US Health Resources and Services Administration (HRSA) National Center for Workforce Analysis projected that demand would exceed growth in the supply of neurologists by 2025 [2, 3] .", [["Workforce Analysis", "TREATMENT", 88, 106]]], ["Based on 2010 National Health Interview Survey (NHIS) data, 86.4% of US adults with active epilepsy (self-reported doctor-diagnosed epilepsy taking antiseizure medications and/or having \u22651 seizure in the past year) had visited a general doctor, and 52.8% had visited a neurologist or epilepsy specialist in the past year [4] .", [["epilepsy", "DISEASE", 91, 99], ["epilepsy", "DISEASE", 132, 140], ["seizure", "DISEASE", 189, 196], ["epilepsy", "DISEASE", 284, 292], ["active epilepsy", "PROBLEM", 84, 99], ["epilepsy", "PROBLEM", 132, 140], ["antiseizure medications", "TREATMENT", 148, 171], ["\u22651 seizure", "PROBLEM", 186, 196], ["active", "OBSERVATION_MODIFIER", 84, 90], ["epilepsy", "OBSERVATION", 91, 99]]], ["National Health Interview Survey data from 2010 to 2013 indicated that 65.3% of adults with uncontrolled epilepsy (taking medication and \u22651 seizure in past year) saw both a general doctor and a specialist in the past year, but 23.2% saw only a general doctor [5] .", [["epilepsy", "DISEASE", 105, 113], ["seizure", "DISEASE", 140, 147], ["adults", "ORGANISM", 80, 86], ["uncontrolled epilepsy", "PROBLEM", 92, 113], ["medication", "TREATMENT", 122, 132], ["\u22651 seizure", "PROBLEM", 137, 147], ["uncontrolled", "OBSERVATION_MODIFIER", 92, 104], ["epilepsy", "OBSERVATION", 105, 113]]], ["National Health Interview Survey data from 2013 to 2015 indicated that 67% of respondents with active epilepsy (taking medication or \u22651 seizure in past year) had seen a neurologist or an epilepsy specialist in the past year [6] .", [["epilepsy", "DISEASE", 102, 110], ["seizure", "DISEASE", 136, 143], ["epilepsy", "DISEASE", 187, 195], ["active epilepsy", "PROBLEM", 95, 110], ["medication", "TREATMENT", 119, 129], ["\u22651 seizure", "PROBLEM", 133, 143], ["active", "OBSERVATION_MODIFIER", 95, 101], ["epilepsy", "OBSERVATION", 102, 110]]], ["Understanding the distribution of provider visits among persons with epilepsy can inform clinical care pathways, especially for those with active epilepsy and with uncontrolled seizures who need evaluation by an epilepsy specialist [1] .", [["epilepsy", "DISEASE", 69, 77], ["epilepsy", "DISEASE", 146, 154], ["seizures", "DISEASE", 177, 185], ["epilepsy", "DISEASE", 212, 220], ["persons", "ORGANISM", 56, 63], ["persons", "SPECIES", 56, 63], ["active epilepsy", "PROBLEM", 139, 154], ["uncontrolled seizures", "PROBLEM", 164, 185], ["evaluation", "TEST", 195, 205], ["epilepsy", "OBSERVATION", 146, 154]]], ["The primary goal of this study was to use the latest national data on epilepsy to examine the proportion of US adults with active epilepsy who have seen a general practitioner, epilepsy specialist, both, or neither in the past year.", [["epilepsy", "DISEASE", 70, 78], ["epilepsy", "DISEASE", 130, 138], ["epilepsy", "DISEASE", 177, 185], ["this study", "TEST", 20, 30], ["epilepsy", "PROBLEM", 70, 78], ["active epilepsy", "PROBLEM", 123, 138]]], ["AContents lists available at ScienceDirectEpilepsy & Behavior j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / y e b e h secondary goal was to compare the 2017 estimates with 2010 estimates to assess any changes in these outcomes.MethodsConducted through personal household interviews, the NHIS is an annual, nationally representative, in-person survey of the noninstitutionalized US civilian population that provides estimates on health status, selected conditions, visit to healthcare providers and specialists, and health conditions including epilepsy, hypertension, cancer, diabetes, stroke, and others [7] .", [["cancer", "ANATOMY", 601, 607], ["Epilepsy", "DISEASE", 42, 50], ["epilepsy", "DISEASE", 577, 585], ["hypertension", "DISEASE", 587, 599], ["cancer", "DISEASE", 601, 607], ["diabetes", "DISEASE", 609, 617], ["stroke", "DISEASE", 619, 625], ["cancer", "CANCER", 601, 607], ["a g e", "TEST", 86, 91], ["any changes in these outcomes", "PROBLEM", 231, 260], ["epilepsy", "PROBLEM", 577, 585], ["hypertension", "PROBLEM", 587, 599], ["cancer", "PROBLEM", 601, 607], ["diabetes", "PROBLEM", 609, 617], ["stroke", "PROBLEM", 619, 625], ["hypertension", "OBSERVATION", 587, 599], ["cancer", "OBSERVATION", 601, 607]]], ["The Centers for Disease Control and Prevention (CDC) Epilepsy Program included supplemental questions on epilepsy on the Sample Adult Core component of the survey both in 2010 and 2017.", [["Epilepsy", "DISEASE", 53, 61], ["epilepsy", "DISEASE", 105, 113], ["Disease Control", "TREATMENT", 16, 31], ["Epilepsy", "PROBLEM", 53, 61], ["epilepsy", "PROBLEM", 105, 113]]], ["Sample sizes and final response rates for sample adults were 27,157 (60.8%) in 2010 and 26,742 (53.0%) in 2017 [7, 8] .MethodsWe used a validated case definition for community-based surveillance of epilepsy from the Sample Adult component of the 2010 and 2017 survey to classify adults aged \u226518 years with \"active epilepsy\" if they reported doctor-diagnosed epilepsy or seizure disorder and reported either taking medication for their epilepsy/seizure disorder or having had one or more seizures in the past year [9] .", [["epilepsy", "DISEASE", 198, 206], ["epilepsy", "DISEASE", 314, 322], ["epilepsy", "DISEASE", 358, 366], ["seizure disorder", "DISEASE", 370, 386], ["epilepsy", "DISEASE", 435, 443], ["seizure disorder", "DISEASE", 444, 460], ["seizures", "DISEASE", 487, 495], ["Sample sizes", "TEST", 0, 12], ["final response rates", "TEST", 17, 37], ["sample adults", "TEST", 42, 55], ["epilepsy", "PROBLEM", 198, 206], ["active epilepsy", "PROBLEM", 307, 322], ["epilepsy", "PROBLEM", 358, 366], ["seizure disorder", "PROBLEM", 370, 386], ["medication", "TREATMENT", 414, 424], ["their epilepsy", "PROBLEM", 429, 443], ["seizure disorder", "PROBLEM", 444, 460], ["more seizures", "PROBLEM", 482, 495], ["sizes", "OBSERVATION_MODIFIER", 7, 12], ["epilepsy", "OBSERVATION", 198, 206], ["active", "OBSERVATION_MODIFIER", 307, 313], ["epilepsy", "OBSERVATION", 314, 322]]], ["For these analyses, active epilepsy was defined for 277 adult respondents in 2010 (weighted estimate = 2.3 million adults) and 335 in 2017 (weighted estimate = 2.9 million adults).MethodsVisit to a general doctor was assessed with the question, \"During the past 12 months, have you seen or talked to any of the following healthcare providers about your own health?", [["epilepsy", "DISEASE", 27, 35], ["these analyses", "TEST", 4, 18], ["active epilepsy", "PROBLEM", 20, 35], ["active", "OBSERVATION_MODIFIER", 20, 26], ["epilepsy", "OBSERVATION", 27, 35]]], ["Visit to a neurologist or to an epilepsy specialist was assessed with the question, \"In the past 12 months, have you seen a neurologist or epilepsy specialist for your epilepsy or seizure disorder?\"MethodsWe used SAS\u00ae 9.4 statistical software (SAS Institute Inc., Cary, NC, USA) to account for the complex survey design using stratification, clustering, and weighting.", [["epilepsy", "DISEASE", 32, 40], ["epilepsy", "DISEASE", 139, 147], ["epilepsy", "DISEASE", 168, 176], ["seizure disorder", "DISEASE", 180, 196], ["your epilepsy", "PROBLEM", 163, 176], ["seizure disorder", "PROBLEM", 180, 196], ["SAS", "TEST", 213, 216]]], ["This software generates variance estimates based on the assumption that sample respondents from within a known cluster, such as people in households within the same zip code, are not completely independent in their health, attitudes, and risk factors.", [["people", "ORGANISM", 128, 134], ["people", "SPECIES", 128, 134]]], ["We estimated age-adjusted percentages of past 12-month visits to a general doctor and an epilepsy specialist using direct age-standardization to the 2000 US projected population using four age groups (18-34, 35-54, 55-64, and \u2265 65).", [["epilepsy", "DISEASE", 89, 97]]], ["We considered these age-standardized percentages to differ statistically significantly at a significance level of 0.05 if their 95% confidence intervals (CI) did not overlap.ResultsThe age-standardized percentage of US adults with active epilepsy in 2017 who saw a general doctor only was 27.1% (95% CI = 22.0%-33.0%; Fig. 1 ); 9.0% (95% CI = 5.6%-13.7%) saw only a neurologist or an epilepsy specialist; 53.0% [95% CI = 46.3%-59.1%] saw both general doctor and a neurologist or epilepsy specialist in the past year; and 11.4% [95% CI = 7.4%-17.0%] saw neither.", [["epilepsy", "DISEASE", 238, 246], ["epilepsy", "DISEASE", 384, 392], ["epilepsy", "DISEASE", 479, 487], ["CI", "TEST", 154, 156], ["active epilepsy", "PROBLEM", 231, 246], ["CI", "TEST", 300, 302], ["Fig.", "TEST", 318, 322], ["CI", "TEST", 338, 340], ["an epilepsy specialist", "TEST", 381, 403], ["CI", "TEST", 416, 418], ["CI", "TEST", 532, 534], ["active", "OBSERVATION_MODIFIER", 231, 237], ["epilepsy", "OBSERVATION", 238, 246]]], ["Overall, 62.0% [95% CI = 55.2%-67.5%] of adults with active epilepsy visited a neurologist or epilepsy specialist in the past year, and 79.8% (95% CI = 73.4%-85.0%) visited a general doctor in the past year.ResultsIn 2017, adults who saw only a general doctor in the past year decreased significantly to 27.1% [95% CI = 22.0%-33.0%] from 41.8% [95% CI = 34.6%-49.3%] in 2010 (Fig. 1 ).", [["epilepsy", "DISEASE", 60, 68], ["epilepsy", "DISEASE", 94, 102], ["adults", "ORGANISM", 41, 47], ["adults", "ORGANISM", 223, 229], ["Overall", "TEST", 0, 7], ["CI", "TEST", 20, 22], ["active epilepsy", "PROBLEM", 53, 68], ["CI", "TEST", 147, 149], ["CI", "TEST", 315, 317], ["CI", "TEST", 349, 351]]], ["There were no changes over time in the percentages of adults with active epilepsy who saw an epilepsy specialist only or who saw neither a general doctor nor an epilepsy specialist.", [["epilepsy", "DISEASE", 73, 81], ["epilepsy", "DISEASE", 93, 101], ["epilepsy", "DISEASE", 161, 169], ["active epilepsy", "PROBLEM", 66, 81], ["no", "UNCERTAINTY", 11, 13], ["changes", "OBSERVATION_MODIFIER", 14, 21], ["active", "OBSERVATION_MODIFIER", 66, 72], ["epilepsy", "OBSERVATION", 73, 81]]], ["There was a nonsignificant increase in 2017 in visits to both a general doctor and an epilepsy specialist (53.0% [95% CI = 46.3%-59.1%]) compared with that in 2010 (46.2% [95% CI = 38.2%-54.3%]; Fig. 1 ).DiscussionIn 2017, most US adults with active epilepsy reported being seen by a general doctor within a 12-month period, and more than one-half reported being seen by a neurologist or epilepsy specialist.", [["epilepsy", "DISEASE", 86, 94], ["epilepsy", "DISEASE", 250, 258], ["epilepsy", "DISEASE", 388, 396], ["CI", "TEST", 118, 120], ["CI", "TEST", 176, 178], ["Fig.", "TEST", 195, 199], ["active epilepsy", "PROBLEM", 243, 258], ["nonsignificant", "OBSERVATION_MODIFIER", 12, 26], ["increase", "OBSERVATION_MODIFIER", 27, 35]]], ["Still, one in 10 US adults with active epilepsy (about 290,000 adults) did not see a general doctor or an epilepsy specialist within a 12-month period.", [["epilepsy", "DISEASE", 39, 47], ["epilepsy", "DISEASE", 106, 114], ["active epilepsy", "PROBLEM", 32, 47], ["active", "OBSERVATION_MODIFIER", 32, 38], ["epilepsy", "OBSERVATION", 39, 47]]], ["These results are comparable with previous studies based on NHIS data using the same epilepsy questions [4] [5] [6] .", [["epilepsy", "DISEASE", 85, 93], ["previous studies", "TEST", 34, 50], ["NHIS data", "TEST", 60, 69]]], ["Results from the US Healthy People 2020 national objective on epilepsy identified that between 58% and 72% of US adults with epilepsy and uncontrolled seizures had past year visits with a neurologist or epilepsy specialist over the decade, although differences between individual years in which data were collected were not statistically significant [10] .", [["epilepsy", "DISEASE", 62, 70], ["epilepsy", "DISEASE", 125, 133], ["seizures", "DISEASE", 151, 159], ["epilepsy", "DISEASE", 203, 211], ["epilepsy", "PROBLEM", 62, 70], ["epilepsy", "PROBLEM", 125, 133], ["uncontrolled seizures", "PROBLEM", 138, 159], ["epilepsy", "OBSERVATION", 125, 133]]], ["These studies based on NHIS data highlight the ability to examine access to provider type by different subgroups of people with epilepsy.", [["epilepsy", "DISEASE", 128, 136], ["people", "ORGANISM", 116, 122], ["people", "SPECIES", 116, 122], ["These studies", "TEST", 0, 13], ["NHIS data", "TEST", 23, 32], ["epilepsy", "PROBLEM", 128, 136], ["epilepsy", "OBSERVATION", 128, 136]]], ["Collectively, these findings suggest that epilepsy stakeholders should continue to ensure that general practitioners have access to the latest information about epilepsy diagnosis and myriad new treatment options [1] .", [["epilepsy", "DISEASE", 42, 50], ["epilepsy", "DISEASE", 161, 169], ["epilepsy stakeholders", "PROBLEM", 42, 63], ["epilepsy diagnosis", "PROBLEM", 161, 179], ["myriad new treatment options", "TREATMENT", 184, 212]]], ["National Health Interview Survey data allow us to see an improvement in visits to neurologists/epilepsy specialists for people with active epilepsy over the decade (53.6% in 2010; 67.0% in 2013 and 2015; 62.0% in 2017), but there is still room for further improvement [1, [4] [5] [6] .", [["epilepsy", "DISEASE", 95, 103], ["epilepsy", "DISEASE", 139, 147], ["people", "ORGANISM", 120, 126], ["[4] [5] [6]", "SIMPLE_CHEMICAL", 272, 283], ["people", "SPECIES", 120, 126], ["active epilepsy", "PROBLEM", 132, 147]]], ["Expanding epilepsy learning collaboratives and use of telementoring programs such as the Extension for Community Healthcare Outcomes (ECHO) epilepsy neurology pilot might supplement traditional provider training approaches [11] .", [["epilepsy", "DISEASE", 10, 18], ["epilepsy", "DISEASE", 140, 148], ["Expanding epilepsy", "PROBLEM", 0, 18], ["telementoring programs", "TREATMENT", 54, 76], ["ECHO", "TEST", 134, 138], ["epilepsy", "PROBLEM", 140, 148], ["epilepsy", "OBSERVATION", 10, 18]]], ["This is especially critical with current and forecasted professional shortages of epilepsy specialists [2, 3] .", [["epilepsy", "DISEASE", 82, 90]]], ["Expanding and sustaining the use of telehealth to conduct virtual neurological visits and exams, as has been done in some settings and more recently in response to the coronavirus disease 2019 pandemic, may also eliminate barriers to specialty care for people with epilepsy [12, 13] .", [["neurological", "ANATOMY", 66, 78], ["coronavirus disease", "DISEASE", 168, 187], ["epilepsy", "DISEASE", 265, 273], ["coronavirus", "ORGANISM", 168, 179], ["people", "ORGANISM", 253, 259], ["people", "SPECIES", 253, 259], ["exams", "TEST", 90, 95], ["the coronavirus disease", "PROBLEM", 164, 187], ["epilepsy", "PROBLEM", 265, 273]]], ["To the extent that some adults with epilepsy have seen only an epilepsy specialist in the past 12 months, epilepsy specialists can assess whether their patients have discussed other preventive screening and health concerns with their general doctor to ensure that all health issues of their patients are addressed and do not complicate epilepsy management.DiscussionStudy limitations include possible recall or reporting biases among survey respondents and the exclusion of adults who do not speak English or Spanish and those in active military service, prison, nursing homes, and other institutionalized settings, which are not captured in the NHIS sample.", [["epilepsy", "DISEASE", 36, 44], ["epilepsy", "DISEASE", 63, 71], ["epilepsy", "DISEASE", 106, 114], ["epilepsy", "DISEASE", 336, 344], ["patients", "ORGANISM", 152, 160], ["patients", "ORGANISM", 291, 299], ["adults", "ORGANISM", 474, 480], ["patients", "SPECIES", 152, 160], ["patients", "SPECIES", 291, 299], ["epilepsy", "PROBLEM", 36, 44], ["preventive screening", "TEST", 182, 202], ["epilepsy management", "TREATMENT", 336, 355]]], ["The NHIS question on visits with a neurologist or epilepsy specialist in the past year does not distinguish between visits with general neurologists and epileptologists or whether only one or multiple visits with these specialists occurred in the 12-month period preceding the survey.", [["epilepsy", "DISEASE", 50, 58]]], ["This study did not examine all possibilities of health provider visits assessed by NHIS such as those with mental health providers, dentists, and other specialists.", [["This study", "TEST", 0, 10]]], ["These limitations may have underestimated the extent to which adults with epilepsy have seen other medical providers.DiscussionNational Health Interview Survey data can be used to track the distribution of visits to general practitioners, epilepsy specialists, and potentially other types of provider in the coming decade to assess changes in access to healthcare, specialty care, or other types of healthcare for people with epilepsy.DisclaimerThe findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.", [["epilepsy", "DISEASE", 74, 82], ["epilepsy", "DISEASE", 239, 247], ["epilepsy", "DISEASE", 426, 434], ["people", "ORGANISM", 414, 420], ["people", "SPECIES", 414, 420], ["epilepsy", "PROBLEM", 74, 82], ["epilepsy", "PROBLEM", 426, 434], ["Disease Control", "TREATMENT", 588, 603]]]], "9bcb416ccb39e058feb1f9e4d022262ab3d1ddf4": [["IntroductionThe World Health Organization (WHO) declared Coronavirus disease (COVID-19) a \"Global Health Emergency of International Concern\" on 12th March 2020.", [["Coronavirus disease", "DISEASE", 57, 76], ["Coronavirus disease", "PROBLEM", 57, 76], ["Coronavirus disease", "OBSERVATION", 57, 76]]], ["As of 12th July 2020, 213 countries have been affected by this disease, with a total of 12,322,395 confirmed COVID-19 cases and 556,335 deaths worldwide.", [["deaths", "DISEASE", 136, 142], ["this disease", "PROBLEM", 58, 70], ["COVID", "TEST", 109, 114], ["disease", "OBSERVATION", 63, 70]]], ["2 As this lockdown continues, the healthcare facilities offer new ways to deal with the patients.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96]]], ["This includes telehealth, restricting patient visiting times as well as remotely seeing the patients.", [["patient", "ORGANISM", 38, 45], ["patients", "ORGANISM", 92, 100], ["patient", "SPECIES", 38, 45], ["patients", "SPECIES", 92, 100]]], ["3 In response to the rapidly evolving situation, WHO has also published interim guidance on public health and social measures.", [["social measures", "TREATMENT", 110, 125]]], ["4Value-added pharmacy services during COVID-19.In the last decade or so, community pharmacies have adopted several new services.", [["COVID-19", "CHEMICAL", 38, 46], ["COVID", "TEST", 38, 43]]], ["These services are especially viable for high-risk populations such as patients with multiple comorbidities, patients with low health literacy, and people with diminished access to care.", [["low health literacy", "DISEASE", 123, 142], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 109, 117], ["people", "ORGANISM", 148, 154], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 109, 117], ["people", "SPECIES", 148, 154], ["high-risk populations", "PROBLEM", 41, 62], ["multiple comorbidities", "PROBLEM", 85, 107]]], ["5 The service-based changes vary according to the role and challenges faced by the pharmacist and are meant to facilitate the convenient access of medication pick up as well as to ease the burden on the pharmacy staff.", [["medication", "TREATMENT", 147, 157]]], ["6, 7 In the United States of America (USA), many medicines are dispensed through mail order or as \"drive-thru service\" to the patients.", [["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134]]], ["8, 9 Australia has introduced several value-added services (VAS) including forward dispensing, prescription reminder system, One-stop-Shops, Rolls Royce service, chronic illness card, drive-thru pharmacy services as well as home delivery services.", [["chronic illness", "DISEASE", 162, 177], ["home delivery services", "TREATMENT", 224, 246]]], ["[10] [11] [12] In the United Kingdom, the click-and-collect technology with a \"human\" service allows collection of medicine order and receiving of advice at a suitable time from the designated pharmacy.", [["human", "ORGANISM", 79, 84], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["the click", "TEST", 38, 47]]], ["13 Similarly, other value-added services (VAS) include the Hub and Spoke dispensing models, the ATM-style prescription collection point, supplementary prescribing, and independent prescribing models.", [["ATM", "PROTEIN", 96, 99]]], ["16, 17 Community pharmacy is not only meeting the general needs of the patients, as pharmacies are also dealing with the pandemic control as well as providing advice to the patients on prevention.", [["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 173, 181], ["the pandemic control", "TREATMENT", 117, 137]]], ["18 In order to respond to the pandemic preparedness, many community pharmacies have taken measures for prevention.", [["pandemic", "DISEASE", 30, 38], ["the pandemic preparedness", "TREATMENT", 26, 51]]], ["This includes placing physical barriers in doorways or at pharmacy counters, cordoning off areas, marking the floor with the tape to guide the patients, or placing the acrylic glass barriers in front of the pharmacy counters.", [["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["the tape", "TREATMENT", 121, 129], ["the acrylic glass barriers", "TREATMENT", 164, 190], ["acrylic glass", "OBSERVATION", 168, 181]]], ["19 Other protectives measures are the use of personal protective equipment (PPEs) and to reduce the interaction between the pharmacy staff and the patients by encouraging the patients to use e-payment or placing money in the baskets.", [["patients", "ORGANISM", 147, 155], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 147, 155], ["patients", "SPECIES", 175, 183], ["Other protectives measures", "TREATMENT", 3, 29], ["personal protective equipment (PPEs", "TREATMENT", 45, 80], ["e-payment", "TREATMENT", 191, 200]]], ["This was inaugurated as a means to cope up with the increased demands of facilitated prescription processing.", [["facilitated prescription processing", "TREATMENT", 73, 108]]], ["9 The aim was to introduce this service for faster dispensing of medicines and to improve the patients' satisfaction and convenience.", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["this service", "TREATMENT", 27, 39], ["faster dispensing of medicines", "TREATMENT", 44, 74]]], ["21 Though drive-thru pharmacies were started in the early 90s, previous studies have shown that both consumers and pharmacists preferred to receive in-person pharmaceutical care.", [["previous studies", "TEST", 63, 79]]], ["22 However, despite these reservations, drive-thru pharmacy services seem to grow.Drive-thru pharmacy-a Value Added ServiceIn the United Kingdom, in 2008, 'Boots launched the service for the ease of medicine access for elderly patients with chronic diseases.", [["chronic diseases", "DISEASE", 241, 257], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 227, 235], ["Boots", "TREATMENT", 156, 161], ["medicine access", "TREATMENT", 199, 214], ["chronic diseases", "PROBLEM", 241, 257], ["chronic", "OBSERVATION_MODIFIER", 241, 248], ["diseases", "OBSERVATION", 249, 257]]], ["6, 7, 11, 24, 25 The \"Drive-thru pharmacy services\" were adopted in line with the principles to save time as well as to facilitate the faster delivery of medicines to the patients.", [["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["the faster delivery of medicines", "TREATMENT", 131, 163]]], ["6, 24 In Malaysia, drive-thru pharmacy service was considered as one of the key performance indicators during COVID-19.", [["COVID", "TEST", 110, 115]]], ["25 Malaysian based studies have also identified this innovation as a way to reduce patients' waiting time, and to ease access of medicines' delivery for disabled or special needs category patients while resolving car-parking problems during peak hours.", [["patients", "ORGANISM", 83, 91], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 188, 196], ["medicines' delivery", "TREATMENT", 129, 148], ["car-parking problems", "PROBLEM", 213, 233]]], ["7, 26 A recent study by Queen Elizabeth Hospital (QEH) in Malaysia showed that a vast majority of the patients were satisfied with this service.", [["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["A recent study", "TEST", 6, 20]]], ["27 In Taiwan, a study has found that \"drive-thru pharmacy service\" has provided patients with convenient access to prescription refilling during a short period .", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["a study", "TEST", 14, 21]]], ["24 A study from Jordan has highlighted the need to introduce the drive-thru concept and emphasized that regulatory bodies take an interest in this very idea to improve patient's access to medicines.", [["patient", "ORGANISM", 168, 175], ["patient", "SPECIES", 168, 175], ["A study", "TEST", 3, 10], ["the drive-thru concept", "TREATMENT", 61, 83], ["medicines", "TREATMENT", 188, 197]]], ["6 Another Jordanian study had also demonstrated positive outcomes regarding customers' awareness and perceptions towards drive-thru pharmacy service when the quality of service was evaluated.", [["Another Jordanian study", "TEST", 2, 25]]], ["Table 1 hereDrive-thru pharmacy services during COVID-19In the face of COVID-19, the introduction of drive-thru pharmacy service is among measures that could improve protection and safety both for the pharmacy staff and patients.", [["patients", "ORGANISM", 220, 228], ["patients", "SPECIES", 220, 228], ["COVID", "TREATMENT", 71, 76]]], ["In a \"drive-thru pharmacy,\" a patient receives pre-ordered medicines from a drive-thru window.Drive-thru pharmacy services during COVID-19The medicine is pre-checked, labeled, and packed in advance, and then the patient receives the medicine without having to exit the vehicle, and in this whole operation, little human interaction is involved.", [["COVID-19", "CHEMICAL", 130, 138], ["patient", "ORGANISM", 30, 37], ["patient", "ORGANISM", 212, 219], ["human", "ORGANISM", 314, 319], ["patient", "SPECIES", 30, 37], ["patient", "SPECIES", 212, 219], ["human", "SPECIES", 314, 319], ["human", "SPECIES", 314, 319], ["pre-ordered medicines", "TREATMENT", 47, 68], ["the medicine", "TREATMENT", 229, 241], ["this whole operation", "TREATMENT", 285, 305]]], ["In this hospital, patients receive the prescription filled, keep the stipulated social distance, and minimize the spread of infection.", [["infection", "DISEASE", 124, 133], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["infection", "PROBLEM", 124, 133], ["infection", "OBSERVATION", 124, 133]]], ["They can either wait in the car to collect their medication or go through the drive-thru.", [["their medication", "TREATMENT", 43, 59]]], ["32 Similarly, in the USA, Madigan Army Medical Center, one of the largest military hospitals has launched the drive-thru service to facilitate the beneficiaries.", [["largest", "OBSERVATION_MODIFIER", 66, 73]]], ["29 During challenging and stressful situations, including pandemics, the use of unbiased, informative standardized educational material is a must; however, with the little interaction with the consumers at drive-thru pharmacies, it is challenging to provide standardized health and medicines information to the patients.Drive-thru pharmacy services during COVID-19Several strategies can balance ease of access and protection from virus spread with the provision of appropriate advice and counseling.", [["patients", "ORGANISM", 311, 319], ["patients", "SPECIES", 311, 319], ["pandemics", "PROBLEM", 58, 67], ["COVID-19Several strategies", "TREATMENT", 356, 382], ["protection", "TREATMENT", 414, 424]]], ["Those include the provision of standard educational material, including leaflet and remote consultations and counseling.", [["standard educational material", "TREATMENT", 31, 60]]], ["Also, information technology (IT) based services have played a useful role in controlling the spread of COVID-19 infections in the UK and South Korea.", [["COVID-19", "CHEMICAL", 104, 112], ["infections", "DISEASE", 113, 123]]], ["33, 34 It would certainly be beneficial to expand the remote consultations in primary care and during the time of pandemics.", [["pandemics", "PROBLEM", 114, 123]]], ["36 The negative effects of drive-thru pharmacies are also worth noting.", [["negative", "OBSERVATION", 7, 15]]], ["These include processing delays, reduced efficiency as well as dispensing errors due to distractions at the windows.", [["processing delays", "PROBLEM", 14, 31], ["reduced efficiency", "PROBLEM", 33, 51], ["dispensing errors", "PROBLEM", 63, 80], ["distractions at the windows", "PROBLEM", 88, 115], ["delays", "OBSERVATION_MODIFIER", 25, 31], ["reduced efficiency", "OBSERVATION", 33, 51]]], ["37Drive-thru pharmacy services during COVID-19Those effects should be taken into consideration when pharmacies plan for the inclusion of this new service particularly during the pandemic.Research implications concerning drive-thru pharmacies and their role during pandemicsMore research is needed on the role of drive-thru pharmacies during times of pandemics such as COVID-19.", [["COVID-19Those", "CHEMICAL", 38, 51], ["COVID-19", "CHEMICAL", 368, 376], ["pandemics", "PROBLEM", 350, 359], ["COVID", "TEST", 368, 373]]], ["The continued and increasing use of drive-thru pharmacies could impact the workforce, workflow, and patient safety, necessitating collecting empirical data to answer research questions, and facilitate implementing evidence-informed policies.", [["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["drive-thru pharmacies", "TREATMENT", 36, 57], ["collecting empirical data", "TEST", 130, 155], ["increasing", "OBSERVATION_MODIFIER", 18, 28]]], ["It has been argued that while dispensing medicines through the drive-thru pharmacies, there could be distraction and pharmacists could make more errors.", [["medicines", "TREATMENT", 41, 50], ["distraction", "PROBLEM", 101, 112], ["distraction", "OBSERVATION", 101, 112]]], ["38 Pharmacy regulatory bodies worldwide need to adopt new ways to ensure patient safety and ensure optimal pharmacistpatient interactions.", [["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80]]], ["Research is also needed to identify the strategies and modalities that could be used to ensure that medicines' information and pharmaceutical care are provided optimally.Research implications concerning drive-thru pharmacies and their role during pandemicsThe provision of pharmaceutical care is possible even under challenging circumstances.", [["modalities", "TREATMENT", 55, 65], ["medicines", "TREATMENT", 100, 109], ["pharmaceutical care", "TREATMENT", 127, 146], ["pharmaceutical care", "TREATMENT", 273, 292]]], ["39 The hospital pharmacy experience in the current COVID-19 pandemic has shown that drive-thru pharmacies provide a patient-centered service and support medicine optimization in a safe and convenient environment.", [["patient", "ORGANISM", 116, 123], ["patient", "SPECIES", 116, 123], ["medicine optimization", "TREATMENT", 153, 174]]], ["40 In the United States, the Centre for Disease Control has also encouraged patients, especially those with severe illness, to use drive-thru pharmacies to pick up their medicines.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["Disease Control", "TREATMENT", 40, 55], ["severe illness", "PROBLEM", 108, 122]]], ["These could include qualitative studies analyzing pharmacists' and patients' interviews with regards to drive-thru experience.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75]]], ["Quantitative data could include medicines use, data on safe dispensing practices, adverse drug events in a pharmacy patient population, drug interactions, and medicines-related harm leading to hospitalization.", [["patient", "ORGANISM", 116, 123], ["patient", "SPECIES", 116, 123], ["safe dispensing practices", "TREATMENT", 55, 80], ["adverse drug events", "PROBLEM", 82, 101], ["drug interactions", "PROBLEM", 136, 153], ["medicines", "TREATMENT", 159, 168]]], ["Research is also needed on the workforce, including staffing levels and pharmacy workflow patterns if this system is adopted on a long-term and large scale basis.Research implications concerning drive-thru pharmacies and their role during pandemicsThough in the current pandemic, measures were taken, and the preference was to promote access to medicines and pharmacy services; however, pharmacy practice under those new conditions needs to be standardized.", [["staffing levels", "TEST", 52, 67], ["a long-term and large scale basis", "TREATMENT", 128, 161]]], ["Regulatory bodies may need to change or amend laws to ensure that drive-thru pharmacies meet patient expectations and safety standards.", [["patient", "ORGANISM", 93, 100], ["patient", "SPECIES", 93, 100]]], ["43 Increasing pressure on healthcare demand has resulted in the development of new roles and services for pharmacists.", [["Increasing pressure on healthcare demand", "PROBLEM", 3, 43], ["Increasing", "OBSERVATION_MODIFIER", 3, 13], ["pressure", "OBSERVATION_MODIFIER", 14, 22], ["new", "OBSERVATION_MODIFIER", 79, 82]]], ["44 In this context, it is vital to look at drive-thru pharmacies in the lens of the future of pharmacy services, particularly in relation to managing the pandemic.Future direction of drive-thru pharmacy servicesOne of the critical limitations of drive-thru pharmacies is the patient's lack of interaction with the pharmacists; however, the pandemic has allowed for a growth in the application of telemedicine.", [["patient", "ORGANISM", 275, 282], ["patient", "SPECIES", 275, 282]]], ["45 The UK's National Health Service (NHS) Long Term Plan encouraged better use of technology stating that digital interaction with patients will necessitate updating pharmacists' skills to provide telepharmacy in the future.", [["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139]]], ["46 A major report by the Royal Pharmaceutical Society also stresses the need for going digital in the future to cater to the patient's needs and demands.", [["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 125, 132]]], ["49 In fact, \"smart system,\" \"going digital,\" and \"the use of technology\" is classed as an \"enabler of change\" to improve patient health outcomes in all three countries; the UK, Australia, and New Zealand.", [["patient", "ORGANISM", 121, 128], ["patient", "SPECIES", 121, 128]]], ["This has significant public health implications particularly when pharmacies, like other health facilities, are managing this long-lasting pandemic.", [["significant", "OBSERVATION_MODIFIER", 9, 20]]], ["The current circumstances, however, might be changing this attitude.Future direction of drive-thru pharmacy servicesStill, there continues to be a need to create awareness of these pharmacy services and facilitate access to them, potentially through a drive-thru delivery model.", [["these pharmacy services", "TREATMENT", 175, 198], ["a drive-thru delivery model", "TREATMENT", 250, 277]]], ["Together with professional competency and economic efficiency, any future pharmacy practice model should have this new context taken into consideration to ensure successful public health initiatives where pharmacy plays a leading role.ConclusionWe can reflect, improve, and the lessons can be learned from the use of drive-thru pharmacies in different countries during the COVID-19 pandemic.", [["economic efficiency", "PROBLEM", 42, 61], ["the COVID", "TEST", 369, 378], ["pandemic", "PROBLEM", 382, 390]]]], "19b9ee3dcd89f01eea3e48b333888b1ce70b296f": [["IntroductionCoronaviruses (CoVs) (order Nidovirales, family Coronaviridae, subfamily Coronavirinae) are enveloped and have large singlestranded, positive-sense RNA.", [["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 60, 73], ["Coronavirinae", "GENE_OR_GENE_PRODUCT", 85, 98], ["CoVs", "PROTEIN", 27, 31], ["subfamily Coronavirinae", "PROTEIN", 75, 98], ["singlestranded, positive-sense RNA", "RNA", 129, 163], ["Nidovirales", "TREATMENT", 40, 51], ["large singlestranded, positive-sense RNA", "PROBLEM", 123, 163], ["large", "OBSERVATION_MODIFIER", 123, 128], ["sense RNA", "OBSERVATION", 154, 163]]], ["Most CoVs cause enteric and/or respiratory diseases in mammals and birds.", [["respiratory", "ANATOMY", 31, 42], ["enteric and/or respiratory diseases", "DISEASE", 16, 51], ["CoVs", "GENE_OR_GENE_PRODUCT", 5, 9], ["enteric and/or respiratory diseases", "PROBLEM", 16, 51], ["respiratory", "ANATOMY", 31, 42], ["diseases", "OBSERVATION", 43, 51]]], ["The 59 two-thirds of the CoV genome consists of two overlapping open reading frames (ORFs 1a and 1b) that encode a non-structural polyprotein, including RNA-dependent RNA polymerase (RdRp).", [["CoV", "ORGANISM", 25, 28], ["1b", "GENE_OR_GENE_PRODUCT", 97, 99], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 153, 181], ["CoV genome", "DNA", 25, 35], ["open reading frames", "DNA", 64, 83], ["ORFs 1a and 1b", "DNA", 85, 99], ["non-structural polyprotein", "RNA", 115, 141], ["RNA-dependent RNA polymerase", "PROTEIN", 153, 181], ["RdRp", "PROTEIN", 183, 187], ["the CoV genome", "TREATMENT", 21, 35], ["ORFs 1a", "TEST", 85, 92], ["a non-structural polyprotein", "PROBLEM", 113, 141], ["RNA", "TEST", 153, 156], ["CoV genome", "OBSERVATION", 25, 35], ["non-structural polyprotein", "OBSERVATION", 115, 141]]], ["The other third of the genome consists of ORFs encoding structural proteins, spike (S), membrane (M), envelope (E) and the nucleocapsid (N), and some non-structural proteins (nsp), 3a, 3b, 3c, 7a and 7b [1] .", [["membrane", "ANATOMY", 88, 96], ["spike (S)", "GENE_OR_GENE_PRODUCT", 77, 86], ["membrane", "CELLULAR_COMPONENT", 88, 96], ["nsp", "GENE_OR_GENE_PRODUCT", 175, 178], ["ORFs", "DNA", 42, 46], ["structural proteins", "PROTEIN", 56, 75], ["spike (S)", "PROTEIN", 77, 86], ["membrane (M), envelope (E)", "PROTEIN", 88, 114], ["nucleocapsid (N)", "PROTEIN", 123, 139], ["non-structural proteins", "PROTEIN", 150, 173], ["nsp", "PROTEIN", 175, 178], ["3a, 3b, 3c, 7a and 7b", "PROTEIN", 181, 202], ["ORFs encoding structural proteins", "PROBLEM", 42, 75], ["the nucleocapsid (N)", "PROBLEM", 119, 139], ["some non-structural proteins", "PROBLEM", 145, 173], ["nsp", "TEST", 175, 178], ["structural proteins", "OBSERVATION", 56, 75], ["non-structural proteins", "OBSERVATION", 150, 173]]], ["Transcription regulatory sequences (TRS) are located at 59-distal position in each mRNA and play an important role in the RNA replication of CoV [2] , [3] .IntroductionCoVs frequently undergo mutation and recombination, and there are three reasons for this [4] .", [["CoV", "ORGANISM", 141, 144], ["[3]", "SIMPLE_CHEMICAL", 151, 154], ["Transcription regulatory sequences", "DNA", 0, 34], ["TRS", "DNA", 36, 39], ["59-distal position", "DNA", 56, 74], ["mRNA", "RNA", 83, 87], ["IntroductionCoVs", "TREATMENT", 156, 172], ["mutation", "PROBLEM", 192, 200]]], ["First, CoV RdRp has low fidelity.", [["CoV", "ORGANISM", 7, 10], ["CoV RdRp", "PROTEIN", 7, 15], ["CoV RdRp", "SPECIES", 7, 15], ["CoV RdRp", "OBSERVATION", 7, 15], ["low fidelity", "OBSERVATION_MODIFIER", 20, 32]]], ["Although CoV encodes nsp14, which possesses 39R59 exonuclease activity for proofreading, the mutation rate approaches 2.0610 26 mutations per site per round of replication [5] .IntroductionSecond, there is a unique RNA replication mechanism using the TRS motif that is known as the ''copy choice'' mechanism, which induces homologous RNA recombination in CoVs [3] , [6] .", [["CoV", "GENE_OR_GENE_PRODUCT", 9, 12], ["nsp14", "GENE_OR_GENE_PRODUCT", 21, 26], ["39R59", "GENE_OR_GENE_PRODUCT", 44, 49], ["CoV", "PROTEIN", 9, 12], ["nsp14", "PROTEIN", 21, 26], ["39R59 exonuclease", "PROTEIN", 44, 61], ["TRS motif", "DNA", 251, 260], ["CoV encodes nsp14", "TEST", 9, 26], ["the mutation rate approaches", "TREATMENT", 89, 117], ["the TRS motif", "TREATMENT", 247, 260]]], ["Third, CoV possesses the largest genome (26-32 kb) among RNA viruses.", [["CoV", "GENE_OR_GENE_PRODUCT", 7, 10], ["CoV", "DNA", 7, 10], ["RNA viruses", "PROBLEM", 57, 68], ["largest", "OBSERVATION_MODIFIER", 25, 32], ["genome", "OBSERVATION", 33, 39], ["RNA viruses", "OBSERVATION", 57, 68]]], ["Furthermore, heterologous recombination that Betacoronavirus subgroup A has the hemagglutinin esterase gene originated from influenza C virus [7] , [8] .", [["hemagglutinin esterase", "GENE_OR_GENE_PRODUCT", 80, 102], ["influenza C virus", "ORGANISM", 124, 141], ["hemagglutinin esterase gene", "DNA", 80, 107], ["influenza C virus", "SPECIES", 124, 141], ["influenza C virus", "SPECIES", 124, 141], ["heterologous recombination", "TREATMENT", 13, 39], ["the hemagglutinin esterase gene", "TREATMENT", 76, 107], ["influenza C virus", "PROBLEM", 124, 141]]], ["These mutation and/or recombination events change viral properties, host range and pathogenicity.IntroductionFeline CoV (FCoV) is classified into genus Alphacoronavirus, species Alphacoronavirus 1, and includes canine CoV (CCoV), transmissible gastroenteritis virus (TGEV) and porcine respiratory CoV (PRCoV).", [["canine CoV (CCoV)", "DISEASE", 211, 228], ["transmissible gastroenteritis virus", "DISEASE", 230, 265], ["IntroductionFeline CoV", "ORGANISM", 97, 119], ["FCoV", "GENE_OR_GENE_PRODUCT", 121, 125], ["Alphacoronavirus 1", "ORGANISM", 178, 196], ["canine CoV", "ORGANISM", 211, 221], ["CCoV", "ORGANISM", 223, 227], ["transmissible gastroenteritis virus", "ORGANISM", 230, 265], ["TGEV", "ORGANISM", 267, 271], ["porcine respiratory CoV", "ORGANISM", 277, 300], ["canine CoV", "SPECIES", 211, 221], ["transmissible gastroenteritis virus", "SPECIES", 230, 265], ["TGEV", "SPECIES", 267, 271], ["porcine respiratory CoV", "SPECIES", 277, 300], ["FCoV", "SPECIES", 121, 125], ["canine CoV", "SPECIES", 211, 221], ["CCoV", "SPECIES", 223, 227], ["transmissible gastroenteritis virus", "SPECIES", 230, 265], ["TGEV", "SPECIES", 267, 271], ["porcine respiratory CoV", "SPECIES", 277, 300], ["PRCoV", "SPECIES", 302, 307], ["These mutation", "PROBLEM", 0, 14], ["recombination events change viral properties", "PROBLEM", 22, 66], ["pathogenicity", "PROBLEM", 83, 96], ["species Alphacoronavirus", "PROBLEM", 170, 194], ["canine CoV (CCoV", "TREATMENT", 211, 227], ["transmissible gastroenteritis virus", "PROBLEM", 230, 265], ["porcine respiratory CoV (PRCoV)", "TREATMENT", 277, 308], ["host range", "OBSERVATION_MODIFIER", 68, 78], ["respiratory CoV", "OBSERVATION", 285, 300]]], ["FCoV is distributed worldwide in cats and mainly induces mild intestinal inflammation in kittens [9] .", [["intestinal", "ANATOMY", 62, 72], ["FCoV", "CHEMICAL", 0, 4], ["inflammation", "DISEASE", 73, 85], ["FCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["cats", "ORGANISM", 33, 37], ["intestinal", "ORGAN", 62, 72], ["cats", "SPECIES", 33, 37], ["FCoV", "SPECIES", 0, 4], ["FCoV", "PROBLEM", 0, 4], ["mild intestinal inflammation in kittens", "PROBLEM", 57, 96], ["distributed", "OBSERVATION_MODIFIER", 8, 19], ["worldwide", "OBSERVATION_MODIFIER", 20, 29], ["mild", "OBSERVATION_MODIFIER", 57, 61], ["intestinal", "ANATOMY", 62, 72], ["inflammation", "OBSERVATION", 73, 85]]], ["FCoV inducing enteric disease is known as feline enteric coronavirus (FECV).", [["FCoV", "CHEMICAL", 0, 4], ["enteric disease", "DISEASE", 14, 29], ["feline enteric coronavirus", "DISEASE", 42, 68], ["FCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["feline enteric coronavirus", "ORGANISM", 42, 68], ["FECV", "CANCER", 70, 74], ["feline enteric coronavirus", "SPECIES", 42, 68], ["feline enteric coronavirus", "SPECIES", 42, 68], ["FECV", "SPECIES", 70, 74], ["FCoV inducing enteric disease", "PROBLEM", 0, 29], ["enteric disease", "OBSERVATION", 14, 29], ["coronavirus", "OBSERVATION", 57, 68]]], ["On the other hand, cats infected with FCoV rarely develop the more severe disease feline infectious peritonitis (FIP), which is caused by a mutant virus that is referred to as FIP virus (FIPV).", [["feline infectious peritonitis", "DISEASE", 82, 111], ["FIP", "DISEASE", 113, 116], ["cats", "ORGANISM", 19, 23], ["feline", "ORGANISM", 82, 88], ["FIP virus", "ORGANISM", 176, 185], ["cats", "SPECIES", 19, 23], ["feline", "SPECIES", 82, 88], ["FCoV", "SPECIES", 38, 42], ["FIP virus", "SPECIES", 176, 185], ["FIPV", "SPECIES", 187, 191], ["FCoV", "PROBLEM", 38, 42], ["the more severe disease feline infectious peritonitis", "PROBLEM", 58, 111], ["FIP", "PROBLEM", 113, 116], ["a mutant virus", "PROBLEM", 138, 152], ["more", "OBSERVATION_MODIFIER", 62, 66], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["disease", "OBSERVATION", 74, 81], ["feline", "OBSERVATION_MODIFIER", 82, 88], ["infectious", "OBSERVATION_MODIFIER", 89, 99], ["peritonitis", "OBSERVATION", 100, 111], ["mutant virus", "OBSERVATION", 140, 152]]], ["In addition, FCoVs can be divided into two serotypes, types I and II, based on antigenicity [10] [11] [12] .", [["FCoVs", "SIMPLE_CHEMICAL", 13, 18], ["FCoVs", "PROTEIN", 13, 18], ["FCoVs", "TREATMENT", 13, 18]]], ["These serotypes differ primarily in growth characteristics in cell culture and in receptor usage.", [["cell culture", "ANATOMY", 62, 74], ["cell culture", "CELL", 62, 74], ["These serotypes", "PROBLEM", 0, 15], ["cell culture", "TEST", 62, 74], ["cell culture", "OBSERVATION", 62, 74]]], ["Type II FCoV is able to use feline aminopeptidase N (fAPN) as its receptor, but type I FCoV cannot [9] , [13] .", [["N", "CHEMICAL", 50, 51], ["Type II FCoV", "GENE_OR_GENE_PRODUCT", 0, 12], ["feline aminopeptidase N", "GENE_OR_GENE_PRODUCT", 28, 51], ["fAPN", "GENE_OR_GENE_PRODUCT", 53, 57], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 80, 91], ["[13]", "SIMPLE_CHEMICAL", 105, 109], ["Type II FCoV", "PROTEIN", 0, 12], ["feline aminopeptidase N", "PROTEIN", 28, 51], ["fAPN", "PROTEIN", 53, 57], ["type I FCoV", "PROTEIN", 80, 91], ["Type II FCoV", "SPECIES", 0, 12], ["Type II FCoV", "PROBLEM", 0, 12], ["feline aminopeptidase N (fAPN)", "TREATMENT", 28, 58], ["type I FCoV", "PROBLEM", 80, 91], ["FCoV", "OBSERVATION", 8, 12]]], ["Recently, it was revealed that the S protein was solely responsible for the differences in types I and II FCoV with regard to growth characteristics in cell culture and fAPN usage [14] .IntroductionCCoV was first isolated in 1971 from dogs with moderate to severe enteritis in Germany [15] .", [["cell", "ANATOMY", 152, 156], ["fAPN", "CHEMICAL", 169, 173], ["enteritis", "DISEASE", 264, 273], ["cell", "CELL", 152, 156], ["fAPN", "SIMPLE_CHEMICAL", 169, 173], ["dogs", "ORGANISM", 235, 239], ["S protein", "PROTEIN", 35, 44], ["dogs", "SPECIES", 235, 239], ["the S protein", "TEST", 31, 44], ["cell culture", "TEST", 152, 164], ["moderate to severe enteritis", "PROBLEM", 245, 273], ["moderate", "OBSERVATION_MODIFIER", 245, 253], ["severe", "OBSERVATION_MODIFIER", 257, 263], ["enteritis", "OBSERVATION", 264, 273]]], ["CCoV is widespread in the dog population and is one of the most important canine enteropathogens [16] [17] [18] [19] [20] [21] [22] .", [["CCoV", "CHEMICAL", 0, 4], ["[16] [17] [18] [19] [20] [21]", "CHEMICAL", 97, 126], ["CCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["dog", "ORGANISM", 26, 29], ["canine", "ORGANISM", 74, 80], ["[16] [17] [18] [19] [20] [21] [22]", "SIMPLE_CHEMICAL", 97, 131], ["dog", "SPECIES", 26, 29], ["canine", "SPECIES", 74, 80], ["widespread", "OBSERVATION_MODIFIER", 8, 18]]], ["CCoVs were also divided into two genotypes; I and II.", [["CCoVs", "GENE_OR_GENE_PRODUCT", 0, 5], ["CCoVs", "PROTEIN", 0, 5], ["CCoVs", "TREATMENT", 0, 5]]], ["Before 2000, it was thought that CCoV had only one genotype, but strain Elmo/02 with a type I FCoV-like S gene was detected in Italy [23] .", [["CCoV", "GENE_OR_GENE_PRODUCT", 33, 37], ["Elmo/02", "ORGANISM", 72, 79], ["type I FCoV-like S", "GENE_OR_GENE_PRODUCT", 87, 105], ["type I FCoV-like S gene", "DNA", 87, 110], ["strain Elmo/02", "PROBLEM", 65, 79], ["a type I FCoV", "PROBLEM", 85, 98]]], ["The Elmo/02 strain possessed a novel ORF3 gene that was absent from other Alphacoronavirus 1 between the S and ORF3a genes [24] .", [["Elmo/02 strain", "ORGANISM", 4, 18], ["ORF3", "GENE_OR_GENE_PRODUCT", 37, 41], ["Alphacoronavirus 1", "GENE_OR_GENE_PRODUCT", 74, 92], ["ORF3a", "GENE_OR_GENE_PRODUCT", 111, 116], ["ORF3 gene", "DNA", 37, 46], ["Alphacoronavirus 1", "DNA", 74, 92], ["S and ORF3a genes", "DNA", 105, 122], ["The Elmo/02 strain", "PROBLEM", 0, 18], ["a novel ORF3 gene", "PROBLEM", 29, 46]]], ["Finally, this type I FCoV like-CCoV was designated type I CCoV and the reference CCoV was designated type II CCoV.", [["FCoV", "GENE_OR_GENE_PRODUCT", 21, 25], ["type I CCoV", "GENE_OR_GENE_PRODUCT", 51, 62], ["CCoV", "CANCER", 81, 85], ["type II CCoV", "CANCER", 101, 113], ["CCoV", "DNA", 31, 35], ["type I CCoV", "DNA", 51, 62], ["CCoV", "DNA", 81, 85], ["type II CCoV", "DNA", 101, 113]]], ["Surprisingly, 36.9%-76.8% of dogs with diarrhea were co-infected with both types I and II CCoV [25] [26] [27] .", [["diarrhea", "DISEASE", 39, 47], ["dogs", "ORGANISM", 29, 33], ["dogs", "SPECIES", 29, 33], ["diarrhea", "PROBLEM", 39, 47]]], ["Furthermore, type II CCoV was divided into two subtypes, IIa and IIb [28] .", [["type II CCoV", "GENE_OR_GENE_PRODUCT", 13, 25], ["type II CCoV", "PROTEIN", 13, 25], ["type II CCoV", "PROBLEM", 13, 25], ["IIa", "OBSERVATION_MODIFIER", 57, 60], ["IIb", "OBSERVATION_MODIFIER", 65, 68]]], ["In type IIb CCoV, the 59-terminal region of the S gene was similar to that of TGEV and it was thought that type IIb CCoV emerged via recombination between type IIa CCoV and TGEV [28] .", [["type IIb CCoV", "GENE_OR_GENE_PRODUCT", 3, 16], ["S", "GENE_OR_GENE_PRODUCT", 48, 49], ["TGEV", "ORGANISM", 78, 82], ["type IIb CCoV", "GENE_OR_GENE_PRODUCT", 107, 120], ["type IIa CCoV", "GENE_OR_GENE_PRODUCT", 155, 168], ["TGEV", "ORGANISM", 173, 177], ["59-terminal region", "DNA", 22, 40], ["S gene", "DNA", 48, 54], ["type IIb CCoV", "DNA", 107, 120], ["TGEV", "SPECIES", 78, 82], ["type IIa CCoV", "SPECIES", 155, 168], ["TGEV", "SPECIES", 173, 177], ["TGEV", "PROBLEM", 78, 82], ["type IIb CCoV", "PROBLEM", 107, 120], ["type IIb", "OBSERVATION_MODIFIER", 3, 11]]], ["Recently, a type IIa CCoV strain CB/05 with high virulence was reported in Europe [29] .", [["CB/05", "ORGANISM", 33, 38], ["type IIa CCoV strain CB/05", "SPECIES", 12, 38], ["high virulence", "PROBLEM", 44, 58]]], ["CB/05-infected pups showed clinical signs such as lethargy, vomiting, diarrhea and acute lymphopenia, and the viral genome was observed in extraintestinal tissues including brain [29] , [30] .", [["pups", "ANATOMY", 15, 19], ["extraintestinal tissues", "ANATOMY", 139, 162], ["brain", "ANATOMY", 173, 178], ["lethargy", "DISEASE", 50, 58], ["vomiting", "DISEASE", 60, 68], ["diarrhea", "DISEASE", 70, 78], ["lymphopenia", "DISEASE", 89, 100], ["CB/05", "ORGANISM", 0, 5], ["pups", "ORGANISM", 15, 19], ["extraintestinal tissues", "TISSUE", 139, 162], ["brain", "ORGAN", 173, 178], ["viral genome", "DNA", 110, 122], ["CB", "TEST", 0, 2], ["infected pups", "PROBLEM", 6, 19], ["clinical signs", "PROBLEM", 27, 41], ["lethargy", "PROBLEM", 50, 58], ["vomiting", "PROBLEM", 60, 68], ["diarrhea", "PROBLEM", 70, 78], ["acute lymphopenia", "PROBLEM", 83, 100], ["the viral genome", "PROBLEM", 106, 122], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["lymphopenia", "OBSERVATION", 89, 100], ["viral genome", "OBSERVATION", 110, 122], ["extraintestinal tissues", "ANATOMY", 139, 162], ["brain", "ANATOMY", 173, 178]]], ["Furthermore, immune response induced by enteric CCoV did not protect dogs from infection with CB/05 [31] .", [["infection", "DISEASE", 79, 88], ["CB/05", "CHEMICAL", 94, 99], ["dogs", "ORGANISM", 69, 73], ["dogs", "SPECIES", 69, 73], ["CCoV", "SPECIES", 48, 52], ["immune response", "PROBLEM", 13, 28], ["enteric CCoV", "TREATMENT", 40, 52], ["infection", "PROBLEM", 79, 88], ["infection", "OBSERVATION", 79, 88]]], ["However, there is little genetic information on CCoV in Japan.IntroductionIn this study, to clarify the mechanisms of emergence of type II FCoV, three type II FCoVs isolated in Japan were genetically and antigenetically compared with ten Japanese type II CCoVs and two Japanese type I FCoVs.Materials and MethodsAll animal procedures were conducted according to the Yamaguchi University Animal Care and Use guidelines and were approved by the Institutional Animal Care and Use Committee of Yamaguchi University.", [["type II FCoV", "DISEASE", 131, 143], ["type I FCoVs", "DISEASE", 278, 290], ["FCoVs", "CANCER", 285, 290], ["type II FCoV", "PROTEIN", 131, 143], ["type II FCoV", "SPECIES", 131, 143], ["Japanese type II CCoVs", "SPECIES", 238, 260], ["Japanese type I FCoVs", "SPECIES", 269, 290], ["this study", "TEST", 77, 87], ["type II FCoV", "PROBLEM", 131, 143], ["three type II FCoVs", "PROBLEM", 145, 164], ["Methods", "TREATMENT", 305, 312], ["All animal procedures", "TREATMENT", 312, 333], ["little", "OBSERVATION_MODIFIER", 18, 24]]], ["All efforts were made to minimize pain and suffering.CellsFelis catus whole fetus-4 cells (fcwf-4 cells; ATCC Number: CRL-2787) [32] were grown in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Carlsbad, CA) containing 10% fetal calf serum (FCS), 100 U/ml penicillin and 100 mg/ml streptomycin (Life Technologies).", [["whole fetus-4 cells", "ANATOMY", 70, 89], ["fcwf-4 cells", "ANATOMY", 91, 103], ["ATCC", "ANATOMY", 105, 109], ["CRL-2787", "ANATOMY", 118, 126], ["fetal calf serum", "ANATOMY", 237, 253], ["pain", "DISEASE", 34, 38], ["CRL-2787", "CHEMICAL", 118, 126], ["penicillin", "CHEMICAL", 270, 280], ["streptomycin", "CHEMICAL", 295, 307], ["penicillin", "CHEMICAL", 270, 280], ["streptomycin", "CHEMICAL", 295, 307], ["fetus-4 cells", "CELL", 76, 89], ["fcwf-4 cells", "CELL", 91, 103], ["ATCC", "CELL", 105, 109], ["CRL-2787", "CELL", 118, 126], ["calf", "ORGANISM", 243, 247], ["serum", "ORGANISM_SUBSTANCE", 248, 253], ["FCS", "ORGANISM_SUBSTANCE", 255, 258], ["penicillin", "SIMPLE_CHEMICAL", 270, 280], ["streptomycin", "SIMPLE_CHEMICAL", 295, 307], ["fcwf-4 cells", "CELL_LINE", 91, 103], ["calf", "SPECIES", 243, 247], ["CellsFelis catus", "SPECIES", 53, 69], ["pain", "PROBLEM", 34, 38], ["CellsFelis", "TEST", 53, 63], ["fcwf", "TEST", 91, 95], ["CRL", "TEST", 118, 121], ["Dulbecco", "TEST", 147, 155], ["Life Technologies", "TEST", 189, 206], ["Carlsbad, CA)", "PROBLEM", 208, 221], ["fetal calf serum", "TEST", 237, 253], ["penicillin", "TREATMENT", 270, 280], ["streptomycin", "TREATMENT", 295, 307], ["calf", "ANATOMY", 243, 247]]], ["Cells were maintained in a humidified 5% CO 2 incubator at 37uC.VirusesType I FCoV strains C3663 and Yayoi, type II FCoV strains M91-267, KUK-H/L and Tokyo/cat/130627 and type II CCoV strains fc1, fc4, fc7, fc9, fc76, fc100, fc94-039, fc97-022, fc00-089 and fc00-016 were analyzed in this study (Table 1) .", [["Cells", "ANATOMY", 0, 5], ["CO 2", "CHEMICAL", 41, 45], ["fc00-016", "CHEMICAL", 258, 266], ["Cells", "CELL", 0, 5], ["Yayoi, type II FCoV strains M91-267", "ORGANISM", 101, 136], ["KUK-H/L", "ORGANISM", 138, 145], ["Tokyo/cat/130627", "ORGANISM", 150, 166], ["type II CCoV strains", "ORGANISM", 171, 191], ["fc1", "GENE_OR_GENE_PRODUCT", 192, 195], ["fc4", "GENE_OR_GENE_PRODUCT", 197, 200], ["fc7", "GENE_OR_GENE_PRODUCT", 202, 205], ["fc9", "GENE_OR_GENE_PRODUCT", 207, 210], ["fc76", "GENE_OR_GENE_PRODUCT", 212, 216], ["fc100", "GENE_OR_GENE_PRODUCT", 218, 223], ["fc94-", "GENE_OR_GENE_PRODUCT", 225, 230], ["fc97-", "GENE_OR_GENE_PRODUCT", 235, 240], ["fc00-089", "GENE_OR_GENE_PRODUCT", 245, 253], ["fc00-016", "GENE_OR_GENE_PRODUCT", 258, 266], ["type II CCoV strains fc1, fc4, fc7, fc9, fc76, fc100, fc94-039, fc97-022, fc00-089 and fc00-016", "DNA", 171, 266], ["Type I FCoV strains C3663", "SPECIES", 71, 96], ["Tokyo/cat/130627", "SPECIES", 150, 166], ["a humidified 5% CO 2 incubator", "TREATMENT", 25, 55], ["Type I FCoV strains", "PROBLEM", 71, 90], ["type II FCoV strains", "PROBLEM", 108, 128], ["M91", "TEST", 129, 132], ["KUK", "TEST", 138, 141], ["Tokyo/cat", "TEST", 150, 159], ["type II CCoV strains", "PROBLEM", 171, 191], ["fc1", "TEST", 192, 195], ["fc4", "TEST", 197, 200], ["fc7", "TEST", 202, 205], ["fc9", "TEST", 207, 210], ["fc76", "TEST", 212, 216], ["fc100", "TEST", 218, 223], ["fc94-", "TEST", 225, 230], ["fc97-", "TEST", 235, 240], ["fc00", "TEST", 245, 249], ["fc00", "TEST", 258, 262], ["this study", "TEST", 284, 294], ["FCoV strains", "OBSERVATION", 78, 90]]], ["Type I and II FCoVs, excluding Tokyo/cat/130627, were characterized by indirect fluorescence assay (IFA) using monoclonal antibodies (MAbs) that were kindly provided by Dr. Hohdatsu [11] , [33] .", [["Type I and II FCoVs", "GENE_OR_GENE_PRODUCT", 0, 19], ["Type I and II FCoVs", "PROTEIN", 0, 19], ["monoclonal antibodies", "PROTEIN", 111, 132], ["MAbs", "PROTEIN", 134, 138], ["Tokyo/cat/130627", "SPECIES", 31, 47], ["Type I and II FCoVs", "PROBLEM", 0, 19], ["Tokyo/cat/130627", "TEST", 31, 47], ["indirect fluorescence assay", "TEST", 71, 98], ["IFA", "TEST", 100, 103], ["monoclonal antibodies (MAbs", "TREATMENT", 111, 138]]], ["Yayoi strain was isolated from a cat with a non-effusive form of FIP in Tokyo by serial passage in suckling mouse brain, and was then adapted to fcwf-4 cells [34] .", [["brain", "ANATOMY", 114, 119], ["fcwf-4 cells", "ANATOMY", 145, 157], ["FIP", "DISEASE", 65, 68], ["Yayoi strain", "ORGANISM", 0, 12], ["cat", "ORGANISM", 33, 36], ["mouse", "ORGANISM", 108, 113], ["brain", "ORGAN", 114, 119], ["fcwf-4 cells", "CELL", 145, 157], ["fcwf-4 cells", "CELL_LINE", 145, 157], ["mouse", "SPECIES", 108, 113], ["mouse", "SPECIES", 108, 113], ["Yayoi strain", "PROBLEM", 0, 12], ["FIP", "PROBLEM", 65, 68], ["FIP", "OBSERVATION", 65, 68], ["brain", "ANATOMY", 114, 119]]], ["C3663 strain was isolated from a cat with an effusive form of FIP in Kagoshima in 1994 [35] .", [["FIP", "DISEASE", 62, 65], ["cat", "ORGANISM", 33, 36], ["strain", "PROBLEM", 6, 12], ["a cat", "PROBLEM", 31, 36], ["FIP", "PROBLEM", 62, 65], ["FIP", "OBSERVATION", 62, 65]]], ["The pathogenicity of C3663 and Yayoi in cats was characterized [36] .", [["C3663", "CHEMICAL", 21, 26], ["Yayoi", "CHEMICAL", 31, 36], ["cats", "ORGANISM", 40, 44], ["cats", "SPECIES", 40, 44]]], ["M91-267 strain was isolated from a cat with an effusive form of FIP in Miyazaki in 1991 [35] .", [["M91-267", "CHEMICAL", 0, 7], ["FIP", "DISEASE", 64, 67], ["M91-267 strain", "CELL", 0, 14], ["cat", "ORGANISM", 35, 38], ["M91-267 strain", "SPECIES", 0, 14], ["M91", "TEST", 0, 3], ["strain", "PROBLEM", 8, 14], ["FIP", "PROBLEM", 64, 67], ["FIP", "OBSERVATION", 64, 67]]], ["Three SPF cats were experimentally infected with M91-267, and all of these died from FIP (unpublished data).", [["M91-267", "CHEMICAL", 49, 56], ["FIP", "DISEASE", 85, 88], ["cats", "ORGANISM", 10, 14], ["cats", "SPECIES", 10, 14], ["M91", "TEST", 49, 52], ["infected", "OBSERVATION_MODIFIER", 35, 43], ["FIP", "OBSERVATION", 85, 88]]], ["KUK-H strain was isolated from a cat with an effusive form of FIP in Kagoshima in 1987, and KUK-H/L that formed large plaques was plaque-purified from the KUK-H strain [35] .", [["plaques", "ANATOMY", 118, 125], ["plaque", "ANATOMY", 130, 136], ["KUK-H", "CHEMICAL", 0, 5], ["FIP", "DISEASE", 62, 65], ["KUK-H", "GENE_OR_GENE_PRODUCT", 0, 5], ["cat", "ORGANISM", 33, 36], ["large plaques", "PATHOLOGICAL_FORMATION", 112, 125], ["KUK", "TEST", 0, 3], ["H strain", "PROBLEM", 4, 12], ["FIP", "PROBLEM", 62, 65], ["KUK", "TEST", 92, 95], ["large plaques", "PROBLEM", 112, 125], ["plaque", "PROBLEM", 130, 136], ["FIP", "OBSERVATION", 62, 65], ["large", "OBSERVATION_MODIFIER", 112, 117], ["plaques", "OBSERVATION", 118, 125], ["plaque", "OBSERVATION", 130, 136]]], ["KUK-H/L caused lethal FIP in cats [35] .", [["KUK-H", "CHEMICAL", 0, 5], ["FIP", "DISEASE", 22, 25], ["cats", "ORGANISM", 29, 33], ["cats", "SPECIES", 29, 33], ["KUK", "TEST", 0, 3], ["lethal FIP in cats", "PROBLEM", 15, 33], ["lethal", "OBSERVATION_MODIFIER", 15, 21], ["FIP", "OBSERVATION", 22, 25]]], ["RNA sequences of Tokyo/cat/130627 were obtained from FIP ascites in a cat in Tokyo in 2013.", [["ascites", "ANATOMY", 57, 64], ["FIP ascites", "DISEASE", 53, 64], ["cat", "ORGANISM", 23, 26], ["cat", "ORGANISM", 70, 73], ["Tokyo/cat/130627", "SPECIES", 17, 33], ["RNA sequences", "TEST", 0, 13], ["Tokyo/cat", "TEST", 17, 26], ["FIP ascites", "PROBLEM", 53, 64], ["ascites", "OBSERVATION", 57, 64]]], ["The FIPV spread quickly in a cattery, and more than twenty cats developed FIP.", [["FIP", "DISEASE", 74, 77], ["cats", "ORGANISM", 59, 63], ["The FIPV spread", "PROBLEM", 0, 15], ["FIP", "PROBLEM", 74, 77], ["FIPV", "OBSERVATION_MODIFIER", 4, 8], ["spread", "OBSERVATION_MODIFIER", 9, 15], ["FIP", "OBSERVATION", 74, 77]]], ["Type II CCoV strains, fc1, fc4, fc7, fc9, fc76, fc100, fc94-039 and fc97-022, were isolated between 1990 and 1997 in Japan [19] , and fc00-016 and fc00-087 were isolated in 2000 in Japan [37] .Reverse transcription (RT)-polymerase chain reaction (PCR)Each virus, excluding Tokyo/cat/130627, was inoculated onto an fcwf-4 cell monolayer and was incubated until cytopathic effects (CPEs) were observed.", [["fcwf-4 cell monolayer", "ANATOMY", 314, 335], ["fc00-016 and fc00-087", "CHEMICAL", 134, 155], ["Type II CCoV", "GENE_OR_GENE_PRODUCT", 0, 12], ["fc1", "GENE_OR_GENE_PRODUCT", 22, 25], ["fc4", "GENE_OR_GENE_PRODUCT", 27, 30], ["fc7", "GENE_OR_GENE_PRODUCT", 32, 35], ["fc9", "GENE_OR_GENE_PRODUCT", 37, 40], ["fc76", "GENE_OR_GENE_PRODUCT", 42, 46], ["fc100", "GENE_OR_GENE_PRODUCT", 48, 53], ["fc94-039", "GENE_OR_GENE_PRODUCT", 55, 63], ["fc97-022", "GENE_OR_GENE_PRODUCT", 68, 76], ["fc00-016", "GENE_OR_GENE_PRODUCT", 134, 142], ["fc00-087", "CELL", 147, 155], ["cat", "ORGANISM", 279, 282], ["fcwf-4 cell monolayer", "CELL", 314, 335], ["fc1", "DNA", 22, 25], ["fc4", "DNA", 27, 30], ["fc7", "DNA", 32, 35], ["fc9", "DNA", 37, 40], ["fc76", "DNA", 42, 46], ["fc100", "DNA", 48, 53], ["fc94", "DNA", 55, 59], ["039", "DNA", 60, 63], ["fc97", "DNA", 68, 72], ["fc00", "DNA", 147, 151], ["fcwf-4 cell monolayer", "CELL_LINE", 314, 335], ["Tokyo/cat/130627", "SPECIES", 273, 289], ["Type II CCoV strains", "PROBLEM", 0, 20], ["fc1", "TEST", 22, 25], ["fc4", "TEST", 27, 30], ["fc7", "TEST", 32, 35], ["fc94", "TEST", 55, 59], ["fc97", "TEST", 68, 72], ["fc00", "TEST", 134, 138], ["fc00", "TEST", 147, 151], ["Reverse transcription", "TREATMENT", 193, 214], ["polymerase chain reaction", "PROBLEM", 220, 245], ["PCR", "TEST", 247, 250], ["Each virus", "PROBLEM", 251, 261], ["an fcwf-4 cell monolayer", "TREATMENT", 311, 335], ["cytopathic effects (CPEs", "PROBLEM", 360, 384]]], ["RNA was then extracted from fcwf-4 cells using an RNeasy Mini kit (Qiagen, Hilden, Germany) and RT reaction was carried out at 30uC for 10 min, 42uC for 30 min, 70uC for 15 min and 5uC for 5 min with random 9-mer oligonucleotide primers or 42uC for 30 min, 70uC for 15 min and 5uC for 5 min with oligo dT-adaptor primer using a TaKaRa RNA LA PCR kit (AMV) Ver.1.1 (TaKaRa, Shiga, Japan).Reverse transcription (RT)-polymerase chain reaction (PCR)For amplification of partial S genes of type II CCoVs and type II FCoVs, primers CCVSF (59-AGCACTTTTCCTATT-GATTG-39) and CCVSR (59-GTTAGTTTGTCTAATAATAC-CAACACC-39) were used [38] .", [["fcwf-4 cells", "ANATOMY", 28, 40], ["fcwf-4 cells", "CELL", 28, 40], ["type II CCoVs", "GENE_OR_GENE_PRODUCT", 485, 498], ["RNA", "RNA", 0, 3], ["fcwf-4 cells", "CELL_LINE", 28, 40], ["S genes", "DNA", 474, 481], ["type II CCoVs", "DNA", 485, 498], ["type II FCoVs", "DNA", 503, 516], ["primers CCVSF", "DNA", 518, 531], ["CCVSR", "DNA", 566, 571], ["CAACACC-39", "DNA", 597, 607], ["type II CCoVs", "SPECIES", 485, 498], ["fcwf", "TEST", 28, 32], ["an RNeasy Mini kit", "TREATMENT", 47, 65], ["RT reaction", "PROBLEM", 96, 107], ["random 9-mer oligonucleotide primers", "TREATMENT", 200, 236], ["oligo dT-adaptor primer", "TREATMENT", 296, 319], ["a TaKaRa RNA", "TREATMENT", 326, 338], ["Reverse transcription", "TREATMENT", 387, 408], ["polymerase chain reaction", "PROBLEM", 414, 439], ["PCR", "TEST", 441, 444], ["partial S genes", "PROBLEM", 466, 481], ["type II CCoVs", "PROBLEM", 485, 498], ["type II FCoVs", "PROBLEM", 503, 516], ["primers CCVSF", "TEST", 518, 531], ["AGCACTTTTCCTATT", "TEST", 536, 551], ["GATTG", "TEST", 552, 557], ["CCVSR", "TEST", 566, 571], ["CAACACC", "TEST", 597, 604], ["type II", "OBSERVATION_MODIFIER", 485, 492]]], ["For amplification of the N gene, primers NF (59-CTAAAGCTGGTGATTACTCAACAG-39) and NR (59-TAATAAATACAGCGTGGAGGAAAAC-39) were used [39] .", [["N gene", "DNA", 25, 31], ["primers NF", "TEST", 33, 43], ["CTAAAGCTGGTGATTACTCAACAG", "TEST", 48, 72], ["NR", "TEST", 81, 83], ["TAATAAATACAGCGTGGAGGAAAAC", "TEST", 88, 113]]], ["PCR was carried out at 94uC for 2 min, followed by 40 cycles at 94uC for 30 s, 55uC for 30 s, 72uC for 2 min and final extension at 72uC for 10 min using a TaKaRa RNA LA PCR kit (AMV) Ver.1.1 (TaKaRa).", [["TaKaRa", "GENE_OR_GENE_PRODUCT", 193, 199], ["PCR", "TEST", 0, 3], ["a TaKaRa RNA", "TREATMENT", 154, 166]]], ["PCR products were analyzed electrophoretically and amplified products were purified using a QIAquick PCR Purification kit (Qiagen) for sequence analysis.Reverse transcription (RT)-polymerase chain reaction (PCR)In order to amplify the subgenomic mRNA of CCoV fc1, PCR was performed using 52F (59-ACTAGCCTTGTGCTAGATTT-39) as a forward primer and CCVScenR (59-CCAGTTTTTA-TAACAGCTG-39), N-RR2 (59-GCGCAATAACGTTCACCA-39) and M13 primer M4 as reverse primers.", [["CCoV fc1", "GENE_OR_GENE_PRODUCT", 254, 262], ["subgenomic mRNA", "RNA", 235, 250], ["CCoV fc1", "DNA", 254, 262], ["forward primer", "DNA", 326, 340], ["RR2", "DNA", 386, 389], ["M13 primer M4", "DNA", 421, 434], ["reverse primers", "DNA", 438, 453], ["CCoV", "SPECIES", 254, 258], ["PCR products", "TREATMENT", 0, 12], ["amplified products", "TREATMENT", 51, 69], ["a QIAquick PCR Purification kit", "TREATMENT", 90, 121], ["sequence analysis", "TEST", 135, 152], ["Reverse transcription", "TREATMENT", 153, 174], ["polymerase chain reaction", "PROBLEM", 180, 205], ["PCR", "TEST", 207, 210], ["PCR", "TEST", 264, 267], ["ACTAGCCTTGTGCTAGATTT", "TEST", 296, 316], ["a forward primer", "TEST", 324, 340], ["CCVScenR", "TEST", 345, 353], ["CCAGTTTTTA", "TEST", 358, 368], ["TAACAGCTG", "TEST", 369, 378], ["RR2", "TEST", 386, 389], ["GCGCAATAACGTTCACCA", "TEST", 394, 412]]], ["Primer 52F recognized the TRS conserved among Alphacoronaviruses [36] .", [["Primer 52F", "DNA", 0, 10], ["TRS", "DNA", 26, 29], ["the TRS", "PROBLEM", 22, 29]]], ["The reaction was carried out under the same conditions as mentioned above.Reverse transcription (RT)-polymerase chain reaction (PCR)For sequence analysis of ORFs M, N, 7a and 7b of M91-267 and KUK-H/L, we carried out TA cloning.", [["M91-267", "GENE_OR_GENE_PRODUCT", 181, 188], ["KUK-H/L", "CELL", 193, 200], ["ORFs", "DNA", 157, 161], ["M91-267", "DNA", 181, 188], ["KUK", "DNA", 193, 196], ["The reaction", "PROBLEM", 0, 12], ["Reverse transcription", "TREATMENT", 74, 95], ["polymerase chain reaction", "PROBLEM", 101, 126], ["PCR", "TEST", 128, 131], ["sequence analysis", "TEST", 136, 153], ["ORFs M", "TEST", 157, 163], ["M91", "TEST", 181, 184], ["KUK", "TEST", 193, 196]]], ["RNA was extracted from fcwf-4 cells infected with M91-267 or KUK-H/L using an RNeasy Mini kit (Qiagen).", [["fcwf-4 cells", "ANATOMY", 23, 35], ["fcwf-4 cells", "CELL", 23, 35], ["M91-267", "CELL", 50, 57], ["KUK-H/L", "CELL", 61, 68], ["RNA", "RNA", 0, 3], ["fcwf-4 cells", "CELL_LINE", 23, 35], ["RNA", "TEST", 0, 3], ["fcwf", "TEST", 23, 27], ["M91", "TEST", 50, 53], ["KUK", "TEST", 61, 64], ["an RNeasy Mini kit (Qiagen)", "TREATMENT", 75, 102]]], ["Extracted RNA was reverse-transcribed with oligo dT-Adaptor primer using a TaKaRa RNA LA PCR kit (AMV) Ver.1.1 (TaKaRa) as mentioned above.", [["oligo dT-Adaptor primer", "DNA", 43, 66], ["Extracted RNA", "PROBLEM", 0, 13], ["oligo dT-Adaptor primer", "TREATMENT", 43, 66], ["a TaKaRa RNA", "TREATMENT", 73, 85]]], ["To amplify the region including ORFs M, N, 7a and 7b, primers 52F, M13 primer M4 were used for PCR with a TaKaRa RNA LA PCR kit (AMV) Ver.1.1 (TaKaRa).", [["7b", "GENE_OR_GENE_PRODUCT", 50, 52], ["TaKaRa", "GENE_OR_GENE_PRODUCT", 143, 149], ["ORFs", "DNA", 32, 36], ["N, 7a and 7b", "DNA", 40, 52], ["primers 52F", "DNA", 54, 65], ["M13 primer M4", "DNA", 67, 80], ["ORFs M", "TEST", 32, 38], ["primers", "TEST", 54, 61], ["M13 primer M4", "TEST", 67, 80], ["PCR", "TEST", 95, 98], ["a TaKaRa RNA", "TEST", 104, 116]]], ["PCR products were directly cloned into pGEM-T Easy (Promega, Madison, WI) according to the manufacturer's instructions.", [["PCR products", "TREATMENT", 0, 12]]], ["Plasmid DNAs were extracted from E. coli strain JM109 using a QIAprep Spin Miniprep Kit (Qiagen).", [["DNAs", "ANATOMY", 8, 12], ["Plasmid DNAs", "CELL", 0, 12], ["E. coli", "ORGANISM", 33, 40], ["JM109", "CELL", 48, 53], ["Plasmid DNAs", "DNA", 0, 12], ["E. coli", "SPECIES", 33, 40], ["E. coli", "SPECIES", 33, 40], ["JM109", "SPECIES", 48, 53], ["Plasmid DNAs", "PROBLEM", 0, 12], ["E. coli strain JM109", "TREATMENT", 33, 53], ["a QIAprep Spin Miniprep Kit (Qiagen)", "TREATMENT", 60, 96], ["E. coli", "OBSERVATION_MODIFIER", 33, 40]]], ["Purified plasmid DNAs were applied for sequencing analysis.Reverse transcription (RT)-polymerase chain reaction (PCR)Viral RNA of Tokyo/cat/130627 was extracted from FIP ascites in a cat using a QIAamp Viral RNA Mini Kit (Qiagen).", [["DNAs", "ANATOMY", 17, 21], ["ascites", "ANATOMY", 170, 177], ["FIP ascites", "DISEASE", 166, 177], ["cat", "ORGANISM", 136, 139], ["FIP", "ORGANISM", 166, 169], ["cat", "ORGANISM", 183, 186], ["Purified plasmid DNAs", "DNA", 0, 21], ["Tokyo/cat/130627", "SPECIES", 130, 146], ["Purified plasmid DNAs", "TREATMENT", 0, 21], ["sequencing analysis", "TEST", 39, 58], ["Reverse transcription", "TREATMENT", 59, 80], ["polymerase chain reaction", "PROBLEM", 86, 111], ["PCR", "TEST", 113, 116], ["Viral RNA", "TEST", 117, 126], ["Tokyo/cat", "TEST", 130, 139], ["FIP ascites", "PROBLEM", 166, 177], ["a QIAamp Viral RNA Mini Kit (Qiagen)", "TREATMENT", 193, 229], ["plasmid DNAs", "OBSERVATION", 9, 21], ["FIP", "OBSERVATION_MODIFIER", 166, 169], ["ascites", "OBSERVATION", 170, 177]]], ["For sequence analysis, five fragments of the Tokyo/cat/130627 gene between the 39-terminus of ORF 1b and poly A were amplified using the following primer pairs: 1bF (59-TTGATTCAAA-GATTTGAGTATTGG-39)-CCVSR; CCVSF-S2cenFR3 (59 -Table 1 .", [["130627", "GENE_OR_GENE_PRODUCT", 55, 61], ["ORF 1b", "GENE_OR_GENE_PRODUCT", 94, 100], ["poly A", "GENE_OR_GENE_PRODUCT", 105, 111], ["Tokyo/cat/130627 gene", "DNA", 45, 66], ["39-terminus", "DNA", 79, 90], ["ORF 1b", "DNA", 94, 100], ["poly A", "DNA", 105, 111], ["CCVSR", "DNA", 199, 204], ["CCVSF-S2cenFR3", "DNA", 206, 220], ["59 -Table 1", "DNA", 222, 233], ["Tokyo/cat/130627", "SPECIES", 45, 61], ["sequence analysis", "TEST", 4, 21], ["TTGATTCAAA", "TEST", 169, 179], ["GATTTGAGTATTGG", "TEST", 180, 194]]], ["Canine and feline coronaviruses analyzed in this study: nucleotide sequence acquisition numbers and serum cross-neutralizing activity.", [["serum", "ANATOMY", 100, 105], ["Canine and feline coronaviruses", "DISEASE", 0, 31], ["nucleotide", "CHEMICAL", 56, 66], ["nucleotide", "CHEMICAL", 56, 66], ["Canine", "ORGANISM", 0, 6], ["feline coronaviruses", "ORGANISM", 11, 31], ["serum", "ORGANISM_SUBSTANCE", 100, 105], ["Canine", "SPECIES", 0, 6], ["feline", "SPECIES", 11, 17], ["Canine", "SPECIES", 0, 6], ["feline coronaviruses", "SPECIES", 11, 31], ["this study", "TEST", 44, 54], ["nucleotide sequence acquisition numbers", "TEST", 56, 95], ["feline coronaviruses", "OBSERVATION", 11, 31]]], ["Serum was collected from the cat that was inoculated intraorally with type I FCoV C3663 [36] . b Serum was collected from the cat that was inoculated intraperitoneally with type II FCoV M91-267 (unpublished data). c [36] . were used as described previously [40] .", [["Serum", "ANATOMY", 0, 5], ["Serum", "ANATOMY", 97, 102], ["intraperitoneally", "ANATOMY", 150, 167], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["cat", "ORGANISM", 29, 32], ["Serum", "ORGANISM_SUBSTANCE", 97, 102], ["cat", "ORGANISM", 126, 129], ["cat", "SPECIES", 29, 32], ["cat", "SPECIES", 126, 129], ["type I FCoV C3663", "SPECIES", 70, 87], ["type II FCoV M91-267", "SPECIES", 173, 193], ["Serum", "TEST", 0, 5], ["b Serum", "TEST", 95, 102], ["type II FCoV M91", "TEST", 173, 189]]], ["PCR products were analyzed electrophoretically and amplified products were purified using a MinElute PCR Purification Kit (Qiagen) for sequence analysis.Nucleotide sequencesSequencing was performed using a BigDye Terminator v3.1 Cycle Sequencing kit (Life Technologies) according to the manufacturer's instructions.", [["Nucleotide sequences", "DNA", 153, 173], ["PCR products", "TREATMENT", 0, 12], ["amplified products", "TREATMENT", 51, 69], ["a MinElute PCR Purification Kit", "TREATMENT", 90, 121], ["sequence analysis", "TEST", 135, 152], ["Nucleotide sequences", "TEST", 153, 173], ["Sequencing", "TEST", 173, 183], ["a BigDye Terminator", "TREATMENT", 204, 223]]], ["Products were purified by ethanol precipitation and analyzed using an ABI PRISM 310 Genetic Analyzer (Life Technologies).", [["ethanol", "CHEMICAL", 26, 33], ["ethanol", "CHEMICAL", 26, 33], ["ethanol", "SIMPLE_CHEMICAL", 26, 33], ["an ABI PRISM", "TEST", 67, 79], ["Genetic Analyzer (Life Technologies", "TREATMENT", 84, 119]]], ["For sequence analysis, primers shown in Table S1 were used and nucleotide sequences were deposited to the DNA database of Japan (DDBJ) under the accession numbers listed in Table 1 .Homology search and phylogenetic analysisHomologies among strains were analyzed using GENETYX Ver.8 (GENETYX Corporation, Tokyo, Japan) and phylogenetic trees were constructed by the neighbor-joining method [41] using MEGA5.0 software [42] based on nucleotide pairwise distance.Sera from catsSera collected from two SPF cats experimentally inoculated with FIPVs were used.", [["nucleotide", "CHEMICAL", 63, 73], ["nucleotide", "CHEMICAL", 63, 73], ["nucleotide", "CHEMICAL", 431, 441], ["DNA", "CELLULAR_COMPONENT", 106, 109], ["Sera", "ORGANISM_SUBSTANCE", 460, 464], ["cats", "ORGANISM", 470, 474], ["Sera", "ORGANISM_SUBSTANCE", 474, 478], ["cats", "ORGANISM", 502, 506], ["cats", "SPECIES", 470, 474], ["cats", "SPECIES", 502, 506], ["sequence analysis", "TEST", 4, 21], ["primers", "TEST", 23, 30], ["nucleotide sequences", "TEST", 63, 83], ["Homology search", "TEST", 182, 197], ["phylogenetic analysis", "TEST", 202, 223], ["Sera from catsSera", "TEST", 460, 478], ["FIPVs", "TREATMENT", 538, 543]]], ["One cat was inoculated intra-orally with type I FCoV C3663 (3.9610 6 PFU/cat) and showed an effusion form of FIP [36] .", [["cat", "ORGANISM", 4, 7], ["cat", "ORGANISM", 73, 76], ["type I FCoV C3663 (3.9610 6 PFU/cat", "SPECIES", 41, 76], ["PFU/cat", "TEST", 69, 76], ["an effusion form of FIP", "PROBLEM", 89, 112], ["effusion", "OBSERVATION", 92, 100], ["FIP", "OBSERVATION", 109, 112]]], ["Another cat was inoculated intraperitoneally with type II FCoV M91-267 (1.0610 6 PFU/cat) and also showed an effusive form of FIP (unpublished data).", [["intraperitoneally", "ANATOMY", 27, 44], ["type II FCoV M91-267", "CHEMICAL", 50, 70], ["FIP", "DISEASE", 126, 129], ["cat", "ORGANISM", 8, 11], ["cat", "ORGANISM", 85, 88], ["type II FCoV M91-267 (1.0610 6 PFU/cat", "SPECIES", 50, 88], ["type II FCoV M91", "TEST", 50, 66], ["PFU/cat", "TEST", 81, 88], ["an effusive form of FIP", "PROBLEM", 106, 129], ["effusive", "OBSERVATION", 109, 117], ["FIP", "OBSERVATION", 126, 129]]], ["When clinical symptoms were severe, cats were euthanized under anesthesia.", [["cats", "ORGANISM", 36, 40], ["cats", "SPECIES", 36, 40], ["clinical symptoms", "PROBLEM", 5, 22], ["anesthesia", "TREATMENT", 63, 73]]], ["These sera were obtained in our previous experiments carried out under approval by the ethics committee for animal experiments, Faculty of Agriculture, Yamaguchi University.Virus-neutralization testVirus-neutralization (VN) test was performed by 75% plaquereduction neutralization test (PRNT 75 ) using cat sera inactivated at 56uC for 30 min [12] , [36] .", [["sera", "ANATOMY", 6, 10], ["sera", "ANATOMY", 307, 311], ["sera", "ORGANISM_SUBSTANCE", 6, 10], ["Virus", "ORGANISM", 173, 178], ["testVirus", "GENE_OR_GENE_PRODUCT", 194, 203], ["cat", "ORGANISM", 303, 306], ["sera", "ORGANISM_SUBSTANCE", 307, 311], ["cat", "SPECIES", 303, 306], ["These sera", "TEST", 0, 10], ["Virus", "TEST", 173, 178], ["neutralization test", "TEST", 266, 285], ["PRNT", "TEST", 287, 291], ["cat sera", "TEST", 303, 311]]], ["Equal volumes of two-fold serially diluted sera and 2.0610 3 PFU/ml virus were mixed and incubated at 37uC for 1 h.", [["sera", "ANATOMY", 43, 47], ["sera", "ORGANISM_SUBSTANCE", 43, 47], ["sera", "TEST", 43, 47], ["3 PFU/ml virus", "TREATMENT", 59, 73], ["volumes", "OBSERVATION_MODIFIER", 6, 13]]], ["Then, 50 ml of this mixture was inoculated onto an fcwf-4 cell monolayer in 24-well plates (Sumitomo Bakelite, Tokyo, Japan).", [["fcwf-4 cell monolayer", "ANATOMY", 51, 72], ["fcwf-4 cell monolayer", "CELL", 51, 72], ["fcwf-4 cell monolayer", "CELL_LINE", 51, 72], ["this mixture", "TREATMENT", 15, 27], ["an fcwf-4 cell monolayer", "TREATMENT", 48, 72]]], ["After adsorption at 37uC for 1 h, inoculum was removed and 0.8% agarose (Seaplaque GTG Agarose; Lonza, Switzerland) in DMEM containing 10% FCS was overlaid.", [["37uC", "CHEMICAL", 20, 24], ["agarose", "SIMPLE_CHEMICAL", 64, 71], ["inoculum", "TREATMENT", 34, 42], ["% agarose (Seaplaque GTG Agarose", "TREATMENT", 62, 94]]], ["Infected cells were incubated at 37uC until CPE was observed, followed by fixing with phosphate-buffered formalin and staining with crystal violet.Comparison of 39-region among type II CCoVs, and type I and II FCoVsNucleotide sequences of the 39-region of the genomes, excluding the poly A, of type II CCoV fc1 (8,959b) and type II FCoVs, M91-267 (8,889b), KUK-H/L (8,930b) and Tokyo/cat/130627 (8,831b), were determined (DDBJ Accession No.", [["cells", "ANATOMY", 9, 14], ["phosphate", "CHEMICAL", 86, 95], ["phosphate", "CHEMICAL", 86, 95], ["formalin", "CHEMICAL", 105, 113], ["cells", "CELL", 9, 14], ["phosphate-buffered formalin", "SIMPLE_CHEMICAL", 86, 113], ["crystal violet", "SIMPLE_CHEMICAL", 132, 146], ["type II CCoVs", "CANCER", 177, 190], ["poly A", "GENE_OR_GENE_PRODUCT", 283, 289], ["type II CCoV fc1 (8,959b", "GENE_OR_GENE_PRODUCT", 294, 318], ["type II FCoVs", "GENE_OR_GENE_PRODUCT", 324, 337], ["39-region", "DNA", 161, 170], ["type II CCoVs", "DNA", 177, 190], ["type I and II FCoVsNucleotide sequences", "DNA", 196, 235], ["39-region", "DNA", 243, 252], ["poly A", "DNA", 283, 289], ["type II CCoV fc1", "DNA", 294, 310], ["8,959b", "DNA", 312, 318], ["type II FCoVs", "DNA", 324, 337], ["M91-267", "DNA", 339, 346], ["KUK", "DNA", 357, 360], ["Tokyo/cat/130627", "DNA", 378, 394], ["8,831b", "DNA", 396, 402], ["Tokyo/cat/130627", "SPECIES", 378, 394], ["Infected cells", "PROBLEM", 0, 14], ["CPE", "PROBLEM", 44, 47], ["phosphate-buffered formalin", "TREATMENT", 86, 113], ["crystal violet", "TREATMENT", 132, 146], ["type II CCoVs", "PROBLEM", 177, 190], ["type I and II FCoVsNucleotide sequences", "PROBLEM", 196, 235], ["type II FCoVs", "PROBLEM", 324, 337], ["M91", "TEST", 339, 342], ["KUK", "TEST", 357, 360], ["Tokyo/cat", "TEST", 378, 387], ["genomes", "OBSERVATION", 260, 267], ["poly", "OBSERVATION", 283, 287]]], ["AB781790 for fc1, AB781788 for M91-267, AB781789 for KUK-H/L and AB907624 for Tokyo/cat/130627) (Table1).", [["AB781790", "CHEMICAL", 0, 8], ["M91-267", "CHEMICAL", 31, 38], ["AB781790", "CHEMICAL", 0, 8], ["Tokyo/cat/130627", "SPECIES", 78, 94], ["fc1", "TEST", 13, 16], ["M91", "TEST", 31, 34], ["KUK", "TEST", 53, 56]]], ["Because of a mutation in the start codon (ATGRACG), Tokyo/cat/130627 lacked ORF3b.", [["ORF3b", "GENE_OR_GENE_PRODUCT", 76, 81], ["start codon", "DNA", 29, 40], ["ATGRACG", "DNA", 42, 49], ["Tokyo/cat/130627", "DNA", 52, 68], ["ORF3b", "DNA", 76, 81], ["Tokyo/cat/130627", "SPECIES", 52, 68], ["a mutation", "PROBLEM", 11, 21]]], ["In addition, type II FCoVs, M91-267 and Tokyo/ cat/130627 possessed a truncated ORF 3c (Fig. 1) .", [["M91-267", "GENE_OR_GENE_PRODUCT", 28, 35], ["type II FCoVs", "PROTEIN", 13, 26], ["truncated ORF 3c", "DNA", 70, 86], ["Tokyo/ cat/130627", "SPECIES", 40, 57], ["type II FCoVs", "PROBLEM", 13, 26], ["M91", "TEST", 28, 31], ["Tokyo/ cat", "TEST", 40, 50], ["a truncated ORF", "PROBLEM", 68, 83]]], ["When compared with KUK-H/L, M91-267 had a 35-nucleotide deletion in the ORF 3c gene, resulting in a truncated ORF 3c.", [["M91-267", "CHEMICAL", 28, 35], ["ORF 3c", "GENE_OR_GENE_PRODUCT", 72, 78], ["KUK", "PROTEIN", 19, 22], ["M91", "DNA", 28, 31], ["35-nucleotide deletion", "DNA", 42, 64], ["ORF 3c gene", "DNA", 72, 83], ["truncated ORF 3c", "DNA", 100, 116], ["KUK", "TEST", 19, 22], ["M91", "TEST", 28, 31], ["a 35-nucleotide deletion", "PROBLEM", 40, 64], ["a truncated ORF 3c", "PROBLEM", 98, 116], ["ORF 3c", "OBSERVATION", 110, 116]]], ["In comparison with C3663, Tokyo/cat/130627 showed a 25nucleotide deletion in the ORF 3c gene, resulting in a truncated ORF 3c gene.", [["ORF 3c", "GENE_OR_GENE_PRODUCT", 81, 87], ["ORF 3c", "GENE_OR_GENE_PRODUCT", 119, 125], ["25nucleotide deletion", "DNA", 52, 73], ["ORF 3c gene", "DNA", 81, 92], ["truncated ORF 3c gene", "DNA", 109, 130], ["Tokyo/cat/130627", "SPECIES", 26, 42], ["a 25nucleotide deletion", "PROBLEM", 50, 73], ["a truncated ORF", "PROBLEM", 107, 122], ["ORF 3c", "OBSERVATION", 119, 125]]], ["Deduced amino acid sequences for ORFs S, 3a, 3b, 3c, E, M, N, 7a and 7b in type II FCoVs were compared with those of type I FCoV C3663 and type II CCoV fc1 (Table S2 , S3).", [["amino acid", "CHEMICAL", 8, 18], ["amino acid", "CHEMICAL", 8, 18], ["amino acid", "AMINO_ACID", 8, 18], ["E", "GENE_OR_GENE_PRODUCT", 53, 54], ["7b", "GENE_OR_GENE_PRODUCT", 69, 71], ["type II FCoVs", "GENE_OR_GENE_PRODUCT", 75, 88], ["ORFs S, 3a, 3b, 3c, E, M, N, 7a and 7b", "DNA", 33, 71], ["type II FCoVs", "DNA", 75, 88], ["type II CCoV fc1", "PROTEIN", 139, 155], ["S3", "PROTEIN", 168, 170], ["type I FCoV C3663", "SPECIES", 117, 134], ["type II CCoV fc1", "SPECIES", 139, 155], ["Deduced amino acid sequences", "TEST", 0, 28], ["ORFs S", "TEST", 33, 39], ["E", "TEST", 53, 54], ["type II FCoVs", "PROBLEM", 75, 88], ["S3", "ANATOMY", 168, 170]]], ["Both M91-267 and KUK-H/L showed low identities with type I FCoV C3663 in ORFs S, 3a, 3b, 3c and E and high identities in ORFs N, 7a and 7b (Table S2 ).", [["M91-267", "GENE_OR_GENE_PRODUCT", 5, 12], ["M91", "PROTEIN", 5, 8], ["type I FCoV C3663", "DNA", 52, 69], ["ORFs", "DNA", 73, 77], ["ORFs N, 7a and 7b", "DNA", 121, 138], ["Table S2", "DNA", 140, 148], ["M91", "TEST", 5, 8], ["KUK", "TEST", 17, 20], ["low identities", "PROBLEM", 32, 46], ["type I FCoV", "PROBLEM", 52, 63], ["ORFs S", "TEST", 73, 79], ["E", "TEST", 96, 97], ["ORFs N", "TEST", 121, 127], ["high identities", "OBSERVATION", 102, 117]]], ["In contrast, the two strains showed high identities with type II CCoV fc1 in ORFs S, 3a, 3b, 3c and E and low identities in ORFs N, 7a and 7b (Table S3 ).", [["type II CCoV fc1", "DNA", 57, 73], ["ORFs", "DNA", 77, 81], ["ORFs N, 7a and 7b", "DNA", 124, 141], ["Table S3", "DNA", 143, 151], ["the two strains", "TEST", 13, 28], ["ORFs N", "TEST", 124, 130], ["high identities", "OBSERVATION", 36, 51], ["low identities", "OBSERVATION_MODIFIER", 106, 120]]], ["In ORF M, the identities among type I FCoV, type II FCoV and CCoV were neither high nor low (Table S2, S3) .", [["type I FCoV", "GENE_OR_GENE_PRODUCT", 31, 42], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 44, 56], ["CCoV", "GENE_OR_GENE_PRODUCT", 61, 65], ["ORF M", "DNA", 3, 8], ["type I FCoV", "PROTEIN", 31, 42], ["type II FCoV", "DNA", 44, 56], ["CCoV", "DNA", 61, 65], ["type I FCoV", "SPECIES", 31, 42], ["type II FCoV", "PROBLEM", 44, 56], ["CCoV", "TEST", 61, 65]]], ["Interestingly, comparison between Tokyo/cat/130627 and type I FCoV showed low identities in ORF S and high identities in ORFs 3a, 3c, E, M, N, 7a and 7b, while comparison with type II CCoV fc1 showed high identity only in ORF S and low identities in ORF 3a, 3c, E, M, N, 7a and 7b (Table S2, Nucleotide sequences of partial RdRp gene in ORF1b (394b) of 15 Japanese CoVs were determined and deduced amino acid sequences were compared (Tables S2, S3, S4 and Fig. 2A ).", [["amino acid", "CHEMICAL", 398, 408], ["amino acid", "CHEMICAL", 398, 408], ["Tokyo/cat/130627", "ORGANISM", 34, 50], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 55, 66], ["ORF S", "GENE_OR_GENE_PRODUCT", 92, 97], ["E", "GENE_OR_GENE_PRODUCT", 134, 135], ["7b", "GENE_OR_GENE_PRODUCT", 150, 152], ["type II CCoV fc1", "GENE_OR_GENE_PRODUCT", 176, 192], ["Table S2", "GENE_OR_GENE_PRODUCT", 282, 290], ["CoVs", "GENE_OR_GENE_PRODUCT", 365, 369], ["amino acid", "AMINO_ACID", 398, 408], ["Tokyo/cat/130627 and type I FCoV", "DNA", 34, 66], ["ORF S", "DNA", 92, 97], ["ORFs", "DNA", 121, 125], ["type II CCoV fc1", "DNA", 176, 192], ["ORF S", "DNA", 222, 227], ["ORF 3a, 3c, E, M, N, 7a and 7b", "DNA", 250, 280], ["Table S2", "DNA", 282, 290], ["Nucleotide sequences", "DNA", 292, 312], ["RdRp gene", "DNA", 324, 333], ["ORF1b", "DNA", 337, 342], ["Japanese CoVs", "DNA", 356, 369], ["S3", "PROTEIN", 445, 447], ["S4", "PROTEIN", 449, 451], ["Tokyo/cat/130627", "SPECIES", 34, 50], ["type I FCoV", "SPECIES", 55, 66], ["low identities in ORF S", "PROBLEM", 74, 97], ["type II CCoV fc1", "TEST", 176, 192], ["high identity", "PROBLEM", 200, 213], ["ORF S", "TEST", 222, 227], ["ORF", "TEST", 250, 253], ["3c", "TEST", 258, 260], ["E", "TEST", 262, 263], ["Table S2", "TEST", 282, 290], ["Nucleotide sequences", "TEST", 292, 312], ["partial RdRp gene", "PROBLEM", 316, 333], ["15 Japanese CoVs", "PROBLEM", 353, 369], ["amino acid sequences", "TEST", 398, 418], ["low identities", "OBSERVATION_MODIFIER", 74, 88], ["high identity", "OBSERVATION", 200, 213], ["partial RdRp", "OBSERVATION", 316, 328]]], ["In comparison with type I FCoVs, C3663, KUK-H/L and Tokyo/ cat/130627 showed higher identity in RdRp than M91-267 (Table S2) .", [["KUK-H", "GENE_OR_GENE_PRODUCT", 40, 45], ["RdRp", "PROTEIN", 96, 100], ["Tokyo/ cat/130627", "SPECIES", 52, 69], ["C3663", "TEST", 33, 38], ["KUK", "TEST", 40, 43], ["Tokyo/ cat", "TEST", 52, 62], ["higher identity in RdRp", "PROBLEM", 77, 100], ["M91", "TEST", 106, 109]]], ["On the other hand, the sequence of RdRp of M91-267 was more similar to that of type II CCoV fc1 than type I FCoV C3663 (Table S3 ).", [["M91-267", "CHEMICAL", 43, 50], ["RdRp", "PROTEIN", 35, 39], ["type II CCoV fc1", "PROTEIN", 79, 95], ["type I FCoV C3663", "PROTEIN", 101, 118], ["type I FCoV C3663", "SPECIES", 101, 118], ["RdRp of M91", "TEST", 35, 46]]], ["All CCoV strains possessed high homology with fc1 strain and M91-267, but showed low homology with KUK-H/L and Tokyo/cat/130627 (Table S4) .Comparison of 39-region among type II CCoVs, and type I and II FCoVsPhylogenetic analysis using partial RdRp genes showed that Japanese type II strains could be divided into two different groups; feline CoV and canine CoV ( Fig. 2A) .", [["M91-267", "CHEMICAL", 61, 68], ["fc1", "GENE_OR_GENE_PRODUCT", 46, 49], ["feline CoV", "ORGANISM", 336, 346], ["canine CoV", "ORGANISM", 351, 361], ["KUK", "PROTEIN", 99, 102], ["39-region", "DNA", 154, 163], ["type II CCoVs", "DNA", 170, 183], ["RdRp genes", "DNA", 244, 254], ["feline", "SPECIES", 336, 342], ["canine", "SPECIES", 351, 357], ["Tokyo/cat/130627", "SPECIES", 111, 127], ["Japanese type II", "SPECIES", 267, 283], ["feline CoV", "SPECIES", 336, 346], ["canine CoV", "SPECIES", 351, 361], ["All CCoV strains", "TEST", 0, 16], ["fc1 strain", "PROBLEM", 46, 56], ["M91", "TEST", 61, 64], ["KUK", "TEST", 99, 102], ["type II CCoVs", "PROBLEM", 170, 183], ["type I and II FCoVsPhylogenetic analysis", "PROBLEM", 189, 229], ["partial RdRp genes", "PROBLEM", 236, 254], ["Japanese type II strains", "PROBLEM", 267, 291], ["feline CoV", "TEST", 336, 346]]], ["KUK-H/L and Tokyo/ cat/130627 belonged to feline CoV group and M91-267 belonged to canine CoV group.", [["M91-267", "CHEMICAL", 63, 70], ["KUK", "GENE_OR_GENE_PRODUCT", 0, 3], ["Tokyo/ cat/130627", "ORGANISM", 12, 29], ["feline CoV", "ORGANISM", 42, 52], ["M91-267", "ORGANISM", 63, 70], ["canine CoV", "ORGANISM", 83, 93], ["feline CoV group", "SPECIES", 42, 58], ["canine CoV group", "SPECIES", 83, 99], ["Tokyo/ cat/130627", "SPECIES", 12, 29], ["feline CoV", "SPECIES", 42, 52], ["canine CoV", "SPECIES", 83, 93], ["KUK", "TEST", 0, 3], ["M91", "TEST", 63, 66]]], ["The other foreign type II FCoVs belonged to the type II CCoV group.Comparison of partial S genes among type II CCoVs and type I and II FCoVsNucleotide sequences of partial S genes (692b) of 15 Japanese CoVs were determined and deduced amino acid sequences were compared (Table S5 and Fig. 2B ).", [["amino acid", "CHEMICAL", 235, 245], ["amino acid", "CHEMICAL", 235, 245], ["type II CCoVs", "GENE_OR_GENE_PRODUCT", 103, 116], ["CoVs", "GENE_OR_GENE_PRODUCT", 202, 206], ["amino acid", "AMINO_ACID", 235, 245], ["foreign type II FCoVs", "PROTEIN", 10, 31], ["type II CCoV group", "PROTEIN", 48, 66], ["partial S genes", "DNA", 81, 96], ["type II CCoVs", "DNA", 103, 116], ["type I and II FCoVsNucleotide sequences", "DNA", 121, 160], ["S genes", "DNA", 172, 179], ["Japanese CoVs", "DNA", 193, 206], ["partial S genes", "PROBLEM", 81, 96], ["type II CCoVs", "PROBLEM", 103, 116], ["type I and II FCoVsNucleotide sequences of partial S genes", "PROBLEM", 121, 179], ["15 Japanese CoVs", "PROBLEM", 190, 206], ["amino acid sequences", "TEST", 235, 255], ["foreign type", "OBSERVATION", 10, 22]]], ["In comparison with type I FCoV C3663, all type II FCoVs showed low identity.", [["type II FCoVs", "PROTEIN", 42, 55], ["type I FCoV C3663", "SPECIES", 19, 36], ["low identity", "OBSERVATION", 63, 75]]], ["All CCoV strains possessed high homology with fc1 strain and type II FCoVs, but showed low homology with type I FCoV C3663 (Table S5) .Comparison of partial S genes among type II CCoVs and type I and II FCoVsPhylogenetic analysis using partial S genes showed that all type II FCoVs were more similar to type II CCoV than type I FCoV (Fig.2B) .", [["fc1", "GENE_OR_GENE_PRODUCT", 46, 49], ["type II CCoVs", "GENE_OR_GENE_PRODUCT", 171, 184], ["type II FCoVs", "GENE_OR_GENE_PRODUCT", 268, 281], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 321, 332], ["type II FCoVs", "PROTEIN", 61, 74], ["type I FCoV C3663", "PROTEIN", 105, 122], ["partial S genes", "DNA", 149, 164], ["S genes", "DNA", 244, 251], ["type II FCoVs", "DNA", 268, 281], ["type II CCoV", "PROTEIN", 303, 315], ["Fig.2B", "DNA", 334, 340], ["type I FCoV C3663", "SPECIES", 105, 122], ["type II CCoV", "SPECIES", 303, 315], ["type I FCoV", "SPECIES", 321, 332], ["All CCoV strains", "TEST", 0, 16], ["fc1 strain", "PROBLEM", 46, 56], ["type II FCoVs", "PROBLEM", 61, 74], ["type I FCoV", "PROBLEM", 105, 116], ["partial S genes", "PROBLEM", 149, 164], ["type II CCoVs", "PROBLEM", 171, 184], ["type I and II FCoVsPhylogenetic analysis", "PROBLEM", 189, 229], ["partial S genes", "PROBLEM", 236, 251], ["all type II FCoVs", "PROBLEM", 264, 281]]], ["Furthermore, Japanese type II FCoVs were more similar to Japanese type II CCoV than type II FCoVs and type II CCoVs from other countries.", [["Japanese type II FCoVs", "SPECIES", 13, 35], ["Japanese type II CCoV", "SPECIES", 57, 78], ["Japanese type II FCoVs", "PROBLEM", 13, 35], ["type II FCoVs", "PROBLEM", 84, 97], ["type II CCoVs", "PROBLEM", 102, 115]]], ["In addition, Japanese FCoVs belonged to different subgroups; KUK-H/L belongs to a cluster with fc1.", [["KUK", "PROTEIN", 61, 64], ["fc1", "DNA", 95, 98], ["Japanese FCoVs", "PROBLEM", 13, 27], ["KUK", "TEST", 61, 64]]], ["M91-267 belongs to the other cluster with fc76 and fc94-039.", [["M91-267", "CHEMICAL", 0, 7], ["fc76", "GENE_OR_GENE_PRODUCT", 42, 46], ["M91", "DNA", 0, 3], ["fc76", "DNA", 42, 46], ["fc94-039", "DNA", 51, 59], ["M91", "TEST", 0, 3], ["fc76", "TEST", 42, 46]]], ["Tokyo/cat/130627 belongs to the cluster with Taiwanese strain NTU156/P/2007 (Fig. 2B) .Comparison of N genes among type II CCoVs and type I and II FCoVsNucleotide sequences of N genes (1149b) of 15 Japanese CoVs were determined and deduced amino acid sequences were compared (Tables S2, S3, S6 and Fig. 2C ).", [["amino acid", "CHEMICAL", 240, 250], ["amino acid", "CHEMICAL", 240, 250], ["type II CCoVs", "GENE_OR_GENE_PRODUCT", 115, 128], ["CoVs", "GENE_OR_GENE_PRODUCT", 207, 211], ["amino acid", "AMINO_ACID", 240, 250], ["N genes", "DNA", 101, 108], ["type II CCoVs", "DNA", 115, 128], ["type I and II FCoVsNucleotide sequences", "DNA", 133, 172], ["N genes", "DNA", 176, 183], ["1149b", "DNA", 185, 190], ["Japanese CoVs", "DNA", 198, 211], ["S3", "PROTEIN", 287, 289], ["S6", "PROTEIN", 291, 293], ["Tokyo/cat/130627", "SPECIES", 0, 16], ["Taiwanese strain NTU156/P/2007 (Fig. 2B", "SPECIES", 45, 84], ["type II CCoVs", "PROBLEM", 115, 128], ["type I and II FCoVsNucleotide sequences", "TREATMENT", 133, 172], ["15 Japanese CoVs", "PROBLEM", 195, 211], ["amino acid sequences", "TEST", 240, 260]]], ["In comparison with type I FCoV C3663, all type II FCoVs showed higher identity than type II CCoV fc1 (Table S2 ).", [["type II FCoVs", "PROTEIN", 42, 55], ["type II CCoV fc1", "PROTEIN", 84, 100], ["type I FCoV C3663", "SPECIES", 19, 36], ["higher identity", "OBSERVATION", 63, 78]]], ["All CCoV strains possessed high homology with fc1 strain, but showed low homology with types I and II FCoV (Table S6 ).Comparison of N genes among type II CCoVs and type I and II FCoVsPhylogenetic analysis using N genes showed that FCoV strains and type II CCoV strains were genetically divided into different groups.", [["fc1", "GENE_OR_GENE_PRODUCT", 46, 49], ["type II CCoVs", "GENE_OR_GENE_PRODUCT", 147, 160], ["FCoV strains", "ORGANISM", 232, 244], ["type II CCoV strains", "ORGANISM", 249, 269], ["FCoV", "PROTEIN", 102, 106], ["S6", "PROTEIN", 114, 116], ["N genes", "DNA", 133, 140], ["N genes", "DNA", 212, 219], ["type II CCoV", "SPECIES", 249, 261], ["All CCoV strains", "TEST", 0, 16], ["fc1 strain", "PROBLEM", 46, 56], ["type II CCoVs", "PROBLEM", 147, 160], ["II FCoVsPhylogenetic analysis", "TEST", 176, 205], ["FCoV strains", "PROBLEM", 232, 244], ["type II CCoV strains", "PROBLEM", 249, 269], ["FCoV strains", "OBSERVATION", 232, 244]]], ["In the feline CoV group, Japanese type II FCoVs M91-267, KUK-H/L and Tokyo/cat/130627 belonged to different clusters (Fig. 2C) .", [["feline CoV", "ORGANISM", 7, 17], ["feline CoV group", "SPECIES", 7, 23], ["feline CoV", "SPECIES", 7, 17], ["Japanese type II FCoVs M91-267", "SPECIES", 25, 55], ["Tokyo/cat/130627", "SPECIES", 69, 85], ["M91", "TEST", 48, 51], ["KUK", "TEST", 57, 60], ["Tokyo/cat", "TEST", 69, 78], ["feline CoV", "OBSERVATION_MODIFIER", 7, 17]]], ["KUK-H/L was similar to Yayoi, M91-267 was similar to C3663, and Tokyo/cat/130627 was similar to Taiwanese strain NTU2/R/2003 (Fig. 2C) .", [["Yayoi, M91-267", "CHEMICAL", 23, 37], ["KUK-H/L", "GENE_OR_GENE_PRODUCT", 0, 7], ["M91-267", "ORGANISM", 30, 37], ["Tokyo/cat/130627", "ORGANISM", 64, 80], ["KUK", "PROTEIN", 0, 3], ["Tokyo/cat/130627", "SPECIES", 64, 80], ["Taiwanese strain NTU2/R/2003 (Fig. 2C", "SPECIES", 96, 133], ["KUK", "TEST", 0, 3], ["Yayoi", "TEST", 23, 28], ["M91", "TEST", 30, 33], ["Tokyo/cat", "TEST", 64, 73]]], ["Japanese CCoVs formed one cluster with Taiwanese strain NTU336/F/2008.Recombination sites of type II FCoVsSimplot analysis showed that the similarity of Tokyo/cat/ 130627 to CCoV fc1 changed at the 39-terminal region of the S gene, and those of M91-267 and KUK-H/L changed within the M gene (Fig. 3) .Recombination sites of type II FCoVsThe M genes were compared among types I and II FCoV and type II CCoV (Fig. 4A) .", [["CCoV fc1", "GENE_OR_GENE_PRODUCT", 174, 182], ["M91-267", "GENE_OR_GENE_PRODUCT", 245, 252], ["KUK-H", "GENE_OR_GENE_PRODUCT", 257, 262], ["type II FCoVs", "GENE_OR_GENE_PRODUCT", 324, 337], ["Tokyo/cat/ 130627", "DNA", 153, 170], ["CCoV fc1", "DNA", 174, 182], ["39-terminal region", "DNA", 198, 216], ["S gene", "DNA", 224, 230], ["M91", "DNA", 245, 248], ["M gene", "DNA", 284, 290], ["type II FCoVs", "PROTEIN", 324, 337], ["M genes", "DNA", 341, 348], ["Tokyo/cat/ 130627", "SPECIES", 153, 170], ["type II CCoV", "SPECIES", 393, 405], ["type II FCoVsSimplot analysis", "TEST", 93, 122], ["CCoV fc1", "TEST", 174, 182], ["M91", "TEST", 245, 248], ["KUK", "TEST", 257, 260], ["type II FCoVs", "PROBLEM", 324, 337], ["one cluster", "OBSERVATION_MODIFIER", 22, 33], ["terminal", "ANATOMY_MODIFIER", 201, 209], ["region", "ANATOMY_MODIFIER", 210, 216], ["type II", "OBSERVATION_MODIFIER", 324, 331], ["FCoVs", "OBSERVATION", 332, 337]]], ["The alignment showed that the 59terminal region of the M genes of M91-267 and KUK-H/L was similar to that of CCoV fc1, but the 39-terminal region was similar to type I FCoV C3663 (Fig. 4A) .", [["M91-267", "GENE_OR_GENE_PRODUCT", 66, 73], ["KUK-H/L", "GENE_OR_GENE_PRODUCT", 78, 85], ["CCoV fc1", "GENE_OR_GENE_PRODUCT", 109, 117], ["59terminal region", "DNA", 30, 47], ["M genes", "DNA", 55, 62], ["M91", "DNA", 66, 69], ["KUK-H/L", "DNA", 78, 85], ["CCoV fc1", "DNA", 109, 117], ["39-terminal region", "DNA", 127, 145], ["type I FCoV C3663", "SPECIES", 161, 178], ["The alignment", "TEST", 0, 13], ["M91", "TEST", 66, 69], ["KUK", "TEST", 78, 81]]], ["The M gene of Tokyo/cat/ 130627 was similar to type I FCoV C3663.", [["M gene", "DNA", 4, 10], ["Tokyo/cat/ 130627", "SPECIES", 14, 31], ["type I FCoV C3663", "SPECIES", 47, 64]]], ["Furthermore, the nucleotide sequences indicated that the recombination sites of these two viruses, M91-267 and KUK-H/L, were different.", [["nucleotide", "CHEMICAL", 17, 27], ["nucleotide", "CHEMICAL", 17, 27], ["M91-267", "ORGANISM", 99, 106], ["the nucleotide sequences", "TEST", 13, 37], ["M91", "TEST", 99, 102], ["KUK", "TEST", 111, 114], ["two", "OBSERVATION_MODIFIER", 86, 89], ["viruses", "OBSERVATION", 90, 97], ["different", "OBSERVATION_MODIFIER", 125, 134]]], ["Among these CoVs, two conserved regions were located at 133-177 and 325-366 in the M gene.", [["CoVs", "GENE_OR_GENE_PRODUCT", 12, 16], ["CoVs", "DNA", 12, 16], ["133-177 and 325-366", "DNA", 56, 75], ["M gene", "DNA", 83, 89], ["CoVs", "OBSERVATION", 12, 16]]], ["KUK-H/L was similar to type II CCoV upstream of the first conserved region (region 133-177), but was similar to type I FCoV downstream of the region.", [["KUK-H/L", "GENE_OR_GENE_PRODUCT", 0, 7], ["type II CCoV", "GENE_OR_GENE_PRODUCT", 23, 35], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 112, 123], ["KUK", "PROTEIN", 0, 3], ["H/L", "PROTEIN", 4, 7], ["type II CCoV upstream", "DNA", 23, 44], ["first conserved region", "DNA", 52, 74], ["region 133-177", "DNA", 76, 90], ["type I FCoV downstream", "DNA", 112, 134], ["type II CCoV", "SPECIES", 23, 35], ["KUK", "TEST", 0, 3], ["type II CCoV upstream", "PROBLEM", 23, 44], ["region", "ANATOMY_MODIFIER", 68, 74], ["FCoV", "OBSERVATION", 119, 123], ["region", "ANATOMY_MODIFIER", 142, 148]]], ["On the other hand, M91-267 was similar to type II CCoV upstream of the second conserved region (region 325-366), and was similar to type I FCoV downstream of the region.Recombination sites of type II FCoVsThe alignment data using type I FCoV C3663, type II FCoV M91-267, KUK-H/L and Tokyo/cat/130627, and type II CCoV fc1 showed that the recombination site of Tokyo/cat/130627 was in the 39-terminal of the S gene.", [["M91-267", "CHEMICAL", 19, 26], ["M91-267", "CHEMICAL", 19, 26], ["M91-267", "GENE_OR_GENE_PRODUCT", 19, 26], ["type II CCoV", "GENE_OR_GENE_PRODUCT", 42, 54], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 132, 143], ["type II FCoVs", "GENE_OR_GENE_PRODUCT", 192, 205], ["KUK-H", "GENE_OR_GENE_PRODUCT", 271, 276], ["type II CCoV fc1", "GENE_OR_GENE_PRODUCT", 305, 321], ["type II CCoV upstream", "DNA", 42, 63], ["region 325-366", "DNA", 96, 110], ["type I FCoV downstream", "DNA", 132, 154], ["type II FCoVs", "DNA", 192, 205], ["type II CCoV fc1", "DNA", 305, 321], ["recombination site", "DNA", 338, 356], ["Tokyo/cat/130627", "DNA", 360, 376], ["39-terminal", "DNA", 388, 399], ["S gene", "DNA", 407, 413], ["Tokyo/cat/130627", "SPECIES", 283, 299], ["Tokyo/cat/130627", "SPECIES", 360, 376], ["M91", "TEST", 19, 22], ["FCoV M91", "TEST", 257, 265], ["KUK", "TEST", 271, 274], ["Tokyo/cat", "TEST", 283, 292], ["type II CCoV fc1", "TEST", 305, 321], ["Tokyo/cat", "TEST", 360, 369], ["second", "ANATOMY_MODIFIER", 71, 77], ["region", "ANATOMY_MODIFIER", 88, 94], ["FCoV", "OBSERVATION", 139, 143], ["region", "ANATOMY_MODIFIER", 162, 168], ["type II", "OBSERVATION_MODIFIER", 192, 199]]], ["Among these FCoVs and CCoVs, region 4183-4202 of the S gene was completely conserved (Fig. 4B) .", [["FCoVs", "GENE_OR_GENE_PRODUCT", 12, 17], ["CCoVs", "GENE_OR_GENE_PRODUCT", 22, 27], ["FCoVs", "DNA", 12, 17], ["CCoVs", "DNA", 22, 27], ["region 4183-4202", "DNA", 29, 45], ["S gene", "DNA", 53, 59]]], ["Upstream of the conserved region, Tokyo/cat/130627 was more similar to type II CCoV fc1 than type I FCoV C3663, and downstream of the conserved region, Tokyo/cat/130627 was more similar to type I FCoV C3663 (Fig. 4B ).Cross-neutralization activity to CCoV by sera collected from cats infected with FCoVIn order to examine whether cats with VN antibody against type I FCoV can be infected with type II CCoV, cross-neutralizing activity of sera from cats experimentally infected with FCoVs was examined (Table 1) .", [["sera", "ANATOMY", 259, 263], ["sera", "ANATOMY", 438, 442], ["type II CCoV fc1", "GENE_OR_GENE_PRODUCT", 71, 87], ["type I FCoV C3663", "GENE_OR_GENE_PRODUCT", 93, 110], ["CCoV", "SIMPLE_CHEMICAL", 251, 255], ["sera", "ORGANISM_SUBSTANCE", 259, 263], ["cats", "ORGANISM", 279, 283], ["cats", "ORGANISM", 330, 334], ["VN antibody against type I FCoV", "GENE_OR_GENE_PRODUCT", 340, 371], ["type II CCoV", "ORGANISM", 393, 405], ["sera", "ORGANISM_SUBSTANCE", 438, 442], ["cats", "ORGANISM", 448, 452], ["FCoVs", "CANCER", 482, 487], ["Tokyo/cat/130627", "DNA", 34, 50], ["type II CCoV fc1", "DNA", 71, 87], ["type I FCoV C3663", "DNA", 93, 110], ["Tokyo/cat/130627", "DNA", 152, 168], ["CCoV", "PROTEIN", 251, 255], ["VN antibody", "PROTEIN", 340, 351], ["type I FCoV", "PROTEIN", 360, 371], ["cats", "SPECIES", 279, 283], ["cats", "SPECIES", 330, 334], ["cats", "SPECIES", 448, 452], ["Tokyo/cat/130627", "SPECIES", 34, 50], ["type II CCoV", "SPECIES", 71, 83], ["type I FCoV C3663", "SPECIES", 93, 110], ["Tokyo/cat/130627", "SPECIES", 152, 168], ["type I FCoV C3663", "SPECIES", 189, 206], ["CCoV", "SPECIES", 251, 255], ["type I FCoV", "SPECIES", 360, 371], ["type II CCoV", "SPECIES", 393, 405], ["sera", "TEST", 259, 263], ["FCoVIn order", "TREATMENT", 298, 310], ["VN antibody", "TEST", 340, 351], ["type I FCoV", "PROBLEM", 360, 371], ["type II CCoV", "PROBLEM", 393, 405], ["cross-neutralizing activity of sera from cats", "PROBLEM", 407, 452]]], ["Cat serum against type I FCoV C3663 was able to neutralize infection of type I FCoV strains C3663 and Yayoi (1:6400 and 1:2000, respectively), but not those of type II CCoV and type II FCoV (less than 1:10) (Table1).", [["serum", "ANATOMY", 4, 9], ["infection", "DISEASE", 59, 68], ["Cat", "ORGANISM", 0, 3], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["type I FCoV C3663", "GENE_OR_GENE_PRODUCT", 18, 35], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 177, 189], ["type II CCoV", "PROTEIN", 160, 172], ["type II FCoV", "PROTEIN", 177, 189], ["type I FCoV C3663", "SPECIES", 18, 35], ["type I FCoV strains C3663", "SPECIES", 72, 97], ["type II CCoV", "SPECIES", 160, 172], ["Cat serum", "TEST", 0, 9], ["type I FCoV", "PROBLEM", 18, 29], ["type I FCoV strains", "PROBLEM", 72, 91], ["Yayoi", "TEST", 102, 107], ["type II FCoV", "PROBLEM", 177, 189]]], ["On the other hand, cat serum against type II FCoV M91-267 was able toDiscussionType II FCoV emerged as a result of recombination events between type I FCoV and type II CCoV [44] , [45] .", [["serum", "ANATOMY", 23, 28], ["M91-267", "CHEMICAL", 50, 57], ["cat", "ORGANISM", 19, 22], ["serum", "ORGANISM_SUBSTANCE", 23, 28], ["Type II FCoV", "PROTEIN", 79, 91], ["type II FCoV M91-267", "SPECIES", 37, 57], ["type I FCoV", "SPECIES", 144, 155], ["cat serum", "TEST", 19, 28], ["type II FCoV M91", "TEST", 37, 53], ["Type II FCoV", "PROBLEM", 79, 91], ["recombination events", "PROBLEM", 115, 135]]], ["Recently, one additional full genome sequence of type II FCoV NTU156/P/ 2007 was determined, and this facilitated understanding of the mechanisms responsible for emergence of type II FCoV [46] .", [["type II FCoV NTU156/P/ 2007", "SPECIES", 49, 76]]], ["The prevalence of type II FCoV in the cat population is lower than that of type I, but the reasons for this remain uncertain [12] , [47] [48] [49] [50] [51] .", [["type II FCoV", "DISEASE", 18, 30], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 18, 30], ["cat", "ORGANISM", 38, 41], ["[47] [48] [49] [50] [51]", "SIMPLE_CHEMICAL", 132, 156], ["type II FCoV", "PROTEIN", 18, 30], ["type II FCoV", "PROBLEM", 18, 30], ["type II", "OBSERVATION_MODIFIER", 18, 25], ["FCoV", "OBSERVATION", 26, 30], ["lower", "OBSERVATION_MODIFIER", 56, 61]]], ["In this study, numerous FCoV and CCoV isolates from Japan were genetically characterized, and the emergence of type II was discussed.DiscussionOur phylogenetic and sequence analysis clearly indicated that type II FCoVs emerged by different recombination events between type I FCoV and type II CCoV.", [["FCoV", "GENE_OR_GENE_PRODUCT", 24, 28], ["CCoV isolates", "CELL", 33, 46], ["type II FCoVs", "GENE_OR_GENE_PRODUCT", 205, 218], ["type II CCoV", "GENE_OR_GENE_PRODUCT", 285, 297], ["type II FCoVs", "PROTEIN", 205, 218], ["FCoV", "SPECIES", 24, 28], ["CCoV", "SPECIES", 33, 37], ["type I FCoV", "SPECIES", 269, 280], ["type II CCoV", "SPECIES", 285, 297], ["this study", "TEST", 3, 13], ["numerous FCoV and CCoV isolates", "PROBLEM", 15, 46], ["phylogenetic and sequence analysis", "TEST", 147, 181], ["type II FCoVs", "PROBLEM", 205, 218], ["different recombination events", "PROBLEM", 230, 260], ["type I FCoV", "PROBLEM", 269, 280], ["type II CCoV", "PROBLEM", 285, 297], ["numerous", "OBSERVATION_MODIFIER", 15, 23], ["FCoV", "OBSERVATION", 24, 28]]], ["In addition, other type II FCoVs isolated from the USA (79-1683 and 79-1146) and Chinese Taipei (NTU156/P/2007) also showed different origins [45] , [46] .", [["type II FCoVs", "GENE_OR_GENE_PRODUCT", 19, 32], ["type II FCoVs", "PROTEIN", 19, 32], ["Chinese Taipei (NTU156/P/2007)", "SPECIES", 81, 111], ["the USA", "TEST", 47, 54]]], ["These results indicate that type II FCoV independently emerged in different cats and did not spread very easily.", [["type II FCoV", "GENE_OR_GENE_PRODUCT", 28, 40], ["cats", "ORGANISM", 76, 80], ["type II FCoV", "PROTEIN", 28, 40], ["type II FCoV", "PROBLEM", 28, 40]]], ["Our previous study also showed that many cats possess VN antibody to type I FCoV, but few cats in Japan possess VN antibody against type II FCoV [12] , supporting the notion that type II FCoV does not readily spread among the cat population.", [["cats", "ORGANISM", 41, 45], ["VN antibody", "GENE_OR_GENE_PRODUCT", 54, 65], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 69, 80], ["cats", "ORGANISM", 90, 94], ["VN antibody", "GENE_OR_GENE_PRODUCT", 112, 123], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 132, 144], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 179, 191], ["cat", "ORGANISM", 226, 229], ["VN antibody", "PROTEIN", 54, 65], ["VN antibody", "PROTEIN", 112, 123], ["type II FCoV", "PROTEIN", 179, 191], ["cats", "SPECIES", 41, 45], ["cats", "SPECIES", 90, 94], ["type I FCoV", "SPECIES", 69, 80], ["Our previous study", "TEST", 0, 18], ["type I FCoV", "PROBLEM", 69, 80], ["VN antibody", "TEST", 112, 123], ["type II FCoV", "PROBLEM", 132, 144], ["type II FCoV", "PROBLEM", 179, 191], ["FCoV", "OBSERVATION", 187, 191]]], ["The reasons why type II FCoV is unable to spread among the cat population are unclear.DiscussionTwo of three stains of Japanese type II FCoV, M91-267 and Tokyo/cat/130627, possessed the truncated ORF 3c gene (Fig. 1 ).", [["type II FCoV", "GENE_OR_GENE_PRODUCT", 16, 28], ["cat", "ORGANISM", 59, 62], ["ORF 3c", "GENE_OR_GENE_PRODUCT", 196, 202], ["type II FCoV", "PROTEIN", 16, 28], ["truncated ORF 3c gene", "DNA", 186, 207], ["cat", "SPECIES", 59, 62], ["Japanese type II FCoV, M91-267", "SPECIES", 119, 149], ["Tokyo/cat/130627", "SPECIES", 154, 170], ["type II FCoV", "PROBLEM", 16, 28], ["M91", "TEST", 142, 145], ["FCoV", "OBSERVATION", 24, 28]]], ["An intact 3c gene is apparently essential for efficient replication of FCoV in the intestinal tract, resulting in the secretion of FCoV from feces and transmission of FCoV among cat population [55] , [56] .", [["intestinal tract", "ANATOMY", 83, 99], ["feces", "ANATOMY", 141, 146], ["FCoV", "GENE_OR_GENE_PRODUCT", 71, 75], ["intestinal tract", "ORGAN", 83, 99], ["FCoV", "GENE_OR_GENE_PRODUCT", 131, 135], ["feces", "ORGANISM_SUBSTANCE", 141, 146], ["FCoV", "GENE_OR_GENE_PRODUCT", 167, 171], ["cat", "ORGANISM", 178, 181], ["intact 3c gene", "DNA", 3, 17], ["FCoV", "PROTEIN", 71, 75], ["FCoV", "PROTEIN", 131, 135], ["FCoV in the intestinal tract", "PROBLEM", 71, 99], ["the secretion of FCoV", "PROBLEM", 114, 135], ["intact", "OBSERVATION", 3, 9], ["FCoV", "OBSERVATION", 71, 75], ["intestinal tract", "ANATOMY", 83, 99]]], ["On the other hand, many FIPV possessed truncated 3c gene and cats with FIP did not excrete virus in feces [57] [58] [59] .", [["FIPV", "GENE_OR_GENE_PRODUCT", 24, 28], ["truncated 3c", "GENE_OR_GENE_PRODUCT", 39, 51], ["cats", "ORGANISM", 61, 65], ["FIPV", "DNA", 24, 28], ["truncated 3c gene", "DNA", 39, 56], ["many FIPV", "TREATMENT", 19, 28]]], ["Furthermore, one outbreak of type II FIPV with intact ORF 3c gene occurred in Taiwan.", [["type II FIPV", "GENE_OR_GENE_PRODUCT", 29, 41], ["ORF 3c", "GENE_OR_GENE_PRODUCT", 54, 60], ["type II FIPV", "DNA", 29, 41], ["ORF 3c gene", "DNA", 54, 65], ["type II FIPV", "SPECIES", 29, 41], ["type II FIPV", "PROBLEM", 29, 41], ["outbreak", "OBSERVATION_MODIFIER", 17, 25], ["type II", "OBSERVATION_MODIFIER", 29, 36], ["FIPV", "OBSERVATION", 37, 41], ["ORF 3c", "OBSERVATION", 54, 60]]], ["In early stages of the outbreak, the type II FIPV possessed intact 3c gene, but lost it in later stages [60] .", [["type II FIPV", "GENE_OR_GENE_PRODUCT", 37, 49], ["intact 3c", "GENE_OR_GENE_PRODUCT", 60, 69], ["type II FIPV", "DNA", 37, 49], ["intact 3c gene", "DNA", 60, 74], ["the outbreak", "PROBLEM", 19, 31], ["the type II FIPV", "TREATMENT", 33, 49], ["early stages", "OBSERVATION_MODIFIER", 3, 15]]], ["Therefore, these type II FCoVs with truncated 3c gene, M91-267 and Tokyo/cat/130627, might not spread well among cats.DiscussionIt is interesting that all FCoVs, both types I and II, possessed the 59-and 39-termini of the FCoV genome, but not CCoV.", [["type II FCoVs", "GENE_OR_GENE_PRODUCT", 17, 30], ["truncated 3c", "GENE_OR_GENE_PRODUCT", 36, 48], ["M91-267", "GENE_OR_GENE_PRODUCT", 55, 62], ["cats", "ORGANISM", 113, 117], ["FCoVs", "GENE_OR_GENE_PRODUCT", 155, 160], ["FCoV", "GENE_OR_GENE_PRODUCT", 222, 226], ["type II FCoVs", "PROTEIN", 17, 30], ["truncated 3c gene", "DNA", 36, 53], ["FCoVs", "DNA", 155, 160], ["59-and 39-termini", "DNA", 197, 214], ["FCoV genome", "DNA", 222, 233], ["CCoV", "PROTEIN", 243, 247], ["cats", "SPECIES", 113, 117], ["Tokyo/cat/130627", "SPECIES", 67, 83], ["M91", "TEST", 55, 58], ["FCoV genome", "OBSERVATION", 222, 233]]], ["These regions may be essential for growth of FCoV in cats and double recombination may be required to maintain both the 59-and 39termini of FCoV.", [["FCoV", "GENE_OR_GENE_PRODUCT", 45, 49], ["cats", "ORGANISM", 53, 57], ["FCoV", "GENE_OR_GENE_PRODUCT", 140, 144], ["FCoV", "PROTEIN", 45, 49], ["FCoV", "PROTEIN", 140, 144], ["growth of FCoV in cats", "PROBLEM", 35, 57], ["double recombination", "TREATMENT", 62, 82], ["growth", "OBSERVATION_MODIFIER", 35, 41], ["FCoV", "OBSERVATION", 45, 49]]], ["Type II FCoVs possessed two types of RdRp element derived from type I FCoV or type II CCoV ( Fig. 2A) , suggesting both types of RdRp were able to function during replication and transcription in cat body.", [["body", "ANATOMY", 200, 204], ["Type II FCoVs", "GENE_OR_GENE_PRODUCT", 0, 13], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 63, 74], ["type II CCoV ( Fig. 2A", "GENE_OR_GENE_PRODUCT", 78, 100], ["RdRp", "GENE_OR_GENE_PRODUCT", 129, 133], ["cat", "ORGANISM", 196, 199], ["body", "ORGANISM_SUBDIVISION", 200, 204], ["Type II FCoVs", "PROTEIN", 0, 13], ["RdRp element", "DNA", 37, 49], ["type I FCoV", "PROTEIN", 63, 74], ["type II CCoV", "PROTEIN", 78, 90], ["RdRp", "PROTEIN", 129, 133], ["type I FCoV", "SPECIES", 63, 74], ["Type II FCoVs", "PROBLEM", 0, 13], ["RdRp element", "PROBLEM", 37, 49], ["type I FCoV", "PROBLEM", 63, 74], ["type II CCoV", "PROBLEM", 78, 90], ["RdRp", "PROBLEM", 129, 133], ["transcription in cat body", "TREATMENT", 179, 204], ["RdRp element", "OBSERVATION", 37, 49]]], ["Furthermore, the region upstream of RdRp might be essential for FCoV infection in cats.", [["infection", "DISEASE", 69, 78], ["RdRp", "GENE_OR_GENE_PRODUCT", 36, 40], ["FCoV", "GENE_OR_GENE_PRODUCT", 64, 68], ["cats", "ORGANISM", 82, 86], ["RdRp", "PROTEIN", 36, 40], ["cats", "SPECIES", 82, 86], ["FCoV", "SPECIES", 64, 68], ["RdRp", "PROBLEM", 36, 40], ["FCoV infection in cats", "PROBLEM", 64, 86], ["RdRp", "OBSERVATION", 36, 40], ["might be essential for", "UNCERTAINTY", 41, 63], ["FCoV", "OBSERVATION_MODIFIER", 64, 68], ["infection", "OBSERVATION", 69, 78]]], ["In addition, it has been reported that N protein is important for viral particle production [52] , and the N gene is conserved among FCoVs.", [["FCoVs", "PATHOLOGICAL_FORMATION", 133, 138], ["N protein", "PROTEIN", 39, 48], ["N gene", "DNA", 107, 113], ["FCoVs", "DNA", 133, 138], ["viral particle production", "PROBLEM", 66, 91]]], ["Therefore, the N protein of FCoV, but not CCoV, may be essential for replication of FCoV in cats.", [["FCoV", "GENE_OR_GENE_PRODUCT", 28, 32], ["CCoV", "GENE_OR_GENE_PRODUCT", 42, 46], ["FCoV", "GENE_OR_GENE_PRODUCT", 84, 88], ["cats", "ORGANISM", 92, 96], ["N protein", "PROTEIN", 15, 24], ["FCoV", "PROTEIN", 28, 32], ["CCoV", "PROTEIN", 42, 46], ["FCoV", "PROTEIN", 84, 88], ["cats", "SPECIES", 92, 96], ["FCoV", "SPECIES", 84, 88], ["the N protein of FCoV", "TREATMENT", 11, 32], ["FCoV", "OBSERVATION", 84, 88]]], ["Interestingly, simplot analysis showed four other candidate recombination sites, one in the 3c gene, two in the N gene and one in the 7a gene, which showed high identity between CCoV and type I FCoV (Fig. 3 ).", [["7a", "GENE_OR_GENE_PRODUCT", 134, 136], ["candidate recombination sites", "DNA", 50, 79], ["3c gene", "DNA", 92, 99], ["N gene", "DNA", 112, 118], ["7a gene", "DNA", 134, 141], ["CCoV", "DNA", 178, 182], ["type I FCoV", "SPECIES", 187, 198], ["simplot analysis", "TEST", 15, 31], ["high identity", "OBSERVATION", 156, 169]]], ["If the M or N genes of type I FCoV are not necessary for growth of FCoV in cats, other recombinant type II FCoVs using these possible recombination sites must occur.", [["type I FCoV", "GENE_OR_GENE_PRODUCT", 23, 34], ["FCoV", "GENE_OR_GENE_PRODUCT", 67, 71], ["cats", "ORGANISM", 75, 79], ["recombinant type II FCoVs", "ORGANISM", 87, 112], ["M or N genes", "DNA", 7, 19], ["type I FCoV", "DNA", 23, 34], ["FCoV", "PROTEIN", 67, 71], ["recombinant type II FCoVs", "PROTEIN", 87, 112], ["cats", "SPECIES", 75, 79], ["FCoV", "SPECIES", 67, 71], ["type I FCoV", "PROBLEM", 23, 34], ["growth of FCoV in cats", "PROBLEM", 57, 79], ["other recombinant type II FCoVs", "TREATMENT", 81, 112], ["recombination sites", "PROBLEM", 134, 153]]], ["Further analysis of type II FCoV is necessary to clarify the recombination events of CoV in cats.DiscussionFour full genome sequences of type II FCoVs (79-1146, 79-1683, DF-2 and NTU156/P/2007) are deposited in GenBank.", [["type II FCoV", "GENE_OR_GENE_PRODUCT", 20, 32], ["CoV", "ORGANISM", 85, 88], ["cats", "ORGANISM", 92, 96], ["type II FCoV", "PROTEIN", 20, 32], ["cats", "SPECIES", 92, 96], ["Further analysis", "TEST", 0, 16], ["type II FCoV", "PROBLEM", 20, 32], ["CoV in cats", "PROBLEM", 85, 96], ["DF", "TEST", 170, 172]]], ["We also reported one-third of the full genome of three type II FCoV strains (M91-267, KUK-H/L and Tokyo/cat/130627) and one type II CCoV fc1.", [["type II CCoV fc1", "DNA", 124, 140], ["Tokyo/cat/130627", "SPECIES", 98, 114], ["three type II FCoV strains", "PROBLEM", 49, 75], ["M91", "TEST", 77, 80], ["KUK", "TEST", 86, 89], ["FCoV strains", "OBSERVATION", 63, 75]]], ["Six of seven type II FCoV strains emerged by recombination events at the E or M gene.", [["FCoV", "GENE_OR_GENE_PRODUCT", 21, 25], ["E or M gene", "DNA", 73, 84], ["seven type II FCoV strains", "PROBLEM", 7, 33], ["type II", "OBSERVATION_MODIFIER", 13, 20], ["FCoV strains", "OBSERVATION", 21, 33]]], ["However, the recombination event of Tokyo/cat/130627 occurred at the 39terminal of the S gene.", [["Tokyo", "ORGANISM", 36, 41], ["Tokyo/cat/130627", "DNA", 36, 52], ["S gene", "DNA", 87, 93], ["Tokyo/cat/130627", "SPECIES", 36, 52]]], ["The nucleotide sequences indicated that M91-267, KUK-H/L and Tokyo/cat/130627 originated from type I FCoV strains similar to C3663, Yayoi and NTU2/R/2003, respectively, and that the central region, including the S gene, was acquired from type II CCoV strains similar to fc94-039, fc1 and fc00-089, respectively.", [["nucleotide", "CHEMICAL", 4, 14], ["fc94-039", "GENE_OR_GENE_PRODUCT", 270, 278], ["fc1", "GENE_OR_GENE_PRODUCT", 280, 283], ["S gene", "DNA", 212, 218], ["fc94", "DNA", 270, 274], ["fc1", "DNA", 280, 283], ["fc00", "DNA", 288, 292], ["Tokyo/cat/130627", "SPECIES", 61, 77], ["type I FCoV", "SPECIES", 94, 105], ["NTU2/R/2003", "SPECIES", 142, 153], ["The nucleotide sequences", "TEST", 0, 24], ["M91", "TEST", 40, 43], ["KUK", "TEST", 49, 52], ["type I FCoV strains", "PROBLEM", 94, 113], ["Yayoi", "TEST", 132, 137], ["type II CCoV strains", "PROBLEM", 238, 258], ["fc94", "TEST", 270, 274], ["fc1", "TEST", 280, 283], ["fc00", "TEST", 288, 292], ["central", "ANATOMY_MODIFIER", 182, 189]]], ["In addition, the recombination sites were clearly different ( Fig.3 and 4A, B) .", [["recombination sites", "DNA", 17, 36], ["the recombination sites", "PROBLEM", 13, 36]]], ["These results indicate that the recombination events between type I FCoV and type II CCoV occurred independently.", [["type I FCoV", "GENE_OR_GENE_PRODUCT", 61, 72], ["type II CCoV", "GENE_OR_GENE_PRODUCT", 77, 89], ["type I FCoV", "PROTEIN", 61, 72], ["type II CCoV", "PROTEIN", 77, 89], ["the recombination events", "PROBLEM", 28, 52], ["type I FCoV", "PROBLEM", 61, 72], ["type II CCoV", "PROBLEM", 77, 89]]], ["In addition, original viruses of foreign type II FCoVs, 79-1146, 79-1683 and NTU156/P/2007 differed from those of these three Japanese type II FCoVs, indicating that the recombination events occurred among cat populations all over the world.DiscussionSera from cats experimentally inoculated with type I FCoV C3663 could not neutralize type II CCoV infection (Table 1) , thus suggesting that the cat infected with type I FCoV could not prevent type II FCoV infection.", [["C3663", "CHEMICAL", 309, 314], ["infection", "DISEASE", 349, 358], ["FCoV", "CHEMICAL", 421, 425], ["type II FCoV infection", "DISEASE", 444, 466], ["foreign type II FCoVs", "ORGANISM", 33, 54], ["cats", "ORGANISM", 261, 265], ["type II CCoV", "GENE_OR_GENE_PRODUCT", 336, 348], ["cat", "ORGANISM", 396, 399], ["type I FCoV", "ORGANISM", 414, 425], ["cats", "SPECIES", 261, 265], ["Japanese type II FCoVs", "SPECIES", 126, 148], ["type I FCoV C3663", "SPECIES", 297, 314], ["type I FCoV", "SPECIES", 414, 425], ["FCoV", "SPECIES", 452, 456], ["NTU", "TEST", 77, 80], ["the recombination events", "PROBLEM", 166, 190], ["type II CCoV infection", "PROBLEM", 336, 358], ["the cat infected", "PROBLEM", 392, 408], ["type I FCoV", "PROBLEM", 414, 425], ["type II FCoV infection", "PROBLEM", 444, 466], ["viruses", "OBSERVATION", 22, 29], ["foreign type", "OBSERVATION", 33, 45], ["infection", "OBSERVATION", 349, 358], ["FCoV", "OBSERVATION_MODIFIER", 452, 456], ["infection", "OBSERVATION", 457, 466]]], ["On the other hand, the cat infected with type II FCoV could neutralize type I FCoV infection (Table 1 ).", [["type II FCoV", "CHEMICAL", 41, 53], ["type I FCoV infection", "DISEASE", 71, 92], ["cat", "ORGANISM", 23, 26], ["type II FCoV", "ORGANISM", 41, 53], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 71, 82], ["type II FCoV", "PROTEIN", 41, 53], ["type II FCoV", "SPECIES", 41, 53], ["type I FCoV", "SPECIES", 71, 82], ["type II FCoV", "PROBLEM", 41, 53], ["type I FCoV infection", "PROBLEM", 71, 92], ["FCoV", "OBSERVATION_MODIFIER", 78, 82], ["infection", "OBSERVATION", 83, 92]]], ["In addition, many sera from type II FCoV-infected cats in the outbreak could cross-neutralize type I FCoV infection, and those from type I FCoV-infected cats in the field could not crossneutralize type II FCoV infection (our unpublished data).", [["sera", "ANATOMY", 18, 22], ["infection", "DISEASE", 106, 115], ["infection", "DISEASE", 210, 219], ["sera", "ORGANISM_SUBSTANCE", 18, 22], ["type II FCoV", "ORGANISM", 28, 40], ["cats", "ORGANISM", 50, 54], ["FCoV", "GENE_OR_GENE_PRODUCT", 101, 105], ["type I FCoV", "ORGANISM", 132, 143], ["cats", "ORGANISM", 153, 157], ["cats", "SPECIES", 50, 54], ["cats", "SPECIES", 153, 157], ["type I FCoV", "SPECIES", 94, 105], ["type II FCoV", "PROBLEM", 28, 40], ["infected cats", "PROBLEM", 41, 54], ["type I FCoV infection", "PROBLEM", 94, 115], ["type I FCoV", "PROBLEM", 132, 143], ["infected cats", "PROBLEM", 144, 157], ["type II FCoV infection", "PROBLEM", 197, 219], ["infected cats", "OBSERVATION", 41, 54], ["FCoV", "OBSERVATION_MODIFIER", 101, 105], ["infection", "OBSERVATION", 106, 115], ["infected", "OBSERVATION", 144, 152], ["FCoV", "OBSERVATION_MODIFIER", 205, 209], ["infection", "OBSERVATION", 210, 219]]], ["These results suggest that the cross-reactivity to type I FCoV in type II FCoV-infected cats might be induced by viral proteins other than S protein.", [["type I FCoV", "GENE_OR_GENE_PRODUCT", 51, 62], ["type II FCoV", "ORGANISM", 66, 78], ["cats", "ORGANISM", 88, 92], ["S protein", "GENE_OR_GENE_PRODUCT", 139, 148], ["type I FCoV", "PROTEIN", 51, 62], ["viral proteins", "PROTEIN", 113, 127], ["S protein", "PROTEIN", 139, 148], ["cats", "SPECIES", 88, 92], ["type I FCoV", "SPECIES", 51, 62], ["the cross-reactivity", "PROBLEM", 27, 47], ["type I FCoV", "PROBLEM", 51, 62], ["type II FCoV", "PROBLEM", 66, 78], ["infected cats", "PROBLEM", 79, 92], ["viral proteins", "TEST", 113, 127], ["infected", "OBSERVATION", 79, 87]]], ["Further analysis will be required to clarify the cross VN activity in type II FCoV-infected cats.DiscussionType II CCoV was able to use ''feline'' aminopeptidase N as a receptor to infect cats [53] , [54] and type I FCoV-infected cats did not possess VN antibody against type II CCoV infection ( Table 1) , indicating that cats infected with type I FCoV could be superinfected with type II CCoV from dogs.", [["infection", "DISEASE", 284, 293], ["type I FCoV", "DISEASE", 342, 353], ["VN", "GENE_OR_GENE_PRODUCT", 55, 57], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 70, 82], ["cats", "ORGANISM", 92, 96], ["feline", "ORGANISM", 138, 144], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 147, 163], ["cats", "ORGANISM", 188, 192], ["[54]", "ORGANISM", 200, 204], ["type I FCoV", "ORGANISM", 209, 220], ["cats", "ORGANISM", 230, 234], ["VN antibody", "GENE_OR_GENE_PRODUCT", 251, 262], ["type II CCoV", "GENE_OR_GENE_PRODUCT", 271, 283], ["cats", "ORGANISM", 323, 327], ["type I FCoV", "ORGANISM", 342, 353], ["dogs", "ORGANISM", 400, 404], ["VN", "PROTEIN", 55, 57], ["Type II CCoV", "PROTEIN", 107, 119], ["feline'' aminopeptidase N", "PROTEIN", 138, 163], ["VN antibody", "PROTEIN", 251, 262], ["cats", "SPECIES", 92, 96], ["cats", "SPECIES", 188, 192], ["cats", "SPECIES", 230, 234], ["cats", "SPECIES", 323, 327], ["dogs", "SPECIES", 400, 404], ["type II CCoV", "SPECIES", 271, 283], ["type I FCoV", "SPECIES", 342, 353], ["type II CCoV", "SPECIES", 382, 394], ["Further analysis", "TEST", 0, 16], ["Type II CCoV", "PROBLEM", 107, 119], ["''feline'' aminopeptidase N", "TREATMENT", 136, 163], ["type I FCoV", "PROBLEM", 209, 220], ["infected cats", "PROBLEM", 221, 234], ["VN antibody", "TEST", 251, 262], ["type II CCoV infection", "PROBLEM", 271, 293], ["type I FCoV", "PROBLEM", 342, 353], ["infected cats", "OBSERVATION", 83, 96], ["infection", "OBSERVATION", 284, 293]]], ["Our hypothesis on the mechanism of emergence of type II FCoV is shown in Fig. 5 .", [["type II FCoV", "GENE_OR_GENE_PRODUCT", 48, 60], ["type II FCoV", "PROTEIN", 48, 60], ["type II FCoV", "PROBLEM", 48, 60]]], ["Cats infected with type I FCoV were unable to produce VN antibody against type II CCoV.", [["VN antibody", "GENE_OR_GENE_PRODUCT", 54, 65], ["type II CCoV", "GENE_OR_GENE_PRODUCT", 74, 86], ["VN antibody", "PROTEIN", 54, 65], ["type II CCoV", "PROTEIN", 74, 86], ["type I FCoV", "SPECIES", 19, 30], ["type II CCoV", "SPECIES", 74, 86], ["type I FCoV", "PROBLEM", 19, 30], ["VN antibody", "TEST", 54, 65], ["type II CCoV", "PROBLEM", 74, 86]]], ["Hence, cats had the possibility of superinfection with type II CCoV.", [["superinfection", "DISEASE", 35, 49], ["cats", "ORGANISM", 7, 11], ["type II CCoV", "SPECIES", 55, 67], ["superinfection", "PROBLEM", 35, 49], ["type II CCoV", "PROBLEM", 55, 67], ["superinfection", "OBSERVATION", 35, 49]]], ["The recombination event between type I FCoV and type II CCoV occurred inside the cat body, leading to emergence of type II FCoV.", [["cat body", "ANATOMY", 81, 89], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 32, 43], ["type II CCoV", "GENE_OR_GENE_PRODUCT", 48, 60], ["cat", "ORGANISM", 81, 84], ["body", "ORGANISM_SUBDIVISION", 85, 89], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 115, 127], ["type II CCoV", "DNA", 48, 60], ["type I FCoV", "SPECIES", 32, 43], ["The recombination event", "PROBLEM", 0, 23], ["type I FCoV", "PROBLEM", 32, 43], ["type II CCoV", "PROBLEM", 48, 60], ["cat body", "OBSERVATION", 81, 89], ["FCoV", "OBSERVATION", 123, 127]]], ["CoVs, such as SARS-CoV, tend to change their host range by mutation and/or recombination [61] .", [["CoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 14, 22], ["CoVs", "PROTEIN", 0, 4], ["SARS-CoV", "SPECIES", 14, 22], ["CoVs", "PROBLEM", 0, 4], ["SARS", "PROBLEM", 14, 18]]], ["Therefore, investigations into homologous recombination of CoVs may help to clarify the mechanisms responsible for changes in host range.", [["CoVs", "GENE_OR_GENE_PRODUCT", 59, 63], ["CoVs", "DNA", 59, 63], ["CoVs", "PROBLEM", 59, 63]]]], "PMC7119663": [["IntroductionInfectious bronchitis (IB) is an acute and highly contagious respiratory disease of chickens.", [["respiratory", "ANATOMY", 73, 84], ["IntroductionInfectious bronchitis", "DISEASE", 0, 33], ["respiratory disease", "DISEASE", 73, 92], ["chickens", "ORGANISM", 96, 104], ["chickens", "SPECIES", 96, 104], ["chickens", "SPECIES", 96, 104], ["IntroductionInfectious bronchitis (IB)", "PROBLEM", 0, 38], ["an acute and highly contagious respiratory disease of chickens", "PROBLEM", 42, 104], ["bronchitis", "OBSERVATION", 23, 33], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["highly", "OBSERVATION_MODIFIER", 55, 61], ["contagious", "OBSERVATION_MODIFIER", 62, 72], ["respiratory disease", "OBSERVATION", 73, 92]]], ["It is still a major health problem in the chicken industry in the world.", [["chicken", "ORGANISM", 42, 49], ["chicken", "SPECIES", 42, 49], ["chicken", "SPECIES", 42, 49], ["major", "OBSERVATION_MODIFIER", 14, 19]]], ["Vaccination to control IB has been practiced for over half a century (Bijlenga et al., 2004, Cavanagh and Naqi, 2003, Cavanagh, 2003).", [["Vaccination", "TREATMENT", 0, 11]]], ["Such conventional vaccines, although generally effective, do have some disadvantages.", [["Such conventional vaccines", "TREATMENT", 0, 26]]], ["Attenuated vaccines, which generally induce long-lasting immunity, have a risk of insufficient attenuation and/or genetic instability (Cook et al., 1986).", [["Attenuated vaccines", "TREATMENT", 0, 19], ["insufficient attenuation", "PROBLEM", 82, 106], ["genetic instability", "PROBLEM", 114, 133]]], ["The limitations of inactivated vaccines include high cost for manufacturing and lack of long-term immunity.", [["inactivated vaccines", "TREATMENT", 19, 39], ["manufacturing", "TREATMENT", 62, 75], ["long-term immunity", "TREATMENT", 88, 106], ["long-term immunity", "OBSERVATION_MODIFIER", 88, 106]]], ["Therefore a new generation of IB vaccines is called for.IntroductionInfectious bronchitis virus (IBV) is an enveloped coronavirus that contains an unsegmented, single-stranded, positive-sense RNA genome.", [["IntroductionInfectious bronchitis virus", "DISEASE", 56, 95], ["IntroductionInfectious bronchitis virus", "ORGANISM", 56, 95], ["IBV", "ORGANISM", 97, 100], ["coronavirus", "ORGANISM", 118, 129], ["unsegmented, single-stranded, positive-sense RNA genome", "DNA", 147, 202], ["IntroductionInfectious bronchitis virus", "SPECIES", 56, 95], ["coronavirus", "SPECIES", 118, 129], ["IntroductionInfectious bronchitis virus", "SPECIES", 56, 95], ["IBV", "SPECIES", 97, 100], ["a new generation of IB vaccines", "TREATMENT", 10, 41], ["IntroductionInfectious bronchitis virus", "PROBLEM", 56, 95], ["an enveloped coronavirus", "PROBLEM", 105, 129], ["new", "OBSERVATION_MODIFIER", 12, 15], ["bronchitis", "OBSERVATION", 79, 89], ["enveloped", "OBSERVATION_MODIFIER", 108, 117], ["coronavirus", "OBSERVATION", 118, 129], ["RNA genome", "OBSERVATION", 192, 202]]], ["In addition to the internally localized nucleocapsid (N) protein, the virion is composed of spike protein, membrane protein and a small envelope protein.", [["membrane", "ANATOMY", 107, 115], ["nucleocapsid", "CELLULAR_COMPONENT", 40, 52], ["virion", "CELLULAR_COMPONENT", 70, 76], ["membrane", "CELLULAR_COMPONENT", 107, 115], ["nucleocapsid (N) protein", "PROTEIN", 40, 64], ["spike protein", "PROTEIN", 92, 105], ["membrane protein", "PROTEIN", 107, 123], ["small envelope protein", "PROTEIN", 130, 152], ["the internally localized nucleocapsid (N) protein", "PROBLEM", 15, 64], ["spike protein", "PROBLEM", 92, 105], ["membrane protein", "TEST", 107, 123], ["a small envelope protein", "PROBLEM", 128, 152], ["small", "OBSERVATION_MODIFIER", 130, 135], ["envelope protein", "OBSERVATION", 136, 152]]], ["N protein carries epitopes inducing cross-reactive antibodies and is the most abundant virus-derived protein produced throughout infection (Seah et al., 2000, Boots et al., 1992, Seo et al., 1997, Yu et al., 2001).", [["infection", "DISEASE", 129, 138], ["N protein", "PROTEIN", 0, 9], ["epitopes", "PROTEIN", 18, 26], ["cross-reactive antibodies", "PROTEIN", 36, 61], ["epitopes inducing cross-reactive antibodies", "PROBLEM", 18, 61], ["the most abundant virus", "PROBLEM", 69, 92], ["cross-reactive antibodies", "OBSERVATION", 36, 61]]], ["The carboxyl end of N protein has CTL epitopes for MHC compatible chickens (Seo and Collisson, 1997).", [["carboxyl", "CHEMICAL", 4, 12], ["chickens", "ORGANISM", 66, 74], ["carboxyl end", "PROTEIN", 4, 16], ["N protein", "PROTEIN", 20, 29], ["CTL epitopes", "PROTEIN", 34, 46], ["MHC", "PROTEIN", 51, 54], ["chickens", "SPECIES", 66, 74], ["chickens", "SPECIES", 66, 74], ["The carboxyl end of N protein", "TREATMENT", 0, 29], ["CTL epitopes", "TREATMENT", 34, 46]]], ["Chickens inoculated with DNA plasmids expressing the carboxyl end of N were protected from IBV infection (Seo et al., 1997).IntroductionIn recent years, the development of DNA vaccines as a potentially safe alternative has been explored.", [["plasmids", "ANATOMY", 29, 37], ["IBV infection", "DISEASE", 91, 104], ["carboxyl", "CHEMICAL", 53, 61], ["Chickens", "ORGANISM", 0, 8], ["DNA", "CELLULAR_COMPONENT", 25, 28], ["IBV", "ORGANISM", 91, 94], ["DNA", "CELLULAR_COMPONENT", 172, 175], ["DNA plasmids", "DNA", 25, 37], ["carboxyl end", "PROTEIN", 53, 65], ["Chickens", "SPECIES", 0, 8], ["Chickens", "SPECIES", 0, 8], ["IBV", "SPECIES", 91, 94], ["Chickens", "TREATMENT", 0, 8], ["DNA plasmids", "TREATMENT", 25, 37], ["IBV infection", "PROBLEM", 91, 104], ["DNA vaccines", "TREATMENT", 172, 184], ["IBV", "OBSERVATION_MODIFIER", 91, 94], ["infection", "OBSERVATION", 95, 104]]], ["DNA immunization is an important vaccination strategy that has many characters desirable for an ideal vaccine, including induction of broad immune responses, long-lasting immunity and simple and cheap production.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA immunization", "TREATMENT", 0, 16], ["an important vaccination strategy", "TREATMENT", 20, 53], ["an ideal vaccine", "TREATMENT", 93, 109], ["broad immune responses", "PROBLEM", 134, 156]]], ["Experimental DNA vaccines against viral, bacterial, and parasitic disease have been described (Tacket et al., 1999, Strugnell et al., 1997, Kalinna, 1997) and DNA vaccines have been licensed for two nonhuman applications: one for West Nile virus for horses (Powell, 2004) and the other for infectious hematopoietic necrosis virus for salmon (Lorenzen and Lapatra, 2005).", [["viral, bacterial, and parasitic disease", "DISEASE", 34, 73], ["infectious hematopoietic necrosis", "DISEASE", 290, 323], ["DNA", "CELLULAR_COMPONENT", 13, 16], ["DNA", "CELLULAR_COMPONENT", 159, 162], ["West Nile virus", "ORGANISM", 230, 245], ["horses", "ORGANISM", 250, 256], ["salmon", "ORGANISM", 334, 340], ["Nile virus", "SPECIES", 235, 245], ["horses", "SPECIES", 250, 256], ["West Nile virus", "SPECIES", 230, 245], ["infectious hematopoietic necrosis virus", "SPECIES", 290, 329], ["salmon", "SPECIES", 334, 340], ["Experimental DNA vaccines", "TREATMENT", 0, 25], ["viral", "PROBLEM", 34, 39], ["bacterial", "PROBLEM", 41, 50], ["parasitic disease", "PROBLEM", 56, 73], ["DNA vaccines", "TREATMENT", 159, 171], ["infectious hematopoietic necrosis virus", "PROBLEM", 290, 329], ["salmon (Lorenzen and Lapatra", "TREATMENT", 334, 362], ["parasitic disease", "OBSERVATION", 56, 73], ["infectious", "OBSERVATION_MODIFIER", 290, 300], ["hematopoietic", "ANATOMY", 301, 314], ["necrosis", "OBSERVATION", 315, 323]]], ["Hence DNA vaccines appear to be a useful technology.IntroductionIt is believed that delivery of only a single DNA plasmid of antigen is not optimal to protect against infection.", [["infection", "DISEASE", 167, 176], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["DNA", "CELLULAR_COMPONENT", 110, 113], ["DNA plasmid", "DNA", 110, 121], ["Hence DNA vaccines", "TREATMENT", 0, 18], ["a single DNA plasmid of antigen", "TREATMENT", 101, 132], ["infection", "PROBLEM", 167, 176], ["infection", "OBSERVATION", 167, 176]]], ["Adjuvants are used widely in various vaccine formulations for the enhancement of immune responses.", [["Adjuvants", "TREATMENT", 0, 9], ["various vaccine formulations", "TREATMENT", 29, 57]]], ["Among the adjuvants, cytokines have been explored extensively to augment the potency of DNA vaccines (Gurunathan et al., 2000, Reyes-Sandoval and Ertl, 2001, Scheerlinck, 2001, Barouch et al., 2004, Calarota and Weiner, 2004, Stevenson, 2004, Barouch, 2006).", [["DNA", "CELLULAR_COMPONENT", 88, 91], ["cytokines", "PROTEIN", 21, 30], ["the adjuvants", "TREATMENT", 6, 19], ["cytokines", "TREATMENT", 21, 30], ["DNA vaccines", "TREATMENT", 88, 100]]], ["Interleukin-2 (IL-2), initially known as T-cell growth factor, is a powerful immunoregulatory lymphokine which produced by lectin- or antigen-activated T-cells (Morgan et al., 1976).", [["T-cells", "ANATOMY", 152, 159], ["Interleukin-2", "GENE_OR_GENE_PRODUCT", 0, 13], ["IL-2", "GENE_OR_GENE_PRODUCT", 15, 19], ["T-cell growth factor", "GENE_OR_GENE_PRODUCT", 41, 61], ["lectin", "GENE_OR_GENE_PRODUCT", 123, 129], ["antigen", "GENE_OR_GENE_PRODUCT", 134, 141], ["T-cells", "CELL", 152, 159], ["Interleukin-2 (IL-2", "PROTEIN", 0, 19], ["T-cell growth factor", "PROTEIN", 41, 61], ["immunoregulatory lymphokine", "PROTEIN", 77, 104], ["lectin", "PROTEIN", 123, 129], ["antigen-activated T-cells", "CELL_TYPE", 134, 159], ["Interleukin-2 (IL", "TEST", 0, 17], ["a powerful immunoregulatory lymphokine", "TEST", 66, 104], ["lectin", "TEST", 123, 129]]], ["It is secreted by mature T-lymphocytes upon stimulation and certain T-cell lymphoma cell lines constitutively.", [["T-lymphocytes", "ANATOMY", 25, 38], ["T-cell lymphoma cell lines", "ANATOMY", 68, 94], ["T-lymphocytes", "CELL", 25, 38], ["T-cell lymphoma cell lines", "CELL", 68, 94], ["mature T-lymphocytes", "CELL_TYPE", 18, 38], ["T-cell lymphoma cell lines", "CELL_LINE", 68, 94], ["stimulation", "TEST", 44, 55], ["mature", "OBSERVATION_MODIFIER", 18, 24], ["-lymphocytes", "OBSERVATION_MODIFIER", 26, 38], ["cell lymphoma cell lines", "OBSERVATION", 70, 94]]], ["Plasmid IL-2 has been investigated as a potential vaccine adjuvant in several studies and has been shown to increase DNA vaccine protective immunity against pathogens (Diane and Carlos, 2004, Rompato et al., 2006, Bu et al., 2003).IntroductionIn the present study, a bicistronic plasmid encoding the nucleocapsid protein and immune-stimulatory interleukin-2 has been constructed and its immunogenicity and protective effect in chickens has been evaluated.", [["plasmid", "ANATOMY", 279, 286], ["IL-2", "GENE_OR_GENE_PRODUCT", 8, 12], ["DNA", "CELLULAR_COMPONENT", 117, 120], ["interleukin-2", "GENE_OR_GENE_PRODUCT", 344, 357], ["chickens", "ORGANISM", 427, 435], ["IL", "PROTEIN", 8, 10], ["bicistronic plasmid", "DNA", 267, 286], ["nucleocapsid protein", "PROTEIN", 300, 320], ["immune-stimulatory interleukin-2", "PROTEIN", 325, 357], ["chickens", "SPECIES", 427, 435], ["chickens", "SPECIES", 427, 435], ["Plasmid IL", "TREATMENT", 0, 10], ["a potential vaccine adjuvant", "TREATMENT", 38, 66], ["DNA vaccine", "TREATMENT", 117, 128], ["the present study", "TEST", 246, 263], ["a bicistronic plasmid", "TREATMENT", 265, 286], ["the nucleocapsid protein", "TEST", 296, 320], ["immune-stimulatory interleukin", "TREATMENT", 325, 355]]], ["It has been shown that the delivery of a bicistronic plasmid containing N gene and IL-2 can accelerate specific antibody induction with an increase T-cell responses.", [["T-cell", "ANATOMY", 148, 154], ["IL-2", "GENE_OR_GENE_PRODUCT", 83, 87], ["T-cell", "CELL", 148, 154], ["bicistronic plasmid", "DNA", 41, 60], ["N gene", "DNA", 72, 78], ["IL-2", "DNA", 83, 87], ["a bicistronic plasmid containing N gene and IL-2", "TREATMENT", 39, 87], ["specific antibody induction", "TREATMENT", 103, 130]]], ["The use of bicistronic vector may enable more efficient delivery of both antigen and cytokine in DNA vaccination and promote synergistic responses.Virus, experimental animals, and cells ::: Materials and methodsThe specific-pathogen-free (SPF) chicken embryos were purchased from Shangdong Institute of Poultry Science, Shandong, PR China.", [["cells", "ANATOMY", 180, 185], ["embryos", "ANATOMY", 252, 259], ["DNA", "CELLULAR_COMPONENT", 97, 100], ["Virus", "ORGANISM", 147, 152], ["cells", "CELL", 180, 185], ["chicken", "ORGANISM", 244, 251], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 252, 259], ["cytokine", "PROTEIN", 85, 93], ["chicken", "SPECIES", 244, 251], ["chicken", "SPECIES", 244, 251], ["bicistronic vector", "TREATMENT", 11, 29], ["both antigen", "TREATMENT", 68, 80], ["cytokine in DNA vaccination", "TREATMENT", 85, 112], ["Virus", "PROBLEM", 147, 152]]], ["Chickens were hatched and housed in a specific-pathogen-free environment at the Laboratory Animal and Resources Facility, Sichuan University.", [["Chickens", "ORGANISM", 0, 8], ["Chickens", "SPECIES", 0, 8], ["Chickens", "SPECIES", 0, 8]]], ["The nephropathogenic strain of IBV, SAIBk strain was propagated in the allantoic cavities of 10-day-old SPF embryonated chicken eggs, and then harvested allantoic fluid 36 h post-inoculation.", [["allantoic cavities", "ANATOMY", 71, 89], ["eggs", "ANATOMY", 128, 132], ["allantoic fluid", "ANATOMY", 153, 168], ["IBV", "ORGANISM", 31, 34], ["SAIBk strain", "ORGANISM", 36, 48], ["allantoic cavities", "MULTI-TISSUE_STRUCTURE", 71, 89], ["SPF", "ORGANISM", 104, 107], ["chicken", "ORGANISM", 120, 127], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 128, 132], ["chicken", "SPECIES", 120, 127], ["IBV", "SPECIES", 31, 34], ["SPF", "SPECIES", 104, 107], ["chicken", "SPECIES", 120, 127], ["The nephropathogenic strain of IBV", "PROBLEM", 0, 34], ["SAIBk strain", "PROBLEM", 36, 48], ["SPF embryonated chicken eggs", "TREATMENT", 104, 132], ["IBV", "OBSERVATION", 31, 34], ["allantoic cavities", "ANATOMY", 71, 89], ["chicken eggs", "OBSERVATION", 120, 132]]], ["The 50% chicken infection dose (EID50) was determined by inoculating serial 10-fold dilutions of virus into 10-day-old SPF embryonated chicken eggs.", [["eggs", "ANATOMY", 143, 147], ["infection", "DISEASE", 16, 25], ["chicken", "ORGANISM", 8, 15], ["SPF", "ORGANISM", 119, 122], ["chicken", "ORGANISM", 135, 142], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 143, 147], ["chicken", "SPECIES", 8, 15], ["chicken", "SPECIES", 135, 142], ["chicken", "SPECIES", 8, 15], ["SPF", "SPECIES", 119, 122], ["chicken", "SPECIES", 135, 142], ["The 50% chicken infection dose", "TREATMENT", 0, 30], ["virus", "PROBLEM", 97, 102]]], ["Vero cells were cultured in Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% FBS, 100 U/ml penicillin and 100 \u03bcg/ml streptomycin at pH 7.2 and were kept at 37 \u00b0C with 5% carbon dioxide.Construction of monocistronic and bicistronic plasmids ::: Materials and methodsThe pIRES-EGFP/DsRed bicistronic plasmid which was constructed and identified previously, was used to construct monocistronic and bicistronic DNA vaccines.", [["Vero cells", "ANATOMY", 0, 10], ["penicillin", "CHEMICAL", 107, 117], ["streptomycin", "CHEMICAL", 132, 144], ["carbon dioxide", "CHEMICAL", 186, 200], ["penicillin", "CHEMICAL", 107, 117], ["streptomycin", "CHEMICAL", 132, 144], ["carbon dioxide", "CHEMICAL", 186, 200], ["Vero cells", "CELL", 0, 10], ["FBS", "ORGANISM_SUBSTANCE", 93, 96], ["penicillin", "SIMPLE_CHEMICAL", 107, 117], ["streptomycin", "SIMPLE_CHEMICAL", 132, 144], ["carbon dioxide", "SIMPLE_CHEMICAL", 186, 200], ["pIRES", "GENE_OR_GENE_PRODUCT", 285, 290], ["EGFP", "GENE_OR_GENE_PRODUCT", 291, 295], ["DsRed", "GENE_OR_GENE_PRODUCT", 296, 301], ["DNA", "CELLULAR_COMPONENT", 423, 426], ["Vero cells", "CELL_LINE", 0, 10], ["monocistronic and bicistronic plasmids", "DNA", 217, 255], ["pIRES-EGFP/DsRed bicistronic plasmid", "DNA", 285, 321], ["monocistronic", "DNA", 393, 406], ["Vero cells", "PROBLEM", 0, 10], ["10% FBS", "TREATMENT", 89, 96], ["penicillin", "TREATMENT", 107, 117], ["streptomycin", "TREATMENT", 132, 144], ["pH", "TEST", 148, 150], ["5% carbon dioxide", "TREATMENT", 183, 200], ["The pIRES", "TEST", 281, 290], ["DsRed bicistronic plasmid", "TREATMENT", 296, 321], ["monocistronic and bicistronic DNA vaccines", "TREATMENT", 393, 435]]], ["This plasmid contained two fluorescent protein genes which were inserted into the multiple cloning sites (MCS) located on either side of the internal ribosome entry site from the encephalomyocarditis virus (ECMV).", [["plasmid", "ANATOMY", 5, 12], ["ribosome", "ANATOMY", 150, 158], ["encephalomyocarditis virus", "ORGANISM", 179, 205], ["ECMV", "CANCER", 207, 211], ["plasmid", "DNA", 5, 12], ["fluorescent protein genes", "DNA", 27, 52], ["multiple cloning sites", "DNA", 82, 104], ["MCS", "DNA", 106, 109], ["internal ribosome entry site", "DNA", 141, 169], ["encephalomyocarditis virus", "SPECIES", 179, 205], ["encephalomyocarditis virus", "SPECIES", 179, 205], ["ECMV", "SPECIES", 207, 211], ["This plasmid", "TREATMENT", 0, 12], ["two fluorescent protein genes", "TREATMENT", 23, 52], ["the encephalomyocarditis virus", "PROBLEM", 175, 205], ["two", "OBSERVATION_MODIFIER", 23, 26], ["fluorescent protein genes", "OBSERVATION", 27, 52], ["multiple", "OBSERVATION_MODIFIER", 82, 90], ["cloning", "OBSERVATION_MODIFIER", 91, 98], ["sites", "OBSERVATION_MODIFIER", 99, 104], ["internal ribosome", "ANATOMY", 141, 158], ["entry site", "OBSERVATION", 159, 169], ["encephalomyocarditis virus", "OBSERVATION", 179, 205]]], ["The IBV N gene was subcloned from recombinant plasmid pIBVN into EGFP of pIRES-EGFP/DsRed between NheI and XhoI restriction sites, and generated the plasmid pIRES-N/DsRed.", [["plasmid", "ANATOMY", 46, 53], ["IBV", "ORGANISM", 4, 7], ["EGFP", "GENE_OR_GENE_PRODUCT", 65, 69], ["pIRES", "GENE_OR_GENE_PRODUCT", 73, 78], ["NheI", "GENE_OR_GENE_PRODUCT", 98, 102], ["XhoI", "GENE_OR_GENE_PRODUCT", 107, 111], ["DsRed", "GENE_OR_GENE_PRODUCT", 165, 170], ["IBV N gene", "DNA", 4, 14], ["recombinant plasmid pIBVN", "DNA", 34, 59], ["EGFP", "DNA", 65, 69], ["pIRES", "DNA", 73, 78], ["EGFP", "DNA", 79, 83], ["DsRed", "DNA", 84, 89], ["NheI and XhoI restriction sites", "DNA", 98, 129], ["pIRES", "DNA", 157, 162], ["N", "DNA", 163, 164], ["DsRed", "DNA", 165, 170], ["IBV", "SPECIES", 4, 7], ["The IBV N gene", "TREATMENT", 0, 14], ["recombinant plasmid pIBVN", "TREATMENT", 34, 59], ["pIRES", "TEST", 73, 78], ["Ds", "PROBLEM", 84, 86], ["NheI and XhoI restriction sites", "TREATMENT", 98, 129], ["the plasmid pIRES", "TREATMENT", 145, 162]]], ["The IL-2 gene was amplified by PCR from the plasmid pDNAIL-2 as a template.", [["plasmid", "ANATOMY", 44, 51], ["IL-2", "GENE_OR_GENE_PRODUCT", 4, 8], ["pDNAIL-2", "GENE_OR_GENE_PRODUCT", 52, 60], ["IL-2 gene", "DNA", 4, 13], ["plasmid pDNAIL-2", "DNA", 44, 60], ["The IL-2 gene", "TREATMENT", 0, 13], ["the plasmid pDNAIL", "TREATMENT", 40, 58]]], ["The forward primer (5\u2032-CCAGGATCCACCATGATGTG AAG-3\u2032) and reverse primer (5\u2032-GAAGCGGCCGCAGATTAGTTAGC-3\u2032) specific for the IL-2 gene were employed.", [["IL-2", "GENE_OR_GENE_PRODUCT", 120, 124], ["forward primer", "DNA", 4, 18], ["reverse primer", "DNA", 56, 70], ["IL-2 gene", "DNA", 120, 129], ["The forward primer", "TEST", 0, 18], ["CCAGGATCCACCATGATGTG", "TEST", 23, 43], ["AAG", "TEST", 44, 47], ["reverse primer", "TREATMENT", 56, 70], ["GAAGCGGCCGCAGATTAGTTAGC", "TEST", 75, 98], ["the IL-2 gene", "TREATMENT", 116, 129]]], ["The PCR product of IL-2 was digested with BamHI and NotI and ligated into similarly digested pIRES-N/DsRed, then the bicistronic plasmid pIRES-N/IL2 was created.", [["plasmid", "ANATOMY", 129, 136], ["IL-2", "GENE_OR_GENE_PRODUCT", 19, 23], ["BamHI", "GENE_OR_GENE_PRODUCT", 42, 47], ["NotI", "GENE_OR_GENE_PRODUCT", 52, 56], ["pIRES", "GENE_OR_GENE_PRODUCT", 93, 98], ["DsRed", "GENE_OR_GENE_PRODUCT", 101, 106], ["pIRES-N", "GENE_OR_GENE_PRODUCT", 137, 144], ["IL2", "GENE_OR_GENE_PRODUCT", 145, 148], ["IL", "PROTEIN", 19, 21], ["BamHI", "DNA", 42, 47], ["NotI", "DNA", 52, 56], ["pIRES", "DNA", 93, 98], ["N", "DNA", 99, 100], ["DsRed", "DNA", 101, 106], ["bicistronic plasmid", "DNA", 117, 136], ["pIRES", "DNA", 137, 142], ["N", "DNA", 143, 144], ["IL2", "DNA", 145, 148], ["The PCR product of IL-2", "TREATMENT", 0, 23], ["BamHI and NotI", "TREATMENT", 42, 56], ["the bicistronic plasmid pIRES", "TREATMENT", 113, 142], ["N/IL2", "TREATMENT", 143, 148]]], ["The plasmid pIRES-N/DsRed was digested with BamHI and NotI, gel purified and blunt ended to create monocistronic pIRES-N.", [["plasmid", "ANATOMY", 4, 11], ["DsRed", "GENE_OR_GENE_PRODUCT", 20, 25], ["BamHI", "GENE_OR_GENE_PRODUCT", 44, 49], ["NotI", "GENE_OR_GENE_PRODUCT", 54, 58], ["pIRES", "DNA", 12, 17], ["N", "DNA", 18, 19], ["DsRed", "DNA", 20, 25], ["BamHI", "DNA", 44, 49], ["NotI", "DNA", 54, 58], ["monocistronic pIRES", "DNA", 99, 118], ["The plasmid pIRES", "TREATMENT", 0, 17], ["BamHI and NotI, gel", "TREATMENT", 44, 63], ["blunt", "PROBLEM", 77, 82], ["monocistronic pIRES", "OBSERVATION", 99, 118]]], ["Identification of the recombinant plasmids was performed by double enzymes digestion and DNA sequencing.RT-PCR analysis ::: In vitro expression of the plasmid DNA ::: Materials and methodsThe transfected cells were harvested after 36 h and total cellular RNA was prepared from the transfected cells by TRIZOL reagent (Gibco BRL, USA).", [["plasmids", "ANATOMY", 34, 42], ["cells", "ANATOMY", 204, 209], ["cellular", "ANATOMY", 246, 254], ["cells", "ANATOMY", 293, 298], ["DNA", "CELLULAR_COMPONENT", 89, 92], ["DNA", "CELLULAR_COMPONENT", 159, 162], ["cells", "CELL", 204, 209], ["cellular", "CELL", 246, 254], ["cells", "CELL", 293, 298], ["recombinant plasmids", "DNA", 22, 42], ["plasmid DNA", "DNA", 151, 162], ["transfected cells", "CELL_LINE", 192, 209], ["cellular RNA", "RNA", 246, 258], ["transfected cells", "CELL_LINE", 281, 298], ["the recombinant plasmids", "TREATMENT", 18, 42], ["double enzymes digestion", "TREATMENT", 60, 84], ["DNA sequencing", "TEST", 89, 103], ["RT-PCR analysis", "TEST", 104, 119], ["The transfected cells", "PROBLEM", 188, 209], ["total cellular RNA", "PROBLEM", 240, 258], ["TRIZOL reagent", "TREATMENT", 302, 316], ["recombinant plasmids", "OBSERVATION", 22, 42], ["transfected cells", "OBSERVATION", 192, 209], ["cellular RNA", "OBSERVATION", 246, 258], ["transfected cells", "OBSERVATION", 281, 298]]], ["The transcription products were detected by reverse-transcription polymerase chain reaction (RT-PCR) with specific primer sets for the N gene and IL-2 as listed.", [["IL-2", "GENE_OR_GENE_PRODUCT", 146, 150], ["transcription products", "PROTEIN", 4, 26], ["N gene", "DNA", 135, 141], ["IL-2", "DNA", 146, 150], ["The transcription products", "TEST", 0, 26], ["RT-PCR", "TREATMENT", 93, 99], ["specific primer sets", "TREATMENT", 106, 126], ["the N gene and IL", "TREATMENT", 131, 148]]], ["N forward primer: 5\u2032-CATCTCGAGTCTTTTATCATGGCAAGC-3\u2032, reverse primer: 5\u2032-GGCGAATTCATTAGAGTTCATTTTCAC-3\u2032; IL-2 forward primer: 5\u2032-CCAGGATCCACCATGATGTGCAAAG-3\u2032, reverse primer: 5\u2032-GAAGCGGCCGCAGATTAGTTAGC-3\u2032.Indirect immunofluorescence analysis ::: In vitro expression of the plasmid DNA ::: Materials and methodsThe medium was aspirated 48 h after transfection, and the cells were washed once with phosphate-buffered-saline (PBS), fixed with 100% acetone for 10 min at \u221220 \u00b0C, then washed three times for 5 min each with PBS.", [["cells", "ANATOMY", 367, 372], ["phosphate", "CHEMICAL", 395, 404], ["acetone", "CHEMICAL", 444, 451], ["phosphate", "CHEMICAL", 395, 404], ["acetone", "CHEMICAL", 444, 451], ["IL-2", "GENE_OR_GENE_PRODUCT", 104, 108], ["DNA", "CELLULAR_COMPONENT", 280, 283], ["cells", "CELL", 367, 372], ["phosphate-buffered-saline", "SIMPLE_CHEMICAL", 395, 420], ["acetone", "SIMPLE_CHEMICAL", 444, 451], ["reverse primer: 5\u2032-GAAGCGGCCGCAGATTAGTTAGC-3\u2032", "DNA", 158, 203], ["plasmid DNA", "DNA", 272, 283], ["CATCTCGAGTCTTTTATCATGGCAAGC", "TEST", 21, 48], ["GGCGAATTCATTAGAGTTCATTTTCAC", "TEST", 72, 99], ["IL", "TEST", 104, 106], ["CCAGGATCCACCATGATGTGCAAAG", "TEST", 128, 153], ["GAAGCGGCCGCAGATTAGTTAGC", "TEST", 177, 200], ["Indirect immunofluorescence analysis", "TEST", 204, 240], ["transfection", "TREATMENT", 345, 357], ["phosphate-buffered-saline (PBS", "TREATMENT", 395, 425], ["100% acetone", "TREATMENT", 439, 451], ["PBS", "TREATMENT", 518, 521], ["medium", "OBSERVATION_MODIFIER", 313, 319]]], ["Thereafter, transfected cells were incubated at 37 \u00b0C for 1 h with the antibody, which was antiserum of rabbit to IBV.", [["cells", "ANATOMY", 24, 29], ["cells", "CELL", 24, 29], ["antiserum", "ORGANISM_SUBSTANCE", 91, 100], ["rabbit", "ORGANISM", 104, 110], ["IBV", "ORGANISM", 114, 117], ["transfected cells", "CELL_LINE", 12, 29], ["rabbit", "SPECIES", 104, 110], ["rabbit", "SPECIES", 104, 110], ["IBV", "SPECIES", 114, 117], ["transfected cells", "PROBLEM", 12, 29], ["the antibody", "TEST", 67, 79]]], ["Then the cells were washed twice for 5 min each with PBS and incubated for a further 1 h at 37 \u00b0C with the secondary FITC-conjugated goat-anti-rabbit IgG antibody that included 0.05% azovan blue (purpose of using azovan blue was to identify the positive Vero cells and negative Vero cells).", [["cells", "ANATOMY", 9, 14], ["Vero cells", "ANATOMY", 254, 264], ["Vero cells", "ANATOMY", 278, 288], ["azovan blue", "CHEMICAL", 183, 194], ["azovan blue", "CHEMICAL", 213, 224], ["FITC", "CHEMICAL", 117, 121], ["azovan blue", "CHEMICAL", 183, 194], ["azovan blue", "CHEMICAL", 213, 224], ["cells", "CELL", 9, 14], ["FITC", "SIMPLE_CHEMICAL", 117, 121], ["goat", "ORGANISM", 133, 137], ["azovan blue", "SIMPLE_CHEMICAL", 183, 194], ["azovan blue", "SIMPLE_CHEMICAL", 213, 224], ["Vero cells", "CELL", 254, 264], ["Vero cells", "CELL", 278, 288], ["secondary FITC-conjugated goat-anti-rabbit IgG antibody", "PROTEIN", 107, 162], ["positive Vero cells", "CELL_LINE", 245, 264], ["negative Vero cells", "CELL_LINE", 269, 288], ["goat", "SPECIES", 133, 137], ["anti-rabbit", "SPECIES", 138, 149], ["goat", "SPECIES", 133, 137], ["anti-rabbit", "SPECIES", 138, 149], ["the cells", "TREATMENT", 5, 14], ["PBS", "TREATMENT", 53, 56], ["the secondary FITC", "TEST", 103, 121], ["conjugated goat", "TREATMENT", 122, 137], ["anti-rabbit IgG antibody", "TEST", 138, 162], ["0.05% azovan blue", "TREATMENT", 177, 194], ["azovan blue", "TREATMENT", 213, 224], ["the positive Vero cells", "PROBLEM", 241, 264], ["Vero cells", "OBSERVATION", 278, 288]]], ["The positive Vero cells expressing N protein were stained green; the negative Vero cells were stained red.", [["Vero cells", "ANATOMY", 13, 23], ["Vero cells", "ANATOMY", 78, 88], ["Vero cells", "CELL", 13, 23], ["N protein", "GENE_OR_GENE_PRODUCT", 35, 44], ["Vero cells", "CELL", 78, 88], ["positive Vero cells", "CELL_LINE", 4, 23], ["N protein", "PROTEIN", 35, 44], ["negative Vero cells", "CELL_LINE", 69, 88], ["The positive Vero cells", "PROBLEM", 0, 23], ["N protein", "TEST", 35, 44], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["Vero cells", "OBSERVATION", 13, 23], ["Vero cells", "OBSERVATION", 78, 88]]], ["The cells were washed twice with PBS and analyzed the expression of the recombinant plasmid by fluorescence microscopy.Immunization of chickens with plasmid DNA vaccines ::: Materials and methodsThe plasmids pIRES-N/IL2, pIRES-N, pIRES were amplified in Escherichia coli JM 109 and extracted using the alkaline lysis method as described previously (Sambrook et al., 1989).", [["cells", "ANATOMY", 4, 9], ["plasmid", "ANATOMY", 84, 91], ["plasmid", "ANATOMY", 149, 156], ["plasmids", "ANATOMY", 199, 207], ["cells", "CELL", 4, 9], ["chickens", "ORGANISM", 135, 143], ["DNA", "CELLULAR_COMPONENT", 157, 160], ["pIRES-N", "GENE_OR_GENE_PRODUCT", 208, 215], ["IL2", "GENE_OR_GENE_PRODUCT", 216, 219], ["pIRES-N", "GENE_OR_GENE_PRODUCT", 221, 228], ["pIRES", "GENE_OR_GENE_PRODUCT", 230, 235], ["Escherichia coli", "ORGANISM", 254, 270], ["JM 109", "ORGANISM", 271, 277], ["recombinant plasmid", "DNA", 72, 91], ["plasmids", "DNA", 199, 207], ["pIRES", "DNA", 208, 213], ["N", "DNA", 214, 215], ["IL2", "DNA", 216, 219], ["pIRES", "DNA", 221, 226], ["N", "DNA", 227, 228], ["pIRES", "DNA", 230, 235], ["chickens", "SPECIES", 135, 143], ["Escherichia coli", "SPECIES", 254, 270], ["chickens", "SPECIES", 135, 143], ["Escherichia coli JM 109", "SPECIES", 254, 277], ["PBS", "TREATMENT", 33, 36], ["the recombinant plasmid", "TREATMENT", 68, 91], ["fluorescence microscopy", "TEST", 95, 118], ["The plasmids pIRES", "TEST", 195, 213], ["IL2", "TREATMENT", 216, 219], ["pIRES", "TEST", 221, 226], ["pIRES", "TREATMENT", 230, 235], ["Escherichia coli JM", "TEST", 254, 273], ["the alkaline lysis method", "TREATMENT", 298, 323], ["Escherichia coli", "OBSERVATION", 254, 270], ["alkaline lysis", "OBSERVATION", 302, 316]]], ["After purification by PEG8000 precipitation, the plasmids were resuspended in phosphate-buffered saline (PBS, pH 7.2) and kept at \u221220 \u00b0C until used for immunization.", [["plasmids", "ANATOMY", 49, 57], ["PEG8000", "CHEMICAL", 22, 29], ["phosphate", "CHEMICAL", 78, 87], ["PEG8000", "CHEMICAL", 22, 29], ["phosphate", "CHEMICAL", 78, 87], ["PEG8000", "SIMPLE_CHEMICAL", 22, 29], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 78, 103], ["plasmids", "DNA", 49, 57], ["PEG8000 precipitation", "TREATMENT", 22, 43], ["the plasmids", "TREATMENT", 45, 57], ["phosphate", "TREATMENT", 78, 87], ["buffered saline (PBS", "TREATMENT", 88, 108], ["pH", "TEST", 110, 112], ["immunization", "TREATMENT", 152, 164]]], ["For vaccination, the chickens were randomly divided into four groups (n= 20 each).", [["chickens", "ORGANISM", 21, 29], ["chickens", "SPECIES", 21, 29], ["chickens", "SPECIES", 21, 29], ["vaccination", "TREATMENT", 4, 15], ["the chickens", "TREATMENT", 17, 29]]], ["The 7-day-old chickens were injected intramuscularly into the quadriceps muscle with 150 \u03bcg of plasmid pIRES-N/IL2 (group 1).", [["intramuscularly", "ANATOMY", 37, 52], ["quadriceps muscle", "ANATOMY", 62, 79], ["plasmid", "ANATOMY", 95, 102], ["chickens", "ORGANISM", 14, 22], ["quadriceps muscle", "TISSUE", 62, 79], ["IL2", "GENE_OR_GENE_PRODUCT", 111, 114], ["pIRES", "PROTEIN", 103, 108], ["IL2", "PROTEIN", 111, 114], ["chickens", "SPECIES", 14, 22], ["chickens", "SPECIES", 14, 22], ["old chickens", "TREATMENT", 10, 22], ["plasmid pIRES", "TREATMENT", 95, 108], ["quadriceps muscle", "ANATOMY", 62, 79]]], ["A second group was given 150 \u03bcg of plasmid pIRES-N (group 2).", [["plasmid pIRES", "TREATMENT", 35, 48]]], ["Other groups included chickens administered with 150 \u03bcg of empty vector pIRES (group 3), and chickens injected with 0.5 ml PBS only (group 4).", [["chickens", "ORGANISM", 22, 30], ["chickens", "ORGANISM", 93, 101], ["chickens", "SPECIES", 22, 30], ["chickens", "SPECIES", 93, 101], ["chickens", "SPECIES", 22, 30], ["chickens", "SPECIES", 93, 101], ["chickens", "TREATMENT", 22, 30], ["empty vector pIRES", "TREATMENT", 59, 77], ["chickens", "TREATMENT", 93, 101]]], ["All groups were boosted with an equivalent dose at 21 days after the initial inoculation.Detection of anti-IBV specific antibodies ::: Materials and methodsPre-vaccination sera were collected from all vaccinated chickens.", [["sera", "ANATOMY", 172, 176], ["anti-IBV", "GENE_OR_GENE_PRODUCT", 102, 110], ["sera", "ORGANISM_SUBSTANCE", 172, 176], ["chickens", "ORGANISM", 212, 220], ["anti-IBV specific antibodies", "PROTEIN", 102, 130], ["chickens", "SPECIES", 212, 220], ["anti-IBV", "SPECIES", 102, 110], ["chickens", "SPECIES", 212, 220], ["the initial inoculation", "TREATMENT", 65, 88], ["Materials", "TREATMENT", 135, 144], ["methodsPre-vaccination sera", "TEST", 149, 176]]], ["Blood was also collected before booster vaccination as well as before challenge.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood", "TEST", 0, 5], ["booster vaccination", "TREATMENT", 32, 51]]], ["Sera were stored at \u221220 \u00b0C for serologic analysis.", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["Sera", "TEST", 0, 4], ["serologic analysis", "TEST", 31, 49]]], ["Total serum immunoglobulin G (IgG) specific for IBV was measured by indirect enzyme-linked immunosorbent assay (ELISA) as described previously, with brief modifications: ELISA plates were coated with IBV lysate at 5 \u03bcg/ml in carbonate buffer, PH 9.6, for overnight at 4 \u00b0C and blocked with 10% non-fat dried milk in PBS at 37 \u00b0C for 3 h.", [["serum", "ANATOMY", 6, 11], ["milk", "ANATOMY", 308, 312], ["carbonate", "CHEMICAL", 225, 234], ["serum", "ORGANISM_SUBSTANCE", 6, 11], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 12, 28], ["IgG", "GENE_OR_GENE_PRODUCT", 30, 33], ["IBV", "ORGANISM", 48, 51], ["IBV", "ORGANISM", 200, 203], ["carbonate", "SIMPLE_CHEMICAL", 225, 234], ["milk", "ORGANISM_SUBSTANCE", 308, 312], ["serum immunoglobulin G", "PROTEIN", 6, 28], ["IgG", "PROTEIN", 30, 33], ["IBV", "SPECIES", 48, 51], ["IBV", "SPECIES", 200, 203], ["Total serum immunoglobulin G", "TEST", 0, 28], ["IgG", "TEST", 30, 33], ["IBV", "PROBLEM", 48, 51], ["indirect enzyme", "TEST", 68, 83], ["immunosorbent assay", "TEST", 91, 110], ["ELISA plates", "TREATMENT", 170, 182], ["IBV lysate", "TREATMENT", 200, 210], ["carbonate buffer", "TREATMENT", 225, 241], ["PH", "TEST", 243, 245], ["fat dried milk in PBS", "TREATMENT", 298, 319]]], ["Serum samples were tested in 1:20 dilution in 10% dried milk in PBST.", [["Serum samples", "ANATOMY", 0, 13], ["milk", "ANATOMY", 56, 60], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["milk", "ORGANISM_SUBSTANCE", 56, 60], ["Serum samples", "TEST", 0, 13]]], ["IgG against IBV was revealed with horseradish peroxidaselabeled goat-anti-chicken conjugate diluted 1:2000 in PBST.", [["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["IBV", "ORGANISM", 12, 15], ["horseradish", "SIMPLE_CHEMICAL", 34, 45], ["chicken", "ORGANISM", 74, 81], ["IgG", "PROTEIN", 0, 3], ["horseradish peroxidaselabeled goat", "PROTEIN", 34, 68], ["horseradish", "SPECIES", 34, 45], ["goat", "SPECIES", 64, 68], ["chicken", "SPECIES", 74, 81], ["IBV", "SPECIES", 12, 15], ["chicken", "SPECIES", 74, 81], ["IgG", "TEST", 0, 3], ["IBV", "PROBLEM", 12, 15], ["horseradish peroxidaselabeled goat", "TEST", 34, 68], ["anti-chicken conjugate", "TREATMENT", 69, 91]]], ["The substrate solution used was TMB microwell peroxidase.", [["TMB", "CHEMICAL", 32, 35], ["peroxidase", "GENE_OR_GENE_PRODUCT", 46, 56], ["TMB microwell peroxidase", "PROTEIN", 32, 56], ["The substrate solution", "TREATMENT", 0, 22], ["TMB microwell peroxidase", "TREATMENT", 32, 56]]], ["After 20 min of incubation in the dark, the reaction was stopped by the addition of 100 \u03bcl of 2 M H2SO4, and the optical density at 450 nm was measured in an ELISA microplate reader.", [["H2SO4", "CHEMICAL", 98, 103], ["incubation", "TREATMENT", 16, 26], ["the reaction", "PROBLEM", 40, 52], ["2 M H2SO4", "TREATMENT", 94, 103]]], ["Sera were run in duplicate.", [["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["Sera", "TEST", 0, 4]]], ["Negative and positive control sera were included in each assay.", [["sera", "ANATOMY", 30, 34], ["sera", "ORGANISM_SUBSTANCE", 30, 34], ["positive", "OBSERVATION_MODIFIER", 13, 21]]], ["Total serum immunoglobulin G (IgG) specific for IBV are represented as the optical density.Analysis of CD4+, CD8+ and CD3+ T-lymphocytes ::: Materials and methodsPeripheral blood samples from immunized chicken were collected from the jugular vein in 2.5 ml syringes preloaded with 0.2 ml of sodium heparin to prevent clotting on day 7 after the boosting vaccination.", [["serum", "ANATOMY", 6, 11], ["CD4+, CD8+ and CD3+ T-lymphocytes", "ANATOMY", 103, 136], ["Peripheral blood samples", "ANATOMY", 162, 186], ["jugular vein", "ANATOMY", 234, 246], ["sodium heparin", "CHEMICAL", 291, 305], ["sodium heparin", "CHEMICAL", 291, 305], ["serum", "ORGANISM_SUBSTANCE", 6, 11], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 12, 28], ["IgG", "GENE_OR_GENE_PRODUCT", 30, 33], ["IBV", "ORGANISM", 48, 51], ["CD4", "GENE_OR_GENE_PRODUCT", 103, 106], ["CD8", "GENE_OR_GENE_PRODUCT", 109, 112], ["CD3", "GENE_OR_GENE_PRODUCT", 118, 121], ["Peripheral blood samples", "ORGANISM_SUBSTANCE", 162, 186], ["chicken", "ORGANISM", 202, 209], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 234, 246], ["sodium heparin", "SIMPLE_CHEMICAL", 291, 305], ["serum immunoglobulin G", "PROTEIN", 6, 28], ["IgG", "PROTEIN", 30, 33], ["CD4", "PROTEIN", 103, 106], ["CD8", "PROTEIN", 109, 112], ["CD3", "PROTEIN", 118, 121], ["T-lymphocytes", "CELL_TYPE", 123, 136], ["chicken", "SPECIES", 202, 209], ["IBV", "SPECIES", 48, 51], ["chicken", "SPECIES", 202, 209], ["Total serum immunoglobulin G", "TEST", 0, 28], ["IgG", "TEST", 30, 33], ["IBV", "PROBLEM", 48, 51], ["Analysis", "TEST", 91, 99], ["CD4", "TEST", 103, 106], ["CD8", "TEST", 109, 112], ["CD3", "TEST", 118, 121], ["Peripheral blood samples", "TEST", 162, 186], ["immunized chicken", "TREATMENT", 192, 209], ["sodium heparin", "TREATMENT", 291, 305], ["clotting", "PROBLEM", 317, 325], ["the boosting vaccination", "TREATMENT", 341, 365], ["optical density", "OBSERVATION", 75, 90], ["lymphocytes", "ANATOMY", 125, 136], ["jugular vein", "ANATOMY", 234, 246], ["clotting", "OBSERVATION", 317, 325]]], ["Peripheral blood mononuclear cells were isolated from each blood sample by Ficoll-Hypaque density gradient centrifugation.", [["Peripheral blood mononuclear cells", "ANATOMY", 0, 34], ["blood sample", "ANATOMY", 59, 71], ["Peripheral blood mononuclear cells", "CELL", 0, 34], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["Peripheral blood mononuclear cells", "CELL_TYPE", 0, 34], ["Peripheral blood mononuclear cells", "TEST", 0, 34], ["blood sample", "TEST", 59, 71], ["Ficoll-Hypaque density gradient centrifugation", "TREATMENT", 75, 121], ["blood", "ANATOMY", 11, 16], ["mononuclear cells", "OBSERVATION", 17, 34], ["Hypaque density", "OBSERVATION", 82, 97], ["gradient centrifugation", "OBSERVATION", 98, 121]]], ["PBMC were adjusted to 1 \u00d7 107cells/ml.", [["PBMC", "ANATOMY", 0, 4], ["PBMC", "CELL", 0, 4], ["PBMC", "CELL_TYPE", 0, 4], ["PBMC", "TREATMENT", 0, 4]]], ["The 100 \u03bcl of samples (1 \u00d7 106cells) were incubated for 1 h at room temperature with antibody as follows: mouse anti-chicken CD4-PE, mouse anti-chicken CD8-FITC, mouse anti-chicken CD3-SPRD (BD Biosciences Pharmingen).", [["samples", "ANATOMY", 14, 21], ["cells", "ANATOMY", 30, 35], ["FITC", "CHEMICAL", 156, 160], ["cells", "CELL", 30, 35], ["mouse", "ORGANISM", 106, 111], ["CD4", "GENE_OR_GENE_PRODUCT", 125, 128], ["mouse", "ORGANISM", 133, 138], ["CD8", "GENE_OR_GENE_PRODUCT", 152, 155], ["FITC", "GENE_OR_GENE_PRODUCT", 156, 160], ["mouse", "ORGANISM", 162, 167], ["CD3", "GENE_OR_GENE_PRODUCT", 181, 184], ["CD4", "PROTEIN", 125, 128], ["PE", "PROTEIN", 129, 131], ["mouse anti-chicken CD8", "PROTEIN", 133, 155], ["FITC", "PROTEIN", 156, 160], ["mouse anti-chicken CD3", "PROTEIN", 162, 184], ["SPRD", "PROTEIN", 185, 189], ["BD Biosciences Pharmingen", "PROTEIN", 191, 216], ["mouse", "SPECIES", 106, 111], ["mouse", "SPECIES", 133, 138], ["mouse", "SPECIES", 162, 167], ["mouse", "SPECIES", 106, 111], ["mouse", "SPECIES", 133, 138], ["mouse", "SPECIES", 162, 167], ["samples", "TEST", 14, 21], ["antibody", "TEST", 85, 93], ["PE", "PROBLEM", 129, 131], ["PE", "OBSERVATION", 129, 131]]], ["Leukocyte samples were triply labeled with CD3, CD4 and CD8 antibodies.", [["Leukocyte samples", "ANATOMY", 0, 17], ["Leukocyte samples", "CELL", 0, 17], ["CD3", "GENE_OR_GENE_PRODUCT", 43, 46], ["CD4", "GENE_OR_GENE_PRODUCT", 48, 51], ["CD8", "GENE_OR_GENE_PRODUCT", 56, 59], ["CD3", "PROTEIN", 43, 46], ["CD4", "PROTEIN", 48, 51], ["CD8 antibodies", "PROTEIN", 56, 70], ["Leukocyte samples", "TEST", 0, 17], ["CD3", "TEST", 43, 46], ["CD4", "TEST", 48, 51], ["CD8 antibodies", "TEST", 56, 70]]], ["The samples were processed on fluorescence activated cell sorter.Virus challenge experiment ::: Materials and methodsAll of the chickens were challenged with 100EID50 of the IBV SAIBk strain in 0.1 ml by the nasal-ocular route at 15 days after the boosting immunization.", [["samples", "ANATOMY", 4, 11], ["cell", "ANATOMY", 53, 57], ["nasal", "ANATOMY", 208, 213], ["ocular", "ANATOMY", 214, 220], ["cell", "CELL", 53, 57], ["Virus", "ORGANISM", 65, 70], ["chickens", "ORGANISM", 128, 136], ["IBV", "ORGANISM", 174, 177], ["chickens", "SPECIES", 128, 136], ["chickens", "SPECIES", 128, 136], ["IBV", "SPECIES", 174, 177], ["The samples", "TEST", 0, 11], ["the IBV SAIBk strain", "TREATMENT", 170, 190], ["the nasal-ocular route", "TREATMENT", 204, 226], ["the boosting immunization", "TREATMENT", 244, 269], ["cell sorter", "OBSERVATION", 53, 64], ["nasal", "ANATOMY", 208, 213], ["ocular", "ANATOMY", 214, 220]]], ["The challenged chickens were examined daily for signs of clinical illness such as coughing, sneezing, ataxia, dyspnea or death for 2 weeks.", [["illness", "DISEASE", 66, 73], ["coughing", "DISEASE", 82, 90], ["sneezing", "DISEASE", 92, 100], ["ataxia", "DISEASE", 102, 108], ["dyspnea", "DISEASE", 110, 117], ["death", "DISEASE", 121, 126], ["chickens", "ORGANISM", 15, 23], ["chickens", "SPECIES", 15, 23], ["chickens", "SPECIES", 15, 23], ["The challenged chickens", "TREATMENT", 0, 23], ["clinical illness", "PROBLEM", 57, 73], ["coughing", "PROBLEM", 82, 90], ["sneezing", "PROBLEM", 92, 100], ["ataxia", "PROBLEM", 102, 108], ["dyspnea", "PROBLEM", 110, 117], ["death", "PROBLEM", 121, 126]]], ["Dead chickens were necropsied to confirm death by IBV infection.", [["death", "DISEASE", 41, 46], ["IBV infection", "DISEASE", 50, 63], ["chickens", "ORGANISM", 5, 13], ["IBV", "ORGANISM", 50, 53], ["chickens", "SPECIES", 5, 13], ["chickens", "SPECIES", 5, 13], ["IBV", "SPECIES", 50, 53], ["Dead chickens", "PROBLEM", 0, 13], ["death", "PROBLEM", 41, 46], ["IBV infection", "PROBLEM", 50, 63], ["IBV", "OBSERVATION_MODIFIER", 50, 53], ["infection", "OBSERVATION", 54, 63]]], ["The challenged chickens generally began to show clinical signs from 4 to 10 days after challenge.", [["chickens", "ORGANISM", 15, 23], ["chickens", "SPECIES", 15, 23], ["chickens", "SPECIES", 15, 23]]], ["Chickens in each group were euthanized at 14 days post-infection.", [["Chickens", "ORGANISM", 0, 8], ["Chickens", "SPECIES", 0, 8], ["Chickens", "SPECIES", 0, 8]]], ["Necropsies were performed immediately postmortem and kidney tissues were collected for further detection of virus.Detecting of virus in kidney tissues by RT-PCR ::: Materials and methodsThe kidney tissues were incised individually from either the dead or euthanized chickens at 14 days post-challenged.", [["kidney tissues", "ANATOMY", 53, 67], ["kidney tissues", "ANATOMY", 136, 150], ["kidney tissues", "ANATOMY", 190, 204], ["kidney tissues", "TISSUE", 53, 67], ["kidney tissues", "TISSUE", 136, 150], ["kidney tissues", "TISSUE", 190, 204], ["chickens", "ORGANISM", 266, 274], ["chickens", "SPECIES", 266, 274], ["chickens", "SPECIES", 266, 274], ["Necropsies", "TEST", 0, 10], ["further detection", "TEST", 87, 104], ["virus", "PROBLEM", 108, 113], ["virus in kidney tissues", "PROBLEM", 127, 150], ["kidney tissues", "ANATOMY", 53, 67], ["virus", "OBSERVATION", 108, 113], ["virus", "OBSERVATION", 127, 132], ["kidney", "ANATOMY", 136, 142], ["kidney tissues", "ANATOMY", 190, 204], ["incised", "OBSERVATION_MODIFIER", 210, 217]]], ["The virus in the kidney tissues of the challenged chicken was detected by RT-PCR.", [["kidney tissues", "ANATOMY", 17, 31], ["kidney tissues", "TISSUE", 17, 31], ["chicken", "ORGANISM", 50, 57], ["chicken", "SPECIES", 50, 57], ["chicken", "SPECIES", 50, 57], ["The virus", "PROBLEM", 0, 9], ["RT-PCR", "TEST", 74, 80], ["virus", "OBSERVATION", 4, 9], ["kidney", "ANATOMY", 17, 23], ["tissues", "ANATOMY_MODIFIER", 24, 31]]], ["Total RNA was extracted using Trizol LS reagent and subjected to RT-PCR using primers directed to the 3\u2032 untranslated region (forward primer: 5\u2032-GATGAGGAGAGGAACAATGC-3\u2032; reverse primer: 5\u2032-TGGGCGTCCTAGTGCTGT-3\u2032).", [["3\u2032 untranslated region", "DNA", 102, 124], ["forward primer", "DNA", 126, 140], ["reverse primer", "DNA", 170, 184], ["Total RNA", "TREATMENT", 0, 9], ["Trizol LS reagent", "TREATMENT", 30, 47], ["RT-PCR using primers", "TREATMENT", 65, 85], ["GATGAGGAGAGGAACAATGC", "TEST", 145, 165], ["TGGGCGTCCTAGTGCTGT", "TEST", 189, 207]]], ["Total protection was defined as negative for the presence of virus in the kidney.Statistical analysis ::: Materials and methodsData were analyzed using the one-sided Student's t test.", [["kidney", "ANATOMY", 74, 80], ["kidney", "ORGAN", 74, 80], ["Total protection", "TREATMENT", 0, 16], ["virus in the kidney", "PROBLEM", 61, 80], ["methodsData", "TEST", 120, 131], ["virus", "OBSERVATION", 61, 66], ["kidney", "ANATOMY", 74, 80]]], ["Differences were considered statistically significant with P< 0.05.Construction of monocistronic and bicistronic DNA vaccine ::: ResultsThe monocistronic and bicistronic DNA vaccine plasmids encoding IBV N protein and IL-2 were constructed using bicistronic plasmid pIRES-EGFP/DsRed as shown in Fig. 1.Transcription of recombinant plasmids in Vero cells ::: ResultsTo confirm the transcription of constructs pIRES-N/IL2, pIRES-N in a eukaryotic system, the plasmids were transfected respectively into Vero cells.", [["plasmids", "ANATOMY", 331, 339], ["Vero cells", "ANATOMY", 343, 353], ["plasmids", "ANATOMY", 457, 465], ["Vero cells", "ANATOMY", 501, 511], ["DNA", "CELLULAR_COMPONENT", 113, 116], ["DNA", "CELLULAR_COMPONENT", 170, 173], ["IBV N protein", "GENE_OR_GENE_PRODUCT", 200, 213], ["IL-2", "GENE_OR_GENE_PRODUCT", 218, 222], ["pIRES", "GENE_OR_GENE_PRODUCT", 266, 271], ["EGFP", "GENE_OR_GENE_PRODUCT", 272, 276], ["DsRed", "GENE_OR_GENE_PRODUCT", 277, 282], ["Vero cells", "CELL", 343, 353], ["pIRES-N", "GENE_OR_GENE_PRODUCT", 408, 415], ["IL2", "GENE_OR_GENE_PRODUCT", 416, 419], ["pIRES-N", "GENE_OR_GENE_PRODUCT", 421, 428], ["Vero cells", "CELL", 501, 511], ["monocistronic", "DNA", 83, 96], ["monocistronic and bicistronic DNA vaccine plasmids", "DNA", 140, 190], ["IBV N protein", "PROTEIN", 200, 213], ["IL", "PROTEIN", 218, 220], ["pIRES", "DNA", 266, 271], ["EGFP", "DNA", 272, 276], ["DsRed", "DNA", 277, 282], ["recombinant plasmids", "DNA", 319, 339], ["Vero cells", "CELL_LINE", 343, 353], ["pIRES", "PROTEIN", 408, 413], ["N", "DNA", 414, 415], ["IL2", "PROTEIN", 416, 419], ["pIRES", "DNA", 421, 426], ["N", "DNA", 427, 428], ["plasmids", "DNA", 457, 465], ["Vero cells", "CELL_LINE", 501, 511], ["IBV", "SPECIES", 200, 203], ["P", "TEST", 59, 60], ["monocistronic and bicistronic DNA vaccine", "TREATMENT", 83, 124], ["The monocistronic", "TREATMENT", 136, 153], ["bicistronic DNA vaccine plasmids", "TREATMENT", 158, 190], ["IBV N protein and IL-2", "TREATMENT", 200, 222], ["bicistronic plasmid pIRES", "TREATMENT", 246, 271], ["EGFP/DsRed", "TREATMENT", 272, 282], ["pIRES", "TEST", 408, 413], ["IL2", "TREATMENT", 416, 419], ["pIRES", "TEST", 421, 426], ["the plasmids", "TREATMENT", 453, 465], ["recombinant plasmids", "OBSERVATION", 319, 339], ["Vero cells", "OBSERVATION", 343, 353], ["eukaryotic system", "ANATOMY", 434, 451], ["Vero cells", "OBSERVATION", 501, 511]]], ["Total RNA was extracted from transfected cells at 38 h and analyzed by RT-PCR for the presence of each corresponding mRNA.", [["cells", "ANATOMY", 41, 46], ["cells", "CELL", 41, 46], ["transfected cells", "CELL_LINE", 29, 46], ["mRNA", "RNA", 117, 121], ["Total RNA", "PROBLEM", 0, 9], ["transfected cells", "PROBLEM", 29, 46], ["RT", "TEST", 71, 73], ["PCR", "TEST", 74, 77], ["each corresponding mRNA", "PROBLEM", 98, 121], ["transfected cells", "OBSERVATION", 29, 46], ["mRNA", "OBSERVATION", 117, 121]]], ["The predicted RT-PCR products were of 1.3 kb in size for N and 0.6 kb for IL2, all of which were confirmed by gel electrophoresis.", [["IL2", "GENE_OR_GENE_PRODUCT", 74, 77], ["RT-PCR products", "DNA", 14, 29], ["IL2", "PROTEIN", 74, 77], ["The predicted RT-PCR products", "TREATMENT", 0, 29], ["IL2", "TREATMENT", 74, 77], ["gel electrophoresis", "TEST", 110, 129], ["size", "OBSERVATION_MODIFIER", 48, 52]]], ["No specific band of a similar size was seen in any of the mRNA samples in the absence of reverse transcription (Fig. 2).", [["samples", "ANATOMY", 63, 70], ["mRNA samples", "RNA", 58, 70], ["a similar size", "PROBLEM", 20, 34], ["the mRNA samples", "TEST", 54, 70], ["specific", "OBSERVATION_MODIFIER", 3, 11], ["band", "OBSERVATION_MODIFIER", 12, 16], ["similar", "OBSERVATION_MODIFIER", 22, 29], ["size", "OBSERVATION_MODIFIER", 30, 34]]], ["This result showed that constructs encoding N and IL-2 gene can be transcribed successfully in the eukaryotic system.Expression of recombinant plasmids in Vero cells ::: ResultsThe expression of pIRES-N/IL2, pIRES-N was demonstrated by indirect immunofluorescence assay.", [["plasmids", "ANATOMY", 143, 151], ["Vero cells", "ANATOMY", 155, 165], ["IL-2", "GENE_OR_GENE_PRODUCT", 50, 54], ["Vero cells", "CELL", 155, 165], ["pIRES-N", "GENE_OR_GENE_PRODUCT", 195, 202], ["IL2", "GENE_OR_GENE_PRODUCT", 203, 206], ["pIRES-N", "GENE_OR_GENE_PRODUCT", 208, 215], ["N and IL-2 gene", "DNA", 44, 59], ["recombinant plasmids", "DNA", 131, 151], ["Vero cells", "CELL_LINE", 155, 165], ["pIRES", "PROTEIN", 195, 200], ["N", "PROTEIN", 201, 202], ["IL2", "PROTEIN", 203, 206], ["pIRES", "PROTEIN", 208, 213], ["N", "DNA", 214, 215], ["constructs encoding N and IL-2 gene", "TREATMENT", 24, 59], ["pIRES", "TEST", 195, 200], ["IL2", "TREATMENT", 203, 206], ["indirect immunofluorescence assay", "TEST", 236, 269], ["recombinant plasmids", "OBSERVATION", 131, 151], ["Vero cells", "OBSERVATION", 155, 165]]], ["After transfection with lipofectamine, the transfected cells displayed positive signals for the protein and located cytoplasm, where there was green fluorescence.", [["cells", "ANATOMY", 55, 60], ["cytoplasm", "ANATOMY", 116, 125], ["lipofectamine", "CHEMICAL", 24, 37], ["lipofectamine", "CHEMICAL", 24, 37], ["lipofectamine", "SIMPLE_CHEMICAL", 24, 37], ["cells", "CELL", 55, 60], ["cytoplasm", "ORGANISM_SUBSTANCE", 116, 125], ["transfected cells", "CELL_LINE", 43, 60], ["lipofectamine", "TREATMENT", 24, 37], ["the transfected cells", "TEST", 39, 60], ["the protein and located cytoplasm", "PROBLEM", 92, 125], ["green fluorescence", "PROBLEM", 143, 161], ["green fluorescence", "OBSERVATION", 143, 161]]], ["Expression of N protein was not detected in transfected empty plasmid control cells (Fig. 3).", [["plasmid", "ANATOMY", 62, 69], ["cells", "ANATOMY", 78, 83], ["cells", "CELL", 78, 83], ["N protein", "PROTEIN", 14, 23], ["transfected empty plasmid control cells", "CELL_LINE", 44, 83], ["N protein", "TEST", 14, 23]]], ["This result shows that constructs encoding N protein can be successfully expressed in the eukaryotic system.Humoral responses to IBV in chickens vaccinated with recombinant plasmids ::: ResultsThe plasmids pIRES-N/IL2, pIRES-N induced detectable antibodies to IBV Ag in chickens one week after injection and the levels increased with subsequent vaccination.", [["plasmids", "ANATOMY", 197, 205], ["Ag", "CHEMICAL", 264, 266], ["Ag", "CHEMICAL", 264, 266], ["N protein", "GENE_OR_GENE_PRODUCT", 43, 52], ["IBV", "ORGANISM", 129, 132], ["chickens", "ORGANISM", 136, 144], ["pIRES-N", "GENE_OR_GENE_PRODUCT", 206, 213], ["IL2", "GENE_OR_GENE_PRODUCT", 214, 217], ["pIRES-N", "GENE_OR_GENE_PRODUCT", 219, 226], ["IBV", "ORGANISM", 260, 263], ["Ag", "GENE_OR_GENE_PRODUCT", 264, 266], ["chickens", "ORGANISM", 270, 278], ["N protein", "PROTEIN", 43, 52], ["recombinant plasmids", "DNA", 161, 181], ["plasmids", "DNA", 197, 205], ["pIRES", "DNA", 206, 211], ["N", "DNA", 212, 213], ["IL2", "PROTEIN", 214, 217], ["pIRES", "DNA", 219, 224], ["N", "DNA", 225, 226], ["Ag", "PROTEIN", 264, 266], ["chickens", "SPECIES", 136, 144], ["chickens", "SPECIES", 270, 278], ["IBV", "SPECIES", 129, 132], ["chickens", "SPECIES", 136, 144], ["IBV", "SPECIES", 260, 263], ["chickens", "SPECIES", 270, 278], ["constructs encoding N protein", "TREATMENT", 23, 52], ["IBV", "TREATMENT", 129, 132], ["The plasmids pIRES", "TREATMENT", 193, 211], ["IL2", "TREATMENT", 214, 217], ["pIRES", "TEST", 219, 224], ["detectable antibodies", "PROBLEM", 235, 256], ["injection", "TREATMENT", 294, 303], ["the levels", "TEST", 308, 318], ["subsequent vaccination", "TREATMENT", 334, 356], ["eukaryotic system", "OBSERVATION", 90, 107]]], ["There was no specific antibody response in the group of chickens receiving PBS and pIRES plasmid.", [["chickens", "ORGANISM", 56, 64], ["PBS and pIRES plasmid", "DNA", 75, 96], ["chickens", "SPECIES", 56, 64], ["chickens", "SPECIES", 56, 64], ["specific antibody response", "PROBLEM", 13, 39], ["PBS", "TREATMENT", 75, 78], ["pIRES plasmid", "TREATMENT", 83, 96], ["no", "UNCERTAINTY", 10, 12], ["specific", "OBSERVATION_MODIFIER", 13, 21], ["antibody response", "OBSERVATION", 22, 39]]], ["There was a significant difference in ELISA antibody levels (P< 0.05) elicited by either monocistronic or bicistronic DNA vaccines since the 14th-day after first inoculation.", [["DNA", "CELLULAR_COMPONENT", 118, 121], ["ELISA antibody", "PROTEIN", 38, 52], ["a significant difference", "PROBLEM", 10, 34], ["ELISA antibody levels", "TEST", 38, 59], ["bicistronic DNA vaccines", "TREATMENT", 106, 130], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["difference", "OBSERVATION_MODIFIER", 24, 34]]], ["The result suggests that the bicistronic pIRES-N/IL2 can enhance humoral responses (Fig. 4).Cellular immune responses induced by recombinant plasmids vaccination ::: ResultsPeripheral blood lymphocytes were analyzed by flow cytometry on day 7 after the boosting immunization.", [["Cellular", "ANATOMY", 92, 100], ["plasmids", "ANATOMY", 141, 149], ["ResultsPeripheral blood lymphocytes", "ANATOMY", 166, 201], ["pIRES-N", "GENE_OR_GENE_PRODUCT", 41, 48], ["IL2", "GENE_OR_GENE_PRODUCT", 49, 52], ["Cellular", "CELL", 92, 100], ["ResultsPeripheral blood lymphocytes", "CELL", 166, 201], ["pIRES", "PROTEIN", 41, 46], ["N", "PROTEIN", 47, 48], ["IL2", "PROTEIN", 49, 52], ["ResultsPeripheral blood lymphocytes", "CELL_TYPE", 166, 201], ["the bicistronic pIRES", "PROBLEM", 25, 46], ["N/IL2", "TREATMENT", 47, 52], ["ResultsPeripheral blood lymphocytes", "TEST", 166, 201], ["flow cytometry", "TEST", 219, 233], ["the boosting immunization", "TREATMENT", 249, 274], ["lymphocytes", "ANATOMY", 190, 201]]], ["The percentage of CD3+ and CD4+CD3+ T-lymphocytes significantly higher (P< 0.05) was observed from chickens immunized with pIRES-N/IL2 than the pIRES-N group.", [["CD3+", "ANATOMY", 18, 22], ["CD4+CD3+ T-lymphocytes", "ANATOMY", 27, 49], ["CD3", "GENE_OR_GENE_PRODUCT", 18, 21], ["CD4", "GENE_OR_GENE_PRODUCT", 27, 30], ["CD3", "GENE_OR_GENE_PRODUCT", 31, 34], ["chickens", "ORGANISM", 99, 107], ["IL2", "GENE_OR_GENE_PRODUCT", 131, 134], ["pIRES-N", "SIMPLE_CHEMICAL", 144, 151], ["CD3", "PROTEIN", 18, 21], ["CD4", "PROTEIN", 27, 30], ["CD3", "PROTEIN", 31, 34], ["T-lymphocytes", "CELL_TYPE", 36, 49], ["pIRES", "PROTEIN", 123, 128], ["IL2", "PROTEIN", 131, 134], ["chickens", "SPECIES", 99, 107], ["chickens", "SPECIES", 99, 107], ["CD3", "TEST", 18, 21], ["CD4", "TEST", 27, 30], ["CD3", "TEST", 31, 34], ["T", "TEST", 36, 37], ["lymphocytes", "TEST", 38, 49], ["pIRES", "TEST", 123, 128], ["IL2", "TREATMENT", 131, 134], ["CD3", "OBSERVATION", 18, 21]]], ["The percentage numbers of CD8+CD3+ T-lymphocytes subgroups of the pIRES-N/IL2-vaccinated group were higher than the pIRES-N-vaccinated group but no significant difference (P> 0.05) (Fig. 5).Protection after challenge ::: ResultsMortality, kidney infection and percent protection after challenge of chickens were summarized in Table 1.", [["CD8+CD3+ T-lymphocytes", "ANATOMY", 26, 48], ["kidney", "ANATOMY", 239, 245], ["kidney infection", "DISEASE", 239, 255], ["CD8", "GENE_OR_GENE_PRODUCT", 26, 29], ["CD3", "GENE_OR_GENE_PRODUCT", 30, 33], ["pIRES", "GENE_OR_GENE_PRODUCT", 66, 71], ["IL2", "GENE_OR_GENE_PRODUCT", 74, 77], ["kidney", "ORGAN", 239, 245], ["chickens", "ORGANISM", 298, 306], ["CD8", "PROTEIN", 26, 29], ["CD3", "PROTEIN", 30, 33], ["IL2", "PROTEIN", 74, 77], ["chickens", "SPECIES", 298, 306], ["chickens", "SPECIES", 298, 306], ["The percentage numbers", "TEST", 0, 22], ["CD8", "TEST", 26, 29], ["CD3", "TEST", 30, 33], ["T", "TEST", 35, 36], ["the pIRES", "TEST", 62, 71], ["IL2", "TREATMENT", 74, 77], ["the pIRES", "TEST", 112, 121], ["significant difference", "PROBLEM", 148, 170], ["P", "TEST", 172, 173], ["kidney infection", "PROBLEM", 239, 255], ["percent protection", "TREATMENT", 260, 278], ["challenge of chickens", "TREATMENT", 285, 306], ["IL2", "ANATOMY", 74, 77], ["no", "UNCERTAINTY", 145, 147], ["significant", "OBSERVATION_MODIFIER", 148, 159], ["kidney", "ANATOMY", 239, 245], ["infection", "OBSERVATION", 246, 255], ["percent", "OBSERVATION_MODIFIER", 260, 267], ["protection", "OBSERVATION_MODIFIER", 268, 278]]], ["Chickens that started to show clinical signs or died from viral infection did so beginning on day 5 after challenge.", [["viral infection", "DISEASE", 58, 73], ["Chickens", "ORGANISM", 0, 8], ["Chickens", "SPECIES", 0, 8], ["Chickens", "SPECIES", 0, 8], ["Chickens", "TREATMENT", 0, 8], ["clinical signs", "PROBLEM", 30, 44], ["viral infection", "PROBLEM", 58, 73], ["viral", "OBSERVATION_MODIFIER", 58, 63], ["infection", "OBSERVATION", 64, 73]]], ["The chickens immunized with either control vector pIRES or PBS were not protected and developed coughing, nasal discharge, dyspnea.", [["nasal", "ANATOMY", 106, 111], ["coughing", "DISEASE", 96, 104], ["dyspnea", "DISEASE", 123, 130], ["chickens", "ORGANISM", 4, 12], ["nasal", "ORGANISM_SUBDIVISION", 106, 111], ["chickens", "SPECIES", 4, 12], ["chickens", "SPECIES", 4, 12], ["The chickens immunized", "TREATMENT", 0, 22], ["PBS", "TREATMENT", 59, 62], ["coughing", "PROBLEM", 96, 104], ["nasal discharge", "PROBLEM", 106, 121], ["dyspnea", "PROBLEM", 123, 130], ["coughing", "OBSERVATION", 96, 104], ["nasal", "ANATOMY", 106, 111], ["dyspnea", "OBSERVATION", 123, 130]]], ["The death rate of the pIRES and PBS immunized chickens was 55 and 65% at 14 days after challenge, respectively.", [["death", "DISEASE", 4, 9], ["pIRES", "CANCER", 22, 27], ["chickens", "ORGANISM", 46, 54], ["chickens", "SPECIES", 46, 54], ["chickens", "SPECIES", 46, 54], ["The death rate", "TEST", 0, 14], ["PBS immunized chickens", "TEST", 32, 54]]], ["The death rate of the pIRES-N/IL2 DNA vaccine immunized chickens was only 5%, lower than that of the chickens injected with the pIRES-N DNA vaccine.", [["death", "DISEASE", 4, 9], ["pIRES-N", "CHEMICAL", 22, 29], ["pIRES-N", "CHEMICAL", 128, 135], ["pIRES-N", "GENE_OR_GENE_PRODUCT", 22, 29], ["IL2", "GENE_OR_GENE_PRODUCT", 30, 33], ["DNA", "CELLULAR_COMPONENT", 34, 37], ["chickens", "ORGANISM", 56, 64], ["chickens", "ORGANISM", 101, 109], ["DNA", "CELLULAR_COMPONENT", 136, 139], ["IL2", "PROTEIN", 30, 33], ["chickens", "SPECIES", 56, 64], ["chickens", "SPECIES", 101, 109], ["chickens", "SPECIES", 56, 64], ["chickens", "SPECIES", 101, 109], ["The death rate", "TEST", 0, 14], ["the pIRES", "TREATMENT", 18, 27], ["N/IL2 DNA vaccine", "TREATMENT", 28, 45], ["the pIRES", "TREATMENT", 124, 133], ["N DNA vaccine", "TREATMENT", 134, 147]]], ["To evaluate the level of protective response after challenge, the collected kidney samples were analyzed by RT-PCR.", [["kidney samples", "ANATOMY", 76, 90], ["kidney samples", "CANCER", 76, 90], ["the collected kidney samples", "TEST", 62, 90], ["RT-PCR", "TEST", 108, 114], ["kidney", "ANATOMY", 76, 82]]], ["PCR results indicated that 20 and 50% of birds vaccinated with the pIRES-N/IL2 and pIRES-N plasmids were positive for the presence of virus in the kidney, respectively.", [["kidney", "ANATOMY", 147, 153], ["birds", "ORGANISM", 41, 46], ["IL2", "GENE_OR_GENE_PRODUCT", 75, 78], ["pIRES-N plasmids", "GENE_OR_GENE_PRODUCT", 83, 99], ["kidney", "ORGAN", 147, 153], ["pIRES-N/IL2 and pIRES-N plasmids", "DNA", 67, 99], ["PCR", "TEST", 0, 3], ["the pIRES", "TEST", 63, 72], ["IL2", "TREATMENT", 75, 78], ["pIRES", "TEST", 83, 88], ["N plasmids", "TREATMENT", 89, 99], ["virus in the kidney", "PROBLEM", 134, 153], ["virus", "OBSERVATION", 134, 139], ["kidney", "ANATOMY", 147, 153]]], ["All chickens immunized with either control vector pIRES or PBS were positive in RT-PCR test.", [["chickens", "ORGANISM", 4, 12], ["pIRES", "GENE_OR_GENE_PRODUCT", 50, 55], ["chickens", "SPECIES", 4, 12], ["chickens", "SPECIES", 4, 12], ["All chickens immunized", "TREATMENT", 0, 22], ["PBS", "TEST", 59, 62], ["PCR test", "TEST", 83, 91]]], ["The protection percent of group that vaccinated with the pIRES-N alone was higher than that of the empty vector or PBS.", [["pIRES-N", "CHEMICAL", 57, 64], ["pIRES-N", "SIMPLE_CHEMICAL", 57, 64], ["pIRES", "PROTEIN", 57, 62], ["the pIRES-N", "TREATMENT", 53, 64]]], ["The group vaccinated with the pIRES-N/IL2 DNA vaccine (80%) had the highest protection rate in all vaccinated groups.", [["IL2", "GENE_OR_GENE_PRODUCT", 38, 41], ["DNA", "CELLULAR_COMPONENT", 42, 45], ["IL2", "PROTEIN", 38, 41], ["the pIRES", "TREATMENT", 26, 35], ["N/IL2 DNA vaccine", "TREATMENT", 36, 53]]], ["This suggests that the plasmid expressing both N protein and IL-2 offers enhanced resistance against a virulent IBV challenge.DiscussionIn order to increase the efficiency of this immunization procedure, cytokine was co-expressed with the viral protein.", [["plasmid", "ANATOMY", 23, 30], ["IL-2", "GENE_OR_GENE_PRODUCT", 61, 65], ["IBV", "ORGANISM", 112, 115], ["plasmid", "DNA", 23, 30], ["N protein", "PROTEIN", 47, 56], ["IL-2", "PROTEIN", 61, 65], ["cytokine", "PROTEIN", 204, 212], ["viral protein", "PROTEIN", 239, 252], ["IBV", "SPECIES", 112, 115], ["the plasmid expressing both N protein and IL", "TREATMENT", 19, 63], ["enhanced resistance", "PROBLEM", 73, 92], ["a virulent IBV challenge", "TREATMENT", 101, 125], ["this immunization procedure", "TREATMENT", 175, 202], ["cytokine", "TREATMENT", 204, 212], ["the viral protein", "TEST", 235, 252], ["virulent", "OBSERVATION_MODIFIER", 103, 111], ["IBV", "OBSERVATION", 112, 115]]], ["This strategy has already been used successfully to enhance the effect of DNA vaccination procedures (Li et al., 2006, Chow et al., 1997, Henke et al., 2004).", [["DNA", "CELLULAR_COMPONENT", 74, 77], ["DNA vaccination procedures", "TREATMENT", 74, 100]]], ["The pIRES-EGFP/DsRed bicistronic plasmid which was constructed and identified previously was used to construct monocistronic and bicistronic DNA vaccines.", [["pIRES", "GENE_OR_GENE_PRODUCT", 4, 9], ["EGFP", "GENE_OR_GENE_PRODUCT", 10, 14], ["DsRed", "GENE_OR_GENE_PRODUCT", 15, 20], ["DNA", "CELLULAR_COMPONENT", 141, 144], ["pIRES-EGFP/DsRed bicistronic plasmid", "DNA", 4, 40], ["monocistronic", "DNA", 111, 124], ["The pIRES", "TEST", 0, 9], ["DsRed bicistronic plasmid", "TREATMENT", 15, 40], ["monocistronic and bicistronic DNA vaccines", "TREATMENT", 111, 153]]], ["The plasmid pIRES-EGFP/DsRed enabled the simultaneous translation of two genes of interest from the same RNA transcript.", [["plasmid", "ANATOMY", 4, 11], ["pIRES", "GENE_OR_GENE_PRODUCT", 12, 17], ["EGFP", "GENE_OR_GENE_PRODUCT", 18, 22], ["pIRES", "DNA", 12, 17], ["EGFP", "DNA", 18, 22], ["DsRed", "DNA", 23, 28], ["RNA transcript", "RNA", 105, 119], ["The plasmid pIRES", "TEST", 0, 17]]], ["Each gene is cloned into one of the multiple cloning sites on either side of the internal ribosomal entry site of the encephalomyocarditis virus (EMCV).", [["ribosomal", "ANATOMY", 90, 99], ["ribosomal", "CELLULAR_COMPONENT", 90, 99], ["encephalomyocarditis virus", "ORGANISM", 118, 144], ["EMCV", "ORGANISM", 146, 150], ["multiple cloning sites", "DNA", 36, 58], ["internal ribosomal entry site", "DNA", 81, 110], ["encephalomyocarditis virus", "SPECIES", 118, 144], ["encephalomyocarditis virus", "SPECIES", 118, 144], ["EMCV", "SPECIES", 146, 150], ["the encephalomyocarditis virus", "PROBLEM", 114, 144], ["multiple", "OBSERVATION_MODIFIER", 36, 44], ["cloning", "OBSERVATION", 45, 52], ["internal ribosomal", "ANATOMY", 81, 99], ["entry site", "OBSERVATION", 100, 110], ["encephalomyocarditis virus", "OBSERVATION", 118, 144]]], ["The entire construct is under control of the cytomegalovirus (CMV) immediate-early promoter allowing the expression of two individual proteins from one plasmid.", [["plasmid", "ANATOMY", 152, 159], ["cytomegalovirus", "ORGANISM", 45, 60], ["CMV", "ORGANISM", 62, 65], ["cytomegalovirus (CMV) immediate-early promoter", "DNA", 45, 91], ["plasmid", "DNA", 152, 159], ["CMV", "SPECIES", 62, 65], ["the cytomegalovirus", "PROBLEM", 41, 60], ["one plasmid", "TREATMENT", 148, 159], ["cytomegalovirus", "OBSERVATION", 45, 60]]], ["In this study, an experimental immunization strategy was developed and tested against IBV.", [["IBV", "ORGANISM", 86, 89], ["IBV", "SPECIES", 86, 89], ["this study", "TEST", 3, 13], ["an experimental immunization strategy", "TREATMENT", 15, 52], ["IBV", "PROBLEM", 86, 89]]], ["Two recombinant plasmids pIRES-N/IL2, pIRES-N were constructed.", [["plasmids", "ANATOMY", 16, 24], ["pIRES-N", "GENE_OR_GENE_PRODUCT", 25, 32], ["IL2", "GENE_OR_GENE_PRODUCT", 33, 36], ["pIRES-N", "GENE_OR_GENE_PRODUCT", 38, 45], ["recombinant plasmids", "DNA", 4, 24], ["pIRES", "DNA", 25, 30], ["N", "DNA", 31, 32], ["IL2", "DNA", 33, 36], ["pIRES", "DNA", 38, 43], ["N", "DNA", 44, 45], ["Two recombinant plasmids pIRES", "TEST", 0, 30]]], ["These recombinant plasmids were inoculated in chickens and tested in a protection-challenge experiment, demonstrating that vaccination with the co-expression plasmid pIRES-N/IL2 can induce stronger immune response than vaccination with pIRES-N.", [["plasmids", "ANATOMY", 18, 26], ["chickens", "ORGANISM", 46, 54], ["pIRES-N", "GENE_OR_GENE_PRODUCT", 166, 173], ["IL2", "GENE_OR_GENE_PRODUCT", 174, 177], ["recombinant plasmids", "DNA", 6, 26], ["co-expression plasmid", "DNA", 144, 165], ["pIRES", "DNA", 166, 171], ["N", "DNA", 172, 173], ["IL2", "PROTEIN", 174, 177], ["pIRES", "PROTEIN", 236, 241], ["chickens", "SPECIES", 46, 54], ["chickens", "SPECIES", 46, 54], ["These recombinant plasmids", "TREATMENT", 0, 26], ["the co-expression plasmid pIRES", "TREATMENT", 140, 171], ["N/IL2", "TREATMENT", 172, 177]]], ["Thus, it seems that vaccination with a bicistronic DNA vaccine expressing both IBV N protein and IL-2 may elicit potent immune response.DiscussionIn this study, the level of specific antibodies developed in pIRES-N/IL2 group was higher than that of pIRES-N group.", [["DNA", "CELLULAR_COMPONENT", 51, 54], ["IBV N protein", "GENE_OR_GENE_PRODUCT", 79, 92], ["IL-2", "GENE_OR_GENE_PRODUCT", 97, 101], ["IL2", "GENE_OR_GENE_PRODUCT", 215, 218], ["pIRES-N", "SIMPLE_CHEMICAL", 249, 256], ["IBV N protein", "PROTEIN", 79, 92], ["IL-2", "PROTEIN", 97, 101], ["specific antibodies", "PROTEIN", 174, 193], ["pIRES", "PROTEIN", 207, 212], ["IL2", "PROTEIN", 215, 218], ["pIRES", "PROTEIN", 249, 254], ["IBV", "SPECIES", 79, 82], ["vaccination", "TREATMENT", 20, 31], ["a bicistronic DNA vaccine", "TREATMENT", 37, 62], ["IBV N protein and IL", "TREATMENT", 79, 99], ["this study", "TEST", 149, 159], ["specific antibodies", "TEST", 174, 193], ["pIRES", "TEST", 207, 212], ["N/IL2 group", "TREATMENT", 213, 224]]], ["However, the precise role of antibodies for the control of IBV infection remains controversial.", [["IBV infection", "DISEASE", 59, 72], ["IBV", "ORGANISM", 59, 62], ["antibodies", "PROTEIN", 29, 39], ["IBV", "SPECIES", 59, 62], ["antibodies", "TREATMENT", 29, 39], ["IBV infection", "PROBLEM", 59, 72], ["infection", "OBSERVATION", 63, 72]]], ["Some reports have shown that circulating antibody titer did not correlate with protection from IBV infection (Gelb et al., 1998, Gough and Alexander, 1979, Raggi and Lee, 1965).", [["IBV infection", "DISEASE", 95, 108], ["IBV", "ORGANISM", 95, 98], ["IBV", "SPECIES", 95, 98], ["circulating antibody titer", "TEST", 29, 55], ["IBV infection", "PROBLEM", 95, 108], ["infection", "OBSERVATION", 99, 108]]], ["Other studies demonstrated that humoral immunity plays an important role in disease recovery and virus clearance (Cook et al., 1991, Thompson et al., 1997, Toro and Fernandez, 1994).", [["Other studies", "TEST", 0, 13]]], ["The antibody-dependence of the mechanism of protection against the disease remains unclear, suggesting an important role of the T-cell response in efficacy protection.DiscussionIn order to evaluate recombinant plasmids induced T-cell response, peripheral blood lymphocytes were analyzed by flow cytometry.", [["T-cell", "ANATOMY", 128, 134], ["plasmids", "ANATOMY", 210, 218], ["T-cell", "ANATOMY", 227, 233], ["peripheral blood lymphocytes", "ANATOMY", 244, 272], ["T-cell", "CELL", 128, 134], ["T-cell", "CELL", 227, 233], ["peripheral blood lymphocytes", "CELL", 244, 272], ["recombinant plasmids", "DNA", 198, 218], ["peripheral blood lymphocytes", "CELL_TYPE", 244, 272], ["The antibody", "TEST", 0, 12], ["the disease", "PROBLEM", 63, 74], ["efficacy protection", "TREATMENT", 147, 166], ["recombinant plasmids", "TREATMENT", 198, 218], ["peripheral blood lymphocytes", "TEST", 244, 272], ["flow cytometry", "TEST", 290, 304], ["disease", "OBSERVATION", 67, 74], ["peripheral", "ANATOMY_MODIFIER", 244, 254], ["blood lymphocytes", "ANATOMY", 255, 272], ["flow cytometry", "OBSERVATION", 290, 304]]], ["Results of T-lymphocytes subgroup detection indicated, that the percentage numbers of CD3+, CD4+CD3+ and CD8+CD3+ T-lymphocytes subgroups in pIRES-N/IL2 vaccinated chickens group were higher than those in the pIRES-N vaccinated chickens.", [["T-lymphocytes", "ANATOMY", 11, 24], ["CD3+, CD4+CD3+", "ANATOMY", 86, 100], ["CD8+CD3+ T-lymphocytes", "ANATOMY", 105, 127], ["T-lymphocytes", "CELL", 11, 24], ["CD3", "GENE_OR_GENE_PRODUCT", 86, 89], ["CD4", "GENE_OR_GENE_PRODUCT", 92, 95], ["CD3", "GENE_OR_GENE_PRODUCT", 96, 99], ["CD8", "GENE_OR_GENE_PRODUCT", 105, 108], ["CD3", "GENE_OR_GENE_PRODUCT", 109, 112], ["IL2", "GENE_OR_GENE_PRODUCT", 149, 152], ["chickens", "ORGANISM", 164, 172], ["pIRES-N vaccinated", "ORGANISM", 209, 227], ["chickens", "ORGANISM", 228, 236], ["CD3", "PROTEIN", 86, 89], ["CD4", "PROTEIN", 92, 95], ["CD3", "PROTEIN", 96, 99], ["CD8", "PROTEIN", 105, 108], ["CD3", "PROTEIN", 109, 112], ["IL2", "PROTEIN", 149, 152], ["chickens", "SPECIES", 164, 172], ["chickens", "SPECIES", 228, 236], ["chickens", "SPECIES", 164, 172], ["chickens", "SPECIES", 228, 236], ["T-lymphocytes subgroup detection", "TEST", 11, 43], ["the percentage numbers", "TEST", 60, 82], ["CD3", "TEST", 86, 89], ["CD4", "TEST", 92, 95], ["CD3", "TEST", 96, 99], ["CD8", "TEST", 105, 108], ["CD3", "TEST", 109, 112], ["T", "TEST", 114, 115], ["lymphocytes", "TEST", 116, 127], ["pIRES", "TEST", 141, 146], ["N/IL2 vaccinated chickens group", "TREATMENT", 147, 178]]], ["This demonstrated that IL-2 has the ability to stimulate T-cell growth.", [["T-cell", "ANATOMY", 57, 63], ["IL-2", "GENE_OR_GENE_PRODUCT", 23, 27], ["T-cell", "CELL", 57, 63], ["IL-2", "PROTEIN", 23, 27]]], ["It has been shown that cell-mediated immunity to IBV is also induced and is believed to be a protective mechanism in IBV infection.", [["cell", "ANATOMY", 23, 27], ["IBV infection", "DISEASE", 117, 130], ["cell", "CELL", 23, 27], ["IBV", "ORGANISM", 49, 52], ["IBV", "ORGANISM", 117, 120], ["IBV", "SPECIES", 49, 52], ["IBV", "SPECIES", 117, 120], ["cell-mediated immunity", "TREATMENT", 23, 45], ["IBV", "PROBLEM", 49, 52], ["IBV infection", "PROBLEM", 117, 130], ["believed to be", "UNCERTAINTY", 76, 90], ["IBV", "OBSERVATION_MODIFIER", 117, 120], ["infection", "OBSERVATION", 121, 130]]], ["CD8+ CTL are critical in the control of infectious bronchitis in poultry (Collisson et al., 2000, Dhinakar and Jones, 1997, Seo et al., 2000).", [["infectious bronchitis", "DISEASE", 40, 61], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD8", "PROTEIN", 0, 3], ["CTL", "CELL_TYPE", 5, 8], ["CD8", "TEST", 0, 3], ["CTL", "PROBLEM", 5, 8], ["infectious bronchitis", "PROBLEM", 40, 61], ["infectious", "OBSERVATION_MODIFIER", 40, 50], ["bronchitis", "OBSERVATION", 51, 61]]], ["CD4+ T-cell responses may increase the proliferation, maturation and functional activity of CD8+ CTL, providing increased help for B-cells and directly producing antiviral cytokines.", [["CD4+ T-cell", "ANATOMY", 0, 11], ["CD8+ CTL", "ANATOMY", 92, 100], ["B-cells", "ANATOMY", 131, 138], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD8", "GENE_OR_GENE_PRODUCT", 92, 95], ["B-cells", "CELL", 131, 138], ["CD4", "PROTEIN", 0, 3], ["CD8", "PROTEIN", 92, 95], ["CTL", "CELL_TYPE", 97, 100], ["B-cells", "CELL_TYPE", 131, 138], ["antiviral cytokines", "PROTEIN", 162, 181], ["CD4", "TEST", 0, 3], ["the proliferation", "PROBLEM", 35, 52], ["CD8+ CTL", "TREATMENT", 92, 100], ["B-cells", "TREATMENT", 131, 138], ["antiviral cytokines", "TREATMENT", 162, 181], ["T-cell", "OBSERVATION", 5, 11], ["proliferation", "OBSERVATION_MODIFIER", 39, 52], ["antiviral cytokines", "OBSERVATION", 162, 181]]], ["By increasing the number of T-cells at the same site being able to respond to N antigen, there might have been a limiting effect on viral replication leading to better protection.DiscussionTo investigate the level of protection elicited by pIRES-N/IL2, vaccinated chickens were challenged with a nephropathogenic strain of IBV.", [["T-cells", "ANATOMY", 28, 35], ["T-cells", "CELL", 28, 35], ["N antigen", "GENE_OR_GENE_PRODUCT", 78, 87], ["pIRES-N", "GENE_OR_GENE_PRODUCT", 240, 247], ["IL2", "GENE_OR_GENE_PRODUCT", 248, 251], ["chickens", "ORGANISM", 264, 272], ["IBV", "ORGANISM", 323, 326], ["T-cells", "CELL_TYPE", 28, 35], ["N antigen", "PROTEIN", 78, 87], ["pIRES", "PROTEIN", 240, 245], ["N", "PROTEIN", 246, 247], ["IL2", "PROTEIN", 248, 251], ["chickens", "SPECIES", 264, 272], ["chickens", "SPECIES", 264, 272], ["IBV", "SPECIES", 323, 326], ["viral replication", "TREATMENT", 132, 149], ["pIRES", "TEST", 240, 245], ["IL2", "TREATMENT", 248, 251], ["vaccinated chickens", "TREATMENT", 253, 272], ["a nephropathogenic strain of IBV", "TREATMENT", 294, 326]]], ["Chickens that received the pIRES-N/IL2 plasmid DNA were better protected than that administered with the plasmid pIRES-N.", [["Chickens", "ORGANISM", 0, 8], ["IL2", "GENE_OR_GENE_PRODUCT", 35, 38], ["DNA", "CELLULAR_COMPONENT", 47, 50], ["pIRES-N/IL2 plasmid DNA", "DNA", 27, 50], ["plasmid pIRES", "DNA", 105, 118], ["Chickens", "SPECIES", 0, 8], ["Chickens", "SPECIES", 0, 8], ["Chickens", "TREATMENT", 0, 8], ["the pIRES", "TREATMENT", 23, 32], ["N/IL2 plasmid DNA", "TREATMENT", 33, 50]]], ["Mortality of pIRES-N/IL2 group was lower than that of pIRES-N group.", [["IL2", "GENE_OR_GENE_PRODUCT", 21, 24], ["pIRES-N", "SIMPLE_CHEMICAL", 54, 61], ["pIRES", "PROTEIN", 13, 18], ["IL2", "PROTEIN", 21, 24], ["pIRES", "TEST", 13, 18], ["N/IL2 group", "TREATMENT", 19, 30]]], ["The protection rate of pIRES-N/IL2 group was the highest in all the vaccination groups, possibly indicating protective immunity overcome by virus aggressiveness.", [["pIRES-N", "CHEMICAL", 23, 30], ["aggressiveness", "DISEASE", 146, 160], ["pIRES-N", "GENE_OR_GENE_PRODUCT", 23, 30], ["IL2", "GENE_OR_GENE_PRODUCT", 31, 34], ["pIRES", "PROTEIN", 23, 28], ["IL2", "PROTEIN", 31, 34], ["The protection rate of pIRES", "TREATMENT", 0, 28], ["N/IL2 group", "TREATMENT", 29, 40], ["possibly indicating", "UNCERTAINTY", 88, 107]]], ["These results suggested that vaccination with the co-expression plasmid of N protein gene and IL-2 may have increased the protection rate against challenge.DiscussionResults of immune response and viral challenge showed that the group inoculated with pIRES-N/IL2 provided stronger immune response and better protection rate than pIRES-N vaccinated group.", [["pIRES-N", "CHEMICAL", 329, 336], ["N protein", "GENE_OR_GENE_PRODUCT", 75, 84], ["IL-2", "GENE_OR_GENE_PRODUCT", 94, 98], ["pIRES-N", "GENE_OR_GENE_PRODUCT", 251, 258], ["IL2", "GENE_OR_GENE_PRODUCT", 259, 262], ["pIRES-N", "SIMPLE_CHEMICAL", 329, 336], ["co-expression plasmid", "DNA", 50, 71], ["N protein gene", "DNA", 75, 89], ["IL-2", "DNA", 94, 98], ["pIRES", "PROTEIN", 251, 256], ["N", "PROTEIN", 257, 258], ["IL2", "PROTEIN", 259, 262], ["vaccination", "TREATMENT", 29, 40], ["the co-expression plasmid of N protein gene", "TREATMENT", 46, 89], ["IL-2", "TREATMENT", 94, 98], ["immune response", "PROBLEM", 177, 192], ["viral challenge", "TEST", 197, 212], ["pIRES", "TEST", 251, 256], ["N/IL2", "TREATMENT", 257, 262], ["pIRES", "TEST", 329, 334]]], ["This indicated that IL-2 might effectively enhanced humoral-mediated immune and cell-mediated immune responses to some extent.", [["cell", "ANATOMY", 80, 84], ["IL-2", "GENE_OR_GENE_PRODUCT", 20, 24], ["immune", "CELL", 69, 75], ["cell", "CELL", 80, 84], ["IL", "PROTEIN", 20, 22], ["IL", "TEST", 20, 22]]], ["This was consistent with the result of previous reports (Li et al., 2006, Chow et al., 1997, Henke et al., 2004).", [["consistent with", "UNCERTAINTY", 9, 24]]], ["These results demonstrated that bicistronic DNA vaccine is an effective approach to increase IBV DNA vaccine immunogenicity.DiscussionOur results showing the induction of both antibody and T-cell responses against the IBV challenge in chickens demonstrate that the delivery of antigens and cytokines via bicistronic vectors is feasible in the chicken model.", [["T-cell", "ANATOMY", 189, 195], ["DNA", "CELLULAR_COMPONENT", 44, 47], ["IBV", "ORGANISM", 93, 96], ["DNA", "CELLULAR_COMPONENT", 97, 100], ["T-cell", "CELL", 189, 195], ["IBV", "ORGANISM", 218, 221], ["chickens", "ORGANISM", 235, 243], ["chicken", "ORGANISM", 343, 350], ["antigens", "PROTEIN", 277, 285], ["cytokines", "PROTEIN", 290, 299], ["chickens", "SPECIES", 235, 243], ["chicken", "SPECIES", 343, 350], ["IBV", "SPECIES", 93, 96], ["IBV", "SPECIES", 218, 221], ["chickens", "SPECIES", 235, 243], ["chicken", "SPECIES", 343, 350], ["bicistronic DNA vaccine", "TREATMENT", 32, 55], ["an effective approach", "TREATMENT", 59, 80], ["IBV DNA vaccine immunogenicity", "TREATMENT", 93, 123], ["both antibody", "TEST", 171, 184], ["the IBV challenge", "TREATMENT", 214, 231], ["the delivery of antigens", "TREATMENT", 261, 285], ["cytokines via bicistronic vectors", "TREATMENT", 290, 323], ["bicistronic DNA", "OBSERVATION", 32, 47]]]], "0fc8c7b924f71a4705b68ba5a897ee2599807a9e": [["BackgroundAerosol characterization, its transportation, coagulation and settlement have been of interest to nuclear, fossil power and chemical process industries and various supporting technologies are available within the country for environmental protection.", [["nuclear", "ANATOMY", 108, 115], ["nuclear", "CELLULAR_COMPONENT", 108, 115], ["BackgroundAerosol characterization", "TEST", 0, 34], ["environmental protection", "TREATMENT", 235, 259]]], ["A National Aerosol Test Facility at IIT Kanpur in collaboration with BARC Trombay has been earlier set up to address specific safety issues related to aerosol transport within the Indian nuclear containment and primary heat transport systems.", [["nuclear", "ANATOMY", 187, 194], ["aerosol transport", "TREATMENT", 151, 168]]], ["With little intervention, it would be possible to evolve an optimal ventilation system for isolation rooms of COVID-19 patients and other viral diseases for the protection of health workers.BackgroundOver the last two decades, with the outbreaks of the severe acute respiratory syndrome (SARS) in [2002] [2003] and the human swine influenza (H1N1) in 2009, global interest has been generated to understand the transportation of pathogen within confined spaces.", [["viral diseases", "DISEASE", 138, 152], ["acute respiratory syndrome", "DISEASE", 260, 286], ["SARS", "DISEASE", 288, 292], ["swine influenza", "DISEASE", 325, 340], ["H1N1", "DISEASE", 342, 346], ["patients", "ORGANISM", 119, 127], ["human", "ORGANISM", 319, 324], ["swine influenza", "ORGANISM", 325, 340], ["patients", "SPECIES", 119, 127], ["human", "SPECIES", 319, 324], ["swine influenza (H1N1", "SPECIES", 325, 346], ["human swine influenza (H1N1)", "SPECIES", 319, 347], ["little intervention", "TREATMENT", 5, 24], ["COVID", "TEST", 110, 115], ["other viral diseases", "PROBLEM", 132, 152], ["the severe acute respiratory syndrome", "PROBLEM", 249, 286], ["the human swine influenza (H1N1", "PROBLEM", 315, 346], ["viral diseases", "OBSERVATION", 138, 152], ["severe", "OBSERVATION_MODIFIER", 253, 259], ["acute", "OBSERVATION_MODIFIER", 260, 265], ["respiratory syndrome", "OBSERVATION", 266, 286]]], ["Moreover, in the present-day scenario of pandemic COVID-19 and for other future applications it is desirable to limit the exposure of health workers.", [["COVID-19", "CHEMICAL", 50, 58], ["pandemic COVID", "TEST", 41, 55]]], ["The optimal design evolution of isolation rooms, quarantine facilities and clinics is desirable as different ventilation schemes are functions of pathogen size, initial velocity at the source, air quality described by its humidity and temperature.", [["different ventilation schemes", "TREATMENT", 99, 128], ["pathogen size", "PROBLEM", 146, 159], ["pathogen", "OBSERVATION_MODIFIER", 146, 154], ["size", "OBSERVATION_MODIFIER", 155, 159], ["velocity", "OBSERVATION_MODIFIER", 169, 177], ["air quality", "OBSERVATION", 193, 204]]], ["Controlling pathogen transport in confined spaces due to coughing, sneezing or talking requires efficient ventilation management for isolation wards, clinics and clean rooms with specified air changes, to protect the health professionals for their sustenance on a long-term basis with protective measures.", [["coughing", "DISEASE", 57, 65], ["sneezing", "DISEASE", 67, 75], ["coughing", "PROBLEM", 57, 65], ["sneezing", "PROBLEM", 67, 75], ["efficient ventilation management", "TREATMENT", 96, 128], ["isolation wards", "TREATMENT", 133, 148], ["a long-term basis", "TREATMENT", 262, 279], ["protective measures", "TREATMENT", 285, 304], ["air", "OBSERVATION", 189, 192]]], ["Ministry of Health and Family Welfare (MoHFW) generic guidelines require maintenance of negative pressure rooms with minimum of 12 air changes per hour or at least 160 l/s per patient in facilities with natural ventilation.", [["patient", "ORGANISM", 176, 183], ["patient", "SPECIES", 176, 183], ["maintenance of negative pressure rooms", "TREATMENT", 73, 111], ["natural ventilation", "TREATMENT", 203, 222], ["natural ventilation", "OBSERVATION", 203, 222]]], ["However, the existing isolation rooms, clinics and quarantine facilities with multiple patients and medical workers need to be provided with an optimum ventilation system.BackgroundIt was observed that within the indoor environments, there is a strong association between transmission of different pathogens, such as measles, tuberculosis, smallpox, and SARS, and the air movement, which is largely influenced by ventilation types as presented by Li et al. (2007) .", [["measles", "DISEASE", 317, 324], ["tuberculosis", "DISEASE", 326, 338], ["smallpox", "DISEASE", 340, 348], ["SARS", "DISEASE", 354, 358], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["an optimum ventilation system", "TREATMENT", 141, 170], ["different pathogens", "PROBLEM", 288, 307], ["measles", "PROBLEM", 317, 324], ["tuberculosis", "PROBLEM", 326, 338], ["smallpox", "PROBLEM", 340, 348], ["SARS", "PROBLEM", 354, 358], ["the air movement", "PROBLEM", 364, 380], ["different", "OBSERVATION_MODIFIER", 288, 297], ["pathogens", "OBSERVATION", 298, 307], ["tuberculosis", "OBSERVATION", 326, 338], ["air movement", "OBSERVATION", 368, 380], ["ventilation types", "OBSERVATION", 413, 430]]], ["Ventilation is the process of supplying fresh air to an enclosed space to refresh/remove the existing atmosphere.", [["Ventilation", "TREATMENT", 0, 11]]], ["Efforts have been IIT Kanpur, Kanpur, India made in the past to understand the effect of ventilation types, human-to-human orientation, sneezing velocities, and droplet sizes on the transmission of exhaled micro droplets in different environments such as office rooms, hospital wards, or air cabins.", [["human", "ORGANISM", 108, 113], ["human", "ORGANISM", 117, 122], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 117, 122], ["Kanpur", "TREATMENT", 30, 36], ["ventilation types", "TREATMENT", 89, 106], ["sneezing velocities", "TEST", 136, 155], ["exhaled micro droplets", "TREATMENT", 198, 220], ["air cabins", "TREATMENT", 288, 298]]], ["However, most of these studies were limited to numerical analysis.", [["these studies", "TEST", 17, 30], ["numerical analysis", "TEST", 47, 65]]], ["A numerical study was carried out with two people sitting opposite to each other in a room by Gao and Niu (2006) .", [["people", "ORGANISM", 43, 49], ["people", "SPECIES", 43, 49], ["A numerical study", "TEST", 0, 17]]], ["It was found that cross infection may occur because of the long distances travelled by the sneezed air in a specific direction.", [["infection", "DISEASE", 24, 33], ["cross infection", "PROBLEM", 18, 33], ["infection", "OBSERVATION", 24, 33], ["air", "OBSERVATION", 99, 102]]], ["Another group studied the transmission of pathogens under different ventilation schemes, such as well mixed ventilation (WMV), displacement ventilation (DV), and under floor air distribution system (UFAD), in an office room as reported by Li et al. (2011) .", [["pathogens", "PROBLEM", 42, 51], ["different ventilation schemes", "TREATMENT", 58, 87], ["displacement ventilation", "TREATMENT", 127, 151], ["ventilation schemes", "OBSERVATION", 68, 87]]], ["Seepana and Lai (2012) conducted experiments and numerical simulation in a controlled chamber with two mannequins (source and susceptible) situated opposite each other at a fixed distance.", [["numerical simulation", "TEST", 49, 69], ["a controlled chamber", "TREATMENT", 73, 93]]], ["The results at measured points indicated that droplet concentrations around the susceptible mannequin were higher when the mannequins were placed near the wall, rather than at the center.", [["wall", "ANATOMY", 155, 159], ["wall", "TISSUE", 155, 159], ["droplet concentrations", "PROBLEM", 46, 68], ["the susceptible mannequin", "TREATMENT", 76, 101], ["the mannequins", "TREATMENT", 119, 133], ["droplet concentrations", "OBSERVATION", 46, 68], ["wall", "ANATOMY_MODIFIER", 155, 159]]], ["In a study conducted in a mock airborne infection isolation room, reported by Thatiparti et al. (2017) , an optimum ventilation configuration involved a linear supply diffuser.", [["infection", "DISEASE", 40, 49], ["a study", "TEST", 3, 10], ["an optimum ventilation configuration", "TREATMENT", 105, 141]]], ["The optimum ventilation was achieved by interchanging the square supply and exhaust locations to place the exhaust closer to the patient source and allow clean air from supply vents to flow in clean-to-dirty flow paths.", [["patient", "ORGANISM", 129, 136], ["patient", "SPECIES", 129, 136], ["The optimum ventilation", "TREATMENT", 0, 23], ["optimum ventilation", "OBSERVATION", 4, 23], ["air", "OBSERVATION", 160, 163]]], ["A recent study applicable to a restaurant in Guangzhou by Lu et al. (2020) suggested an improved ventilation for reducing droplet transmission.", [["A recent study", "TEST", 0, 14], ["an improved ventilation", "TREATMENT", 85, 108], ["reducing droplet transmission", "TREATMENT", 113, 142], ["improved ventilation", "OBSERVATION", 88, 108]]], ["Thus, ventilation and air flow in a room or any controlled space plays a very important role in the spread of viruses like COVID-19.", [["COVID-19", "CHEMICAL", 123, 131], ["ventilation", "TREATMENT", 6, 17], ["air flow", "TEST", 22, 30], ["COVID", "TEST", 123, 128], ["air flow", "OBSERVATION", 22, 30]]], ["This knowledge will help to design optimal ventilation systems for hospitals and quarantine zones very efficiently to reduce spread in highrisk areas.", [["optimal ventilation systems", "TREATMENT", 35, 62], ["quarantine zones", "TREATMENT", 81, 97]]], ["The existing experimental and modelling setup at the National Aerosol Facility, IIT Kanpur, with minor modifications, can be used to understand the efficacy of isolation rooms considering virus as being produced from a group of sources (taking more number of patients) and studying its concentration distribution inside the room for an optimized ventilation strategy.National Aerosol Facility (NAF)The National Aerosol Facility, IIT Kanpur is a multi-purpose aerosol study facility to investigate the dynamics, microphysics, chemistry and behaviour of airborne as well as laboratory-generated aerosol particles in different atmospheric conditions in relevance to health and climatic effects, see e.g. Dwivedi et al. (2019 Dwivedi et al. ( , 2020 , and Mishra et al. (2019 Mishra et al. ( , 2020 .", [["patients", "ORGANISM", 259, 267], ["patients", "SPECIES", 259, 267], ["IIT Kanpur", "TREATMENT", 80, 90], ["minor modifications", "TREATMENT", 97, 116], ["isolation rooms", "TREATMENT", 160, 175], ["virus", "PROBLEM", 188, 193], ["an optimized ventilation strategy", "TREATMENT", 333, 366], ["aerosol particles", "TREATMENT", 593, 610]]], ["The facility is well equipped with sophisticated instruments for precise measurements of particle size ranging from nanometres to several microns, i.e. from bio-aerosols to coarse particles.", [["sophisticated instruments", "TREATMENT", 35, 60], ["particle size", "PROBLEM", 89, 102], ["coarse particles", "PROBLEM", 173, 189], ["particle size", "OBSERVATION_MODIFIER", 89, 102]]], ["The velocity of the particles in a flow can also be measured without physical contact using electromagnetic radiation based instruments.", [["electromagnetic radiation based instruments", "TREATMENT", 92, 135], ["velocity", "OBSERVATION_MODIFIER", 4, 12], ["particles", "OBSERVATION_MODIFIER", 20, 29], ["flow", "OBSERVATION", 35, 39]]], ["The facility may be utilized to determine the efficacy of the isolation wards by designing a chamber with proper ventilation with the help of modelling and experimentation in relevance to COVID-19 outbreak from the knowledge of pre-existing chamber experiments.", [["a chamber", "TREATMENT", 91, 100], ["proper ventilation", "TREATMENT", 106, 124], ["COVID", "TEST", 188, 193], ["chamber experiments", "OBSERVATION", 241, 260]]], ["The available aerosol instruments relevant to COVID-19 are described in the following section.Available Aerosol InstrumentsScanning mobility particle sizer spectrometer (SMPS): this instrument is capable of measuring the size distribution of airborne submicron particles with accuracy and precision.", [["COVID-19", "CHEMICAL", 46, 54], ["COVID-19", "DNA", 46, 54], ["The available aerosol instruments", "TREATMENT", 0, 33], ["COVID", "TEST", 46, 51], ["Available Aerosol InstrumentsScanning mobility particle sizer spectrometer (SMPS)", "TREATMENT", 94, 175], ["this instrument", "TREATMENT", 177, 192], ["size", "OBSERVATION_MODIFIER", 221, 225], ["airborne submicron", "OBSERVATION", 242, 260]]], ["The size range of the measurement from SMPS is 15 nm to 0.7 \u00b5m and the concentration range is up to 10 7 particles/ cm 3 .", [["the measurement", "TEST", 18, 33], ["SMPS", "TEST", 39, 43], ["the concentration range", "TEST", 67, 90], ["size", "OBSERVATION_MODIFIER", 4, 8], ["range", "OBSERVATION_MODIFIER", 9, 14], ["SMPS", "OBSERVATION_MODIFIER", 39, 43], ["15 nm", "OBSERVATION_MODIFIER", 47, 52]]], ["Aerodynamic particle sizer spectrometer (APS): it measures the aerodynamic size of particles from 0.5 to 20 \u00b5m.", [["particle sizer", "OBSERVATION", 12, 26], ["aerodynamic", "OBSERVATION_MODIFIER", 63, 74], ["size", "OBSERVATION_MODIFIER", 75, 79], ["particles", "OBSERVATION_MODIFIER", 83, 92], ["0.5 to 20 \u00b5m", "OBSERVATION_MODIFIER", 98, 110]]], ["Time-of-flight aerodynamic sizing determines the particle's behaviour while airborne and is unaffected by the index of refraction or Mie scattering.Available Aerosol InstrumentsPhase Doppler particle analyser system (PDPA): it provides accurate and reliable flow velocity and particle size data from all measurement situations-from simple flows to high-speed, low SNR situations.", [["all measurement situations", "TEST", 300, 326], ["simple flows", "TEST", 332, 344], ["flow velocity", "OBSERVATION", 258, 271], ["particle", "OBSERVATION_MODIFIER", 276, 284], ["size", "OBSERVATION_MODIFIER", 285, 289]]], ["This instrument is best suited for spray diagnostics and turbulence measurements within the droplet size range of 0.5 \u00b5m to 5 mm.Available Aerosol InstrumentsCondensation particle counter (CPC): it is a general-purpose counter that detects airborne particles down to 4 nm.", [["spray diagnostics", "TEST", 35, 52], ["turbulence measurements", "TEST", 57, 80], ["the droplet size range", "TEST", 88, 110], ["droplet", "OBSERVATION_MODIFIER", 92, 99], ["size", "OBSERVATION_MODIFIER", 100, 104]]], ["It provides highly accurate measurements over a wide concentration range from 0 to 10 7 particles/cm 3 .Available Aerosol InstrumentsAerosol generator: it is a rugged, compact atomizer that generates particles in concentrations up to 10 8 particles/ cm 3 and offers an adjustable flow rate from 1.2 to 5.0 l/min.Current CFD Modelling StatusOur recent research has focused on aerosol generation from a high-temperature system (hot wire generator).", [["Available Aerosol InstrumentsAerosol generator", "TREATMENT", 104, 150], ["a rugged, compact atomizer", "TREATMENT", 158, 184], ["an adjustable flow rate", "TREATMENT", 266, 289], ["aerosol generation", "TREATMENT", 375, 393], ["a high-temperature system (hot wire generator", "TREATMENT", 399, 444]]], ["We have developed a detailed numerical model where we have coupled aerosol microphysics with computational fluid dynamics (CFD) for high-temperature aerosol source.", [["coupled aerosol microphysics", "TREATMENT", 59, 87], ["computational fluid dynamics", "TEST", 93, 121], ["high-temperature aerosol source", "PROBLEM", 132, 163]]], ["The governing equations of the model include Navier-Stokes framework for the fluid flow and general dynamic equations for the aerosol particles.", [["fluid", "ANATOMY", 77, 82], ["the fluid flow", "TEST", 73, 87], ["general dynamic equations", "TREATMENT", 92, 117], ["the aerosol particles", "TREATMENT", 122, 143], ["fluid flow", "OBSERVATION", 77, 87]]], ["The formulation uniquely couples standard k-epsilon scheme (including mass, momentum, energy and boundary layer equations) with aerosol dynamics equations (nucleation, condensation, coagulation and deposition) through residence time.", [["standard k-epsilon scheme", "TREATMENT", 33, 58], ["mass", "PROBLEM", 70, 74], ["boundary layer equations", "TREATMENT", 97, 121], ["aerosol dynamics equations", "TREATMENT", 128, 154]]], ["The model can be used to simulate spatial and temporal characteristics of evolving aerosol spectrum using experimentally measured input parameters and wire composition data.", [["wire composition data", "TEST", 151, 172]]], ["The coupling of CFD and aerosol dynamics offers better insights in comparison to standalone aerosol microphysics models or standalone CFD models.", [["CFD and aerosol dynamics", "TREATMENT", 16, 40], ["standalone aerosol microphysics models", "TREATMENT", 81, 119]]], ["This work was published in January 2020 in an international journal of high repute by Ghosh et al. (2017 Ghosh et al. ( , 2020 .Modelling of PathogenThe existing model requires very minimal tweaks to achieve 2-D modelling of ventilation system.", [["ventilation system", "TREATMENT", 225, 243], ["Pathogen", "OBSERVATION", 141, 149], ["very", "OBSERVATION_MODIFIER", 177, 181], ["minimal", "OBSERVATION_MODIFIER", 182, 189]]], ["The fundamental equations are the same as used in previously reported studies conducted in Hong Kong by Seepana and Lai (2012) .", [["fundamental equations", "OBSERVATION", 4, 25]]], ["The advanced aerosol microphysics and CFD embedded in the model will help to understand the behaviour of sneeze droplet generated from a COVID-19 patient.", [["patient", "ORGANISM", 146, 153], ["patient", "SPECIES", 146, 153], ["The advanced aerosol microphysics", "TREATMENT", 0, 33], ["advanced", "OBSERVATION_MODIFIER", 4, 12], ["aerosol microphysics", "OBSERVATION", 13, 33]]], ["Based on the results of the model and confirmation with calibrated aerosol experiments, an effective ventilation system can be designed.", [["calibrated aerosol experiments", "TREATMENT", 56, 86], ["an effective ventilation system", "TREATMENT", 88, 119]]], ["A schematic diagram showing the overall plan for the modelling scheme is shown in Fig. 1 .Experimental Approach for Pathogen-Aerosol StudiesAt different positions of the designed experimental chamber, the concentration of the particles is to be measured to validate the numerical simulations.", [["A schematic diagram", "TEST", 0, 19], ["the modelling scheme", "TREATMENT", 49, 69], ["Experimental Approach", "TREATMENT", 90, 111], ["Pathogen", "PROBLEM", 116, 124], ["Aerosol Studies", "TEST", 125, 140], ["positions", "OBSERVATION_MODIFIER", 153, 162], ["experimental chamber", "OBSERVATION", 179, 199]]], ["The aerosol measurement instruments will be deployed near the source and far away from the source at different locations, which will give us the knowledge of concentration gradient with respect to time.", [["The aerosol measurement instruments", "TREATMENT", 0, 35], ["concentration gradient", "PROBLEM", 158, 180]]], ["The ideal isolation chamber should have concentrations less than 350 particles per cubic meter.", [["The ideal isolation chamber", "TREATMENT", 0, 27]]], ["To maintain an optimum concentration in the chamber; the position of the exhaust, flow and supply of clean air is an important parameter; see Vohra et al. (2017) .", [["an optimum concentration in the chamber", "TREATMENT", 12, 51], ["optimum", "OBSERVATION_MODIFIER", 15, 22], ["concentration", "OBSERVATION_MODIFIER", 23, 36], ["chamber", "OBSERVATION_MODIFIER", 44, 51], ["position", "OBSERVATION_MODIFIER", 57, 65], ["exhaust", "OBSERVATION", 73, 80], ["clean air", "OBSERVATION", 101, 110]]], ["The schematic diagram of this proposed study for an isolation chamber is given below in Fig. 2 .", [["this proposed study", "TEST", 25, 44], ["an isolation chamber", "TREATMENT", 49, 69]]], ["For the pathogen-aerosol management, there is need to analyse its transient distribution and particle deposition patterns on different solid surfaces as an output parameter from a number of controlled experiments that would help to evolve an efficient ventilation strategy for the protection of health professionals.Way Forward for the Present ProposalIt is desirable to pursue this research in consultation with the end users from the medical fraternity.", [["the pathogen-aerosol management", "TREATMENT", 4, 35], ["particle deposition patterns", "PROBLEM", 93, 121], ["different solid surfaces", "TREATMENT", 125, 149], ["an output parameter", "TEST", 153, 172], ["an efficient ventilation strategy", "TREATMENT", 239, 272], ["particle deposition", "OBSERVATION", 93, 112]]], ["For the design of pathogen-aerosol experiments, data collection should be relevant for the present application.", [["pathogen-aerosol experiments", "TREATMENT", 18, 46]]], ["Additional aerosol sensors and instruments suitable for the simulated pathogen aerosols would be procured in consultation with them.", [["Additional aerosol sensors", "TREATMENT", 0, 26], ["instruments", "TREATMENT", 31, 42], ["the simulated pathogen aerosols", "TREATMENT", 56, 87]]], ["Further, it is proposed to conduct a round robin numerical analysis using various CFD codes available with a team of national experts who would be invited to participate in this exercise.", [["a round robin numerical analysis", "TEST", 35, 67]]], ["They would be required to provide their numerical results before the set of identified experiments during the pre-test phase, which would form the basis for the optimal data collection scheme during the various pathogen transport experiments.", [["the pre-test phase", "TEST", 106, 124]]], ["This would be followed by a post-test analysis phase for improved understanding of the experimental results obtained during this study.", [["a post-test analysis phase", "TEST", 26, 52], ["this study", "TEST", 124, 134]]], ["It is suggested that a panel of experts from the medical fraternity, CFD numerical analysts and aerosol scientists be formed in consultation with us for this important study related to COVID-19.", [["COVID-19", "CHEMICAL", 185, 193], ["COVID-19", "DNA", 185, 193], ["this important study", "TEST", 153, 173], ["COVID", "TEST", 185, 190]]], ["The overall timeline for this study is 24 months, which includes a set of experiments, CFD analysis, validation of results and evolution of the optimum ventilation system suitable for health professionals.ConclusionThe proposed experimental and modelling studies will together generate useful results which can be used to design an efficient ventilation system for isolation rooms and hospitals that may be made as the national standard.", [["this study", "TEST", 25, 35], ["CFD analysis", "TEST", 87, 99], ["the optimum ventilation system", "TREATMENT", 140, 170], ["modelling studies", "TEST", 245, 262]]], ["It will also help to overcome the limitations with the existing ventilation systems towards the spread of COVID-19, especially for the protection of health-care professionals.", [["the existing ventilation systems", "TREATMENT", 51, 83], ["COVID", "TEST", 106, 111]]], ["This study will not only be relevant for isolation or treatment facilities, but also other enclosed establishments such as office space, shop floors, and classrooms, including public transit vehicles like buses and train coaches.", [["This study", "TEST", 0, 10], ["treatment facilities", "TREATMENT", 54, 74]]]], "84f4ba9567dc9b3d8e9bec5d9918da1826c5424e": [["INTRODUCTIONAn emerging respiratory disease COVID-19 started to circulate among human in December 2019.", [["respiratory", "ANATOMY", 24, 35], ["respiratory disease", "DISEASE", 24, 43], ["human", "ORGANISM", 80, 85], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["emerging respiratory disease COVID", "PROBLEM", 15, 49], ["respiratory disease", "OBSERVATION", 24, 43]]], ["Since its first outbreak in China from an unknown origin, it quickly became a global pandemic.", [["a global pandemic", "PROBLEM", 76, 93], ["first", "OBSERVATION_MODIFIER", 10, 15], ["outbreak", "OBSERVATION_MODIFIER", 16, 24], ["global", "OBSERVATION_MODIFIER", 78, 84], ["pandemic", "OBSERVATION", 85, 93]]], ["As of May 26, 2020, there are 343,562 deaths among 5,406,282 confirmed cases in 215 countries (https://www.who.int/ emergencies/diseases/novel-coronavirus-2019).", [["deaths", "DISEASE", 38, 44], ["coronavirus", "PROBLEM", 143, 154]]], ["The etiological pathogen of COVID-19 is a new coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also called novel coronavirus (nCoV-2019).", [["COVID-19", "CHEMICAL", 28, 36], ["coronavirus", "DISEASE", 46, 57], ["acute respiratory syndrome coronavirus", "DISEASE", 70, 108], ["COVID-19", "ORGANISM", 28, 36], ["coronavirus", "ORGANISM", 46, 57], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 63, 110], ["SARS-CoV-2", "ORGANISM", 112, 122], ["coronavirus", "ORGANISM", 143, 154], ["coronavirus", "SPECIES", 46, 57], ["COVID-19", "SPECIES", 28, 36], ["severe acute respiratory syndrome coronavirus", "SPECIES", 63, 108], ["SARS-CoV-2", "SPECIES", 112, 122], ["COVID", "TEST", 28, 33], ["a new coronavirus", "PROBLEM", 40, 57], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 59, 108], ["SARS", "TEST", 112, 116], ["CoV", "TEST", 117, 120], ["novel coronavirus", "PROBLEM", 137, 154], ["new", "OBSERVATION_MODIFIER", 42, 45], ["coronavirus", "OBSERVATION", 46, 57], ["severe", "OBSERVATION_MODIFIER", 63, 69], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["respiratory syndrome", "OBSERVATION", 76, 96]]], ["As the name indicates, SARS-CoV-2 is similar to SARS-CoV, the virus that causes severe acute respiratory symptoms in human and killed 774 people among 8098 infected worldwide in 2003.", [["respiratory", "ANATOMY", 93, 104], ["SARS-CoV", "DISEASE", 48, 56], ["acute respiratory symptoms", "DISEASE", 87, 113], ["SARS-CoV-2", "ORGANISM", 23, 33], ["SARS-CoV", "ORGANISM", 48, 56], ["human", "ORGANISM", 117, 122], ["people", "ORGANISM", 138, 144], ["human", "SPECIES", 117, 122], ["people", "SPECIES", 138, 144], ["SARS-CoV", "SPECIES", 23, 31], ["SARS-CoV", "SPECIES", 48, 56], ["human", "SPECIES", 117, 122], ["SARS", "PROBLEM", 23, 27], ["SARS", "PROBLEM", 48, 52], ["CoV", "PROBLEM", 53, 56], ["the virus", "PROBLEM", 58, 67], ["severe acute respiratory symptoms", "PROBLEM", 80, 113], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["acute", "OBSERVATION_MODIFIER", 87, 92], ["respiratory symptoms", "OBSERVATION", 93, 113]]], ["1 SARS-CoV-2 shares~82% of sequence identity with SARS-CoV and to a less extent with Middle East respiratory syndrome coronavirus (MERS-CoV) (~50%).", [["SARS-CoV", "DISEASE", 50, 58], ["Middle East respiratory syndrome coronavirus", "DISEASE", 85, 129], ["SARS-CoV", "ORGANISM", 50, 58], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 85, 129], ["MERS-CoV", "ORGANISM", 131, 139], ["SARS-CoV", "SPECIES", 50, 58], ["Middle East respiratory syndrome coronavirus", "SPECIES", 85, 129], ["MERS-CoV", "SPECIES", 131, 139], ["CoV", "TEST", 7, 10], ["sequence identity", "TEST", 27, 44], ["SARS", "PROBLEM", 50, 54], ["CoV", "PROBLEM", 55, 58], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 85, 129], ["Middle", "ANATOMY_MODIFIER", 85, 91], ["respiratory syndrome", "OBSERVATION", 97, 117]]], ["2,3 SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus that belongs to the \u03b2-lineage of the coronavirus.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 4, 14], ["coronavirus", "ORGANISM", 111, 122], ["coronavirus", "SPECIES", 111, 122], ["CoV", "TEST", 9, 12], ["single-stranded RNA virus", "PROBLEM", 48, 73], ["the coronavirus", "PROBLEM", 107, 122], ["coronavirus", "OBSERVATION", 111, 122]]], ["4 The \u03b2lineage also contains two other important human pathogens, the SARS-CoV and MERS-CoV.", [["SARS", "DISEASE", 70, 74], ["human", "ORGANISM", 49, 54], ["SARS-CoV", "ORGANISM", 70, 78], ["MERS-CoV", "ORGANISM", 83, 91], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["SARS-CoV", "SPECIES", 70, 78], ["MERS-CoV", "SPECIES", 83, 91], ["the SARS", "TEST", 66, 74], ["two", "OBSERVATION_MODIFIER", 29, 32], ["important", "OBSERVATION_MODIFIER", 39, 48], ["human", "OBSERVATION_MODIFIER", 49, 54], ["pathogens", "OBSERVATION", 55, 64]]], ["The mortality rate of COVID-19 is around 6.35% as of May 26, 2020 , which is lower than that of SARS (~10%) and MERS (~34%).", [["COVID-19", "CHEMICAL", 22, 30], ["SARS", "DISEASE", 96, 100], ["The mortality rate", "TEST", 0, 18], ["COVID", "TEST", 22, 27], ["SARS", "PROBLEM", 96, 100], ["MERS", "TEST", 112, 116]]], ["1 However, current data indicate that COVID-19 is more contagious and has a larger R0 value than SARS and MERS 5 , resulting in higher overall death tolls than SARS and MERS.INTRODUCTIONThe SARS-CoV-2 virus is currently spreading at an alarming speed in Europe and the United States.INTRODUCTIONThere is currently no antiviral or vaccine for SARS-CoV-2.", [["SARS", "DISEASE", 97, 101], ["death", "DISEASE", 143, 148], ["SARS", "DISEASE", 160, 164], ["SARS", "DISEASE", 190, 194], ["SARS", "DISEASE", 342, 346], ["SARS-CoV-2 virus", "ORGANISM", 190, 206], ["SARS-CoV-2", "ORGANISM", 342, 352], ["CoV-2 virus", "SPECIES", 195, 206], ["SARS-CoV-2 virus", "SPECIES", 190, 206], ["SARS-CoV", "SPECIES", 342, 350], ["COVID", "TEST", 38, 43], ["SARS", "PROBLEM", 160, 164], ["CoV-2 virus", "PROBLEM", 195, 206], ["antiviral", "TREATMENT", 317, 326], ["vaccine", "TREATMENT", 330, 337], ["SARS", "PROBLEM", 342, 346], ["CoV", "TEST", 347, 350], ["larger", "OBSERVATION_MODIFIER", 76, 82], ["R0 value", "OBSERVATION_MODIFIER", 83, 91], ["higher", "OBSERVATION_MODIFIER", 128, 134], ["overall", "OBSERVATION_MODIFIER", 135, 142], ["death", "OBSERVATION", 143, 148]]], ["The SARS-CoV-2 viral genome encodes a number of structural proteins (e.g., capsid spike glycoprotein), non-structural proteins (e.g., 3chymotrypsin-like protease (3CL or main protease), papain-like protease, helicase, and RNA-dependent RNA polymerase), and accessary proteins.", [["SARS", "DISEASE", 4, 8], ["SARS-CoV-2", "ORGANISM", 4, 14], ["capsid spike glycoprotein", "GENE_OR_GENE_PRODUCT", 75, 100], ["3chymotrypsin-like protease", "GENE_OR_GENE_PRODUCT", 134, 161], ["3CL", "GENE_OR_GENE_PRODUCT", 163, 166], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 186, 206], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 222, 250], ["SARS-CoV-2 viral genome", "DNA", 4, 27], ["structural proteins", "PROTEIN", 48, 67], ["capsid spike glycoprotein", "PROTEIN", 75, 100], ["non-structural proteins", "PROTEIN", 103, 126], ["3chymotrypsin", "PROTEIN", 134, 147], ["like protease", "PROTEIN", 148, 161], ["3CL", "PROTEIN", 163, 166], ["protease", "PROTEIN", 175, 183], ["papain", "PROTEIN", 186, 192], ["protease", "PROTEIN", 198, 206], ["helicase", "PROTEIN", 208, 216], ["RNA-dependent RNA polymerase", "PROTEIN", 222, 250], ["accessary proteins", "PROTEIN", 257, 275], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["structural proteins", "PROBLEM", 48, 67], ["capsid spike glycoprotein", "PROBLEM", 75, 100], ["non-structural proteins", "PROBLEM", 103, 126], ["3chymotrypsin", "TEST", 134, 147], ["protease", "TREATMENT", 153, 161], ["main protease", "TREATMENT", 170, 183], ["papain", "TREATMENT", 186, 192], ["protease", "TREATMENT", 198, 206], ["helicase", "TREATMENT", 208, 216], ["RNA", "TEST", 222, 225], ["dependent RNA polymerase", "PROBLEM", 226, 250], ["accessary proteins", "PROBLEM", 257, 275], ["viral genome", "OBSERVATION", 15, 27]]], ["Compounds that target any of these viral proteins might be potential antiviral drug candidates.", [["viral proteins", "PROTEIN", 35, 49], ["these viral proteins", "PROBLEM", 29, 49], ["antiviral drug candidates", "TREATMENT", 69, 94]]], ["6, 7 In this study, we focus on the viral 3CL protease, also called the main protease (M pro ), and aim to develop potent M pro inhibitors as SAR-CoV-2 antivirals.", [["3CL protease", "GENE_OR_GENE_PRODUCT", 42, 54], ["CoV-2", "ORGANISM", 146, 151], ["viral 3CL protease", "PROTEIN", 36, 54], ["protease", "PROTEIN", 77, 85], ["M pro", "PROTEIN", 87, 92], ["this study", "TEST", 8, 18], ["the viral 3CL protease", "TREATMENT", 32, 54], ["potent M pro inhibitors", "TREATMENT", 115, 138], ["SAR", "TEST", 142, 145], ["CoV", "TEST", 146, 149], ["antivirals", "TREATMENT", 152, 162]]], ["The M pro plays an essential role in coronavirus replication by digesting the viral polyproteins at more than 11 sites, and it appears like a high-profile target for antiviral drug discovery.", [["M pro", "GENE_OR_GENE_PRODUCT", 4, 9], ["coronavirus", "ORGANISM", 37, 48], ["M pro", "PROTEIN", 4, 9], ["viral polyproteins", "PROTEIN", 78, 96], ["coronavirus", "SPECIES", 37, 48], ["coronavirus replication", "TREATMENT", 37, 60], ["the viral polyproteins", "PROBLEM", 74, 96], ["antiviral drug discovery", "TREATMENT", 166, 190], ["viral polyproteins", "OBSERVATION", 78, 96], ["antiviral drug", "OBSERVATION", 166, 180]]], ["[8] [9] [10] [11] The M pro has a unique substrate preference for glutamine at the P1 site (Leu-Gln\u2193(Ser, Ala, Gly)), a feature that is absent in closely related host proteases, suggesting that it is feasible to achieve high selectivity by targeting viral M pro .", [["glutamine", "CHEMICAL", 66, 75], ["Leu-Gln\u2193", "CHEMICAL", 92, 100], ["glutamine", "CHEMICAL", 66, 75], ["Leu-Gln\u2193", "CHEMICAL", 92, 100], ["Ser", "CHEMICAL", 101, 104], ["Ala", "CHEMICAL", 106, 109], ["Gly", "CHEMICAL", 111, 114], ["[8] [9] [10] [11]", "SIMPLE_CHEMICAL", 0, 17], ["glutamine", "AMINO_ACID", 66, 75], ["Leu-Gln\u2193", "SIMPLE_CHEMICAL", 92, 100], ["Ser,", "AMINO_ACID", 101, 105], ["Ala, Gly)", "AMINO_ACID", 106, 115], ["host proteases", "PROTEIN", 162, 176], ["viral M pro", "PROTEIN", 250, 261], ["glutamine", "TREATMENT", 66, 75], ["Leu-Gln\u2193(Ser, Ala, Gly)", "TEST", 92, 115]]], ["As such, we developed the fluorescence resonance energy transfer (FRET)based enzymatic assay for the SARS-CoV-2 M pro and applied it to screen a focused library of protease inhibitors.", [["enzymatic assay", "TEST", 77, 92], ["the SARS", "TEST", 97, 105], ["protease inhibitors", "TREATMENT", 164, 183]]], ["Here we report our findings of several novel hits targeting SARS-CoV-2 M pro and their mechanism of action.", [["SARS-CoV-2 M pro", "PROTEIN", 60, 76]]], ["The in vitro antiviral activity of the hits was also evaluated in cell culture using infectious SARS-CoV-2 virus.", [["cell", "ANATOMY", 66, 70], ["cell", "CELL", 66, 70], ["infectious SARS-CoV-2 virus", "ORGANISM", 85, 112], ["CoV-2 virus", "SPECIES", 101, 112], ["SARS-CoV-2 virus", "SPECIES", 96, 112], ["cell culture", "TEST", 66, 78], ["infectious SARS", "PROBLEM", 85, 100], ["CoV", "TEST", 101, 104], ["antiviral activity", "OBSERVATION", 13, 31]]], ["Overall, our study provides a list of drug candidates for SARS-CoV-2 with a confirmed mechanism of action, and the results might help speed up the drug discovery efforts in combating COVID-19.", [["COVID-19", "CHEMICAL", 183, 191], ["SARS-CoV", "SPECIES", 58, 66], ["our study", "TEST", 9, 18], ["SARS", "PROBLEM", 58, 62]]], ["The compounds identified herein represent some of the most potent and selective SARS-CoV-2 M pro inhibitors so far with both enzymatic inhibition and cellular antiviral activity.", [["cellular", "ANATOMY", 150, 158], ["cellular", "CELL", 150, 158], ["CoV-2 M pro inhibitors", "TREATMENT", 85, 107], ["both enzymatic inhibition", "TREATMENT", 120, 145], ["cellular antiviral activity", "TREATMENT", 150, 177], ["most potent", "OBSERVATION_MODIFIER", 54, 65], ["cellular antiviral activity", "OBSERVATION", 150, 177]]], ["8, 10, 11 The X-ray crystal structure of SARS-CoV-2 M pro with GC-376 showed that the compound can adopt two configurations R and S, offering a molecular explanation of the high binding affinity of the aldehyde-containing inhibitors.", [["GC-376", "CHEMICAL", 63, 69], ["aldehyde", "CHEMICAL", 202, 210], ["aldehyde", "CHEMICAL", 202, 210], ["GC-376", "SIMPLE_CHEMICAL", 63, 69], ["aldehyde", "SIMPLE_CHEMICAL", 202, 210], ["The X-ray crystal structure", "TEST", 10, 37], ["SARS", "TEST", 41, 45], ["CoV", "TEST", 46, 49], ["GC", "TEST", 63, 65], ["the aldehyde-containing inhibitors", "TREATMENT", 198, 232]]], ["Significantly, the discovery of calpain II and XII inhibitors as potent SARS-CoV-2 antivirals suggests that it might be feasible to design dual inhibitors against the viral M pro and the host calpains/cathepsins, both of which are important for viral replication.RESULTSEstablishing the FRET-based assay for the SARS-CoV-2 M pro The M pro gene from SARS-CoV-2 strain BetaCoV/Wuhan/WIV04/ 2019 was inserted into pET-29a(+) vector and expressed in BL21 (DE3) Escherichia Coli. with a His-tag in its C-terminus.", [["His", "CHEMICAL", 482, 485], ["calpain II", "GENE_OR_GENE_PRODUCT", 32, 42], ["XII", "GENE_OR_GENE_PRODUCT", 47, 50], ["SARS-CoV-2", "ORGANISM", 72, 82], ["calpains", "GENE_OR_GENE_PRODUCT", 192, 200], ["cathepsins", "GENE_OR_GENE_PRODUCT", 201, 211], ["SARS-CoV-2", "ORGANISM", 349, 359], ["BetaCoV", "ORGANISM", 367, 374], ["Wuhan", "ORGANISM", 375, 380], ["pET-29a", "GENE_OR_GENE_PRODUCT", 411, 418], ["calpain II", "PROTEIN", 32, 42], ["viral M pro", "PROTEIN", 167, 178], ["calpains", "PROTEIN", 192, 200], ["cathepsins", "PROTEIN", 201, 211], ["SARS-CoV-2 M pro", "DNA", 312, 328], ["M pro gene", "DNA", 333, 343], ["Wuhan/WIV04/ 2019", "DNA", 375, 392], ["pET-29a(+) vector", "DNA", 411, 428], ["His-tag", "DNA", 482, 489], ["C-terminus", "PROTEIN", 497, 507], ["SARS-CoV", "SPECIES", 312, 320], ["SARS-CoV-2 strain BetaCoV/Wuhan/WIV04/ 2019", "SPECIES", 349, 392], ["BL21", "SPECIES", 446, 450], ["calpain II", "TREATMENT", 32, 42], ["XII inhibitors", "TREATMENT", 47, 61], ["potent SARS", "PROBLEM", 65, 76], ["CoV-2 antivirals", "TREATMENT", 77, 93], ["dual inhibitors", "TREATMENT", 139, 154], ["the viral M pro", "PROBLEM", 163, 178], ["cathepsins", "TREATMENT", 201, 211], ["viral replication", "TREATMENT", 245, 262], ["the SARS", "TEST", 308, 316], ["CoV", "TEST", 317, 320], ["SARS", "PROBLEM", 349, 353], ["CoV", "TEST", 354, 357], ["pET", "TEST", 411, 414], ["Escherichia Coli.", "PROBLEM", 457, 474], ["BL21", "ANATOMY", 446, 450]]], ["The M pro protein was purified with Ni-NTA column to high purity (Fig. 1a) .", [["Ni-NTA", "CHEMICAL", 36, 42], ["Ni-NTA", "CHEMICAL", 36, 42], ["M pro", "GENE_OR_GENE_PRODUCT", 4, 9], ["Ni-NTA", "SIMPLE_CHEMICAL", 36, 42], ["M pro protein", "PROTEIN", 4, 17], ["The M pro protein", "TEST", 0, 17], ["Ni-NTA column", "TREATMENT", 36, 49]]], ["The determined molecular weight of M pro is 34,861 Da from native mass spectrometry, which matches the calculated molecular weight of M pro without the N-terminal methionine (Supplementary information, Fig. S1 ).", [["methionine", "CHEMICAL", 163, 173], ["N-", "CHEMICAL", 152, 154], ["methionine", "CHEMICAL", 163, 173], ["methionine", "AMINO_ACID", 163, 173], ["S1", "GENE_OR_GENE_PRODUCT", 207, 209], ["N-terminal methionine", "PROTEIN", 152, 173], ["S1", "PROTEIN", 207, 209], ["native mass spectrometry", "PROBLEM", 59, 83], ["the N-terminal methionine", "TREATMENT", 148, 173], ["mass spectrometry", "OBSERVATION", 66, 83]]], ["The first methionine might be cleaved by the methionine aminopeptidase as reported before.", [["methionine", "CHEMICAL", 10, 20], ["methionine", "CHEMICAL", 45, 55], ["methionine", "CHEMICAL", 10, 20], ["methionine", "CHEMICAL", 45, 55], ["methionine", "SIMPLE_CHEMICAL", 10, 20], ["methionine aminopeptidase", "GENE_OR_GENE_PRODUCT", 45, 70], ["methionine aminopeptidase", "PROTEIN", 45, 70], ["The first methionine", "TREATMENT", 0, 20], ["the methionine aminopeptidase", "TREATMENT", 41, 70]]], ["12 To establish the FRET assay condition, we designed a FRET based substrate using the sequence between viral polypeptide NSP4-NSP5 junction from SARS-CoV-2: Dabcyl-KTSAVLQ/SGFRKME(Edans).", [["NSP4", "GENE_OR_GENE_PRODUCT", 122, 126], ["Dabcyl-KTSAVLQ", "SIMPLE_CHEMICAL", 158, 172], ["NSP4", "PROTEIN", 122, 126], ["NSP5 junction", "PROTEIN", 127, 140], ["Dabcyl", "PROTEIN", 158, 164], ["KTSAVLQ", "PROTEIN", 165, 172], ["SGFRKME", "PROTEIN", 173, 180], ["Edans", "PROTEIN", 181, 186], ["the FRET assay condition", "TEST", 16, 40], ["a FRET based substrate", "TREATMENT", 54, 76], ["the sequence", "TEST", 83, 95], ["viral polypeptide NSP4", "TEST", 104, 126], ["SARS", "TEST", 146, 150], ["CoV", "TEST", 151, 154], ["Dabcyl", "TEST", 158, 164]]], ["We found that M pro displays the highest activity in pH 6.5 buffer (Fig. 1b) , which contains 20 mM HEPES, 120 mM NaCl, 0.4 mM EDTA, 4 mM 1,4-dithiothreitol (DTT) and 20% glycerol.", [["NaCl", "CHEMICAL", 114, 118], ["EDTA", "CHEMICAL", 127, 131], ["1,4-dithiothreitol", "CHEMICAL", 138, 156], ["DTT", "CHEMICAL", 158, 161], ["glycerol", "CHEMICAL", 171, 179], ["HEPES", "CHEMICAL", 100, 105], ["NaCl", "CHEMICAL", 114, 118], ["EDTA", "CHEMICAL", 127, 131], ["1,4-dithiothreitol", "CHEMICAL", 138, 156], ["DTT", "CHEMICAL", 158, 161], ["glycerol", "CHEMICAL", 171, 179], ["M pro", "GENE_OR_GENE_PRODUCT", 14, 19], ["EDTA", "SIMPLE_CHEMICAL", 127, 131], ["1,4-dithiothreitol", "SIMPLE_CHEMICAL", 138, 156], ["DTT", "SIMPLE_CHEMICAL", 158, 161], ["glycerol", "SIMPLE_CHEMICAL", 171, 179], ["pH", "TEST", 53, 55], ["HEPES", "TEST", 100, 105], ["NaCl", "TEST", 114, 118], ["EDTA", "TEST", 127, 131], ["dithiothreitol (DTT", "TREATMENT", 142, 161], ["20% glycerol", "TREATMENT", 167, 179], ["highest", "OBSERVATION_MODIFIER", 33, 40], ["activity", "OBSERVATION_MODIFIER", 41, 49]]], ["As such, all the following proteolytic assay was conducted using this pH 6.5 buffer.", [["proteolytic assay", "TEST", 27, 44], ["this pH", "TREATMENT", 65, 72]]], ["A standard curve was generated to convert the relative fluorescence unit (RFU) to the amount of the cleaved substrate (nM) such that k cat can be calculated (Fig. 1c) .", [["k cat", "TEST", 133, 138]]], ["Next, we characterized the enzymatic activity of this SARS-CoV-2 M pro by measuring the K m and V max values.", [["this SARS", "TEST", 49, 58], ["CoV", "TEST", 59, 62], ["the K m", "TEST", 84, 91], ["V max values", "TEST", 96, 108], ["enzymatic activity", "OBSERVATION", 27, 45]]], ["When 200 nM M pro was mixed with various concentration of FRET substrate (0-100 \u00b5M), the initial velocity was measured and plotted against substrate concentration.", [["FRET", "SIMPLE_CHEMICAL", 58, 62], ["various concentration of FRET substrate", "TREATMENT", 33, 72], ["the initial velocity", "TEST", 85, 105]]], ["Curve fitting with Michaelis-Menten equation gave the best-fit values of K m and V max as 28.2 \u00b1 3.4 \u00b5M and 31.7 \u00b1 1.6 RFU/s, respectively (Fig. 1d) .", [["Michaelis", "TEST", 19, 28], ["Menten equation", "TEST", 29, 44], ["K m", "TEST", 73, 76], ["V max", "TEST", 81, 86], ["\u00b5M", "TEST", 101, 103], ["RFU/s", "TEST", 119, 124]]], ["The calculated k cat /K m was 5,624 s \u22121 M \u22121 , which is similar to the previously reported value of 3,426.1 s \u22121 M \u22121 by Hilgenfeld et al. 8 ,RESULTSsuggesting that the C-terminal His-tag M pro is as active as the native M pro .RESULTSPrimary screening of a focused protease inhibitor library against the SARS-CoV-2 M pro With the established FRET assay condition, we screened a collection of protease inhibitors from the Selleckchem bioactive compound library to identify potential SARS-CoV-2 M pro inhibitors ( Table 1 ).", [["C", "CHEMICAL", 170, 171], ["His", "CHEMICAL", 181, 184], ["C-terminal His-tag M pro", "PROTEIN", 170, 194], ["native M pro", "PROTEIN", 215, 227], ["SARS-CoV", "SPECIES", 306, 314], ["The calculated k cat /K m", "TEST", 0, 25], ["the C-terminal His-tag M pro", "TREATMENT", 166, 194], ["RESULTSPrimary screening", "TEST", 229, 253], ["a focused protease inhibitor library", "TREATMENT", 257, 293], ["the SARS", "TEST", 302, 310], ["protease inhibitors", "TREATMENT", 394, 413], ["potential SARS", "PROBLEM", 474, 488], ["CoV-2 M pro inhibitors", "TREATMENT", 489, 511]]], ["The protease inhibitors are grouped based on their targets and mechanism of action, including proteasome inhibitors (1) (2) (3) (4) (5) (6) (7) (8) , HIV protease inhibitors (9) (10) (11) (12) (13) (14) , \u03b3-secretase inhibitors (15) (16) (17) (18) (19) (20) (21) (22) , HCV NS3-4A protease inhibitors (23) (24) (25) (26) (27) (28) (29) , DPP-4 inhibitors (30) (31) (32) (33) (34) (35) , miscellaneous serine protease inhibitors (36) (37) (38) (39) , cathepsin and calpain protease inhibitors (40) (41) (42) (43) , miscellaneous cysteine protease inhibitors (44) (45) (46) (47) (48) , matrix metalloprotease inhibitors (49) (50) (51) , and miscellaneous protease inhibitors (52) (53) (54) (55) .", [["serine", "CHEMICAL", 401, 407], ["cysteine", "CHEMICAL", 528, 536], ["1) (2) (3) (4) (5) (6) (7)", "SIMPLE_CHEMICAL", 117, 143], ["HIV protease inhibitors (9) (10) (11) (12) (13) (14) , \u03b3-secretase inhibitors (15) (16) (17) (18) (19) (20) (21", "SIMPLE_CHEMICAL", 150, 261], ["HCV", "ORGANISM", 270, 273], ["NS3-4A protease inhibitors (23) (24) (25) (26) (27) (28", "SIMPLE_CHEMICAL", 274, 329], ["DPP-4 inhibitors (30) (31) (32) (33) (34", "SIMPLE_CHEMICAL", 338, 378], ["miscellaneous serine protease inhibitors (36) (37) (38", "SIMPLE_CHEMICAL", 387, 441], ["cathepsin", "GENE_OR_GENE_PRODUCT", 450, 459], ["calpain protease inhibitors (40) (41) (42", "SIMPLE_CHEMICAL", 464, 505], ["miscellaneous cysteine protease inhibitors (44) (45) (46) (47", "SIMPLE_CHEMICAL", 514, 575], ["matrix metalloprotease inhibitors (49)", "SIMPLE_CHEMICAL", 584, 622], ["cathepsin", "PROTEIN", 450, 459], ["The protease inhibitors", "TREATMENT", 0, 23], ["proteasome inhibitors", "TREATMENT", 94, 115], ["HIV protease inhibitors", "TREATMENT", 150, 173], ["\u03b3-secretase inhibitors", "TREATMENT", 205, 227], ["HCV NS3-4A protease inhibitors", "TREATMENT", 270, 300], ["DPP", "TEST", 338, 341], ["miscellaneous serine protease inhibitors", "TREATMENT", 387, 427], ["cathepsin and calpain protease inhibitors", "TREATMENT", 450, 491], ["miscellaneous cysteine protease inhibitors", "TREATMENT", 514, 556], ["matrix metalloprotease inhibitors", "TREATMENT", 584, 617], ["miscellaneous protease inhibitors", "TREATMENT", 639, 672]]], ["The inhibitors were pre-incubated with 100 nM of M pro at 30\u00b0C for 30 min in the presence of 4 mM DTT before the addition of 10 \u00b5M FRET substrate.", [["DTT", "CHEMICAL", 98, 101], ["DTT", "CHEMICAL", 98, 101], ["DTT", "SIMPLE_CHEMICAL", 98, 101], ["The inhibitors", "TREATMENT", 0, 14], ["M pro", "TREATMENT", 49, 54], ["4 mM DTT", "TREATMENT", 93, 101], ["10 \u00b5M FRET substrate", "TREATMENT", 125, 145]]], ["The addition of DTT was to quench nonspecific thiol reactive compounds and to ensure that M pro is in the reducing condition.", [["DTT", "CHEMICAL", 16, 19], ["thiol", "CHEMICAL", 46, 51], ["DTT", "CHEMICAL", 16, 19], ["thiol", "CHEMICAL", 46, 51], ["DTT", "SIMPLE_CHEMICAL", 16, 19], ["DTT", "TREATMENT", 16, 19], ["quench nonspecific thiol reactive compounds", "PROBLEM", 27, 70], ["reactive compounds", "OBSERVATION", 52, 70]]], ["Among the hits, simeprevir (24) , boceprevir (28) , and narlaprevir (29) are HCV NS3-4A serine protease inhibitors, and compound MG-132 (43) inhibits both proteasome and calpain.RESULTSSecondary screening of a focused library of calpain/cathepsin inhibitors and known viral 3CL pro inhibitors Given the encouraging results from the primary screening, we then further characterized the four hits (24, 28, 29, and 43) in a combination of assays including dose-response titration, thermal shift binding assay (TSA), and counter screening assays with two other viral cysteine proteases, the enterovirus A71 (EV-A71) 2A and 3C proteases, both of which are cysteine proteases ( Table 2 ).", [["simeprevir", "CHEMICAL", 16, 26], ["boceprevir", "CHEMICAL", 34, 44], ["narlaprevir", "CHEMICAL", 56, 67], ["MG-132", "CHEMICAL", 129, 135], ["simeprevir", "CHEMICAL", 16, 26], ["boceprevir", "CHEMICAL", 34, 44], ["narlaprevir", "CHEMICAL", 56, 67], ["serine", "CHEMICAL", 88, 94], ["MG-132", "CHEMICAL", 129, 135], ["cysteine", "CHEMICAL", 563, 571], ["cysteine", "CHEMICAL", 651, 659], ["simeprevir", "SIMPLE_CHEMICAL", 16, 26], ["boceprevir", "SIMPLE_CHEMICAL", 34, 44], ["narlaprevir", "SIMPLE_CHEMICAL", 56, 67], ["HCV", "ORGANISM", 77, 80], ["NS3-4A", "GENE_OR_GENE_PRODUCT", 81, 87], ["MG-132 (43)", "SIMPLE_CHEMICAL", 129, 140], ["calpain", "GENE_OR_GENE_PRODUCT", 170, 177], ["calpain", "GENE_OR_GENE_PRODUCT", 229, 236], ["cathepsin", "GENE_OR_GENE_PRODUCT", 237, 246], ["enterovirus A71", "ORGANISM", 587, 602], ["EV-A71) 2A", "GENE_OR_GENE_PRODUCT", 604, 614], ["3C", "GENE_OR_GENE_PRODUCT", 619, 621], ["NS3", "PROTEIN", 81, 84], ["proteasome", "PROTEIN", 155, 165], ["calpain", "PROTEIN", 170, 177], ["calpain", "PROTEIN", 229, 236], ["viral cysteine proteases", "PROTEIN", 557, 581], ["enterovirus A71 (EV-A71) 2A and 3C proteases", "PROTEIN", 587, 631], ["cysteine proteases", "PROTEIN", 651, 669], ["HCV", "SPECIES", 77, 80], ["enterovirus A71 (EV-A71", "SPECIES", 587, 610], ["simeprevir", "TREATMENT", 16, 26], ["boceprevir", "TREATMENT", 34, 44], ["narlaprevir", "TREATMENT", 56, 67], ["HCV NS3", "TREATMENT", 77, 84], ["4A serine protease inhibitors", "TREATMENT", 85, 114], ["compound MG", "TEST", 120, 131], ["calpain", "TREATMENT", 170, 177], ["RESULTSSecondary screening", "TEST", 178, 204], ["calpain/cathepsin inhibitors", "TREATMENT", 229, 257], ["known viral 3CL pro inhibitors", "TREATMENT", 262, 292], ["the primary screening", "TEST", 328, 349], ["assays", "TEST", 436, 442], ["dose-response titration", "TREATMENT", 453, 476], ["thermal shift binding assay", "TEST", 478, 505], ["counter screening assays", "TEST", 517, 541], ["viral cysteine proteases", "TREATMENT", 557, 581], ["the enterovirus", "TEST", 583, 598], ["3C proteases", "TREATMENT", 619, 631], ["cysteine proteases", "TREATMENT", 651, 669]]], ["The HCV NS3-4A protease inhibitors boceprevir (28) and narlaprevir (29) inhibited M pro with 50% inhibitory concentration (IC 50 ) values of 4.13 and 4.73 \u00b5M, respectively (Table 2) , more potent than simeprevir (24) (IC 50 = 13.74 \u00b5M).", [["boceprevir", "CHEMICAL", 35, 45], ["narlaprevir", "CHEMICAL", 55, 66], ["simeprevir", "CHEMICAL", 201, 211], ["boceprevir", "CHEMICAL", 35, 45], ["narlaprevir", "CHEMICAL", 55, 66], ["simeprevir", "CHEMICAL", 201, 211], ["HCV", "ORGANISM", 4, 7], ["NS3-4A", "GENE_OR_GENE_PRODUCT", 8, 14], ["boceprevir", "SIMPLE_CHEMICAL", 35, 45], ["narlaprevir", "SIMPLE_CHEMICAL", 55, 66], ["NS3", "PROTEIN", 8, 11], ["HCV", "SPECIES", 4, 7], ["The HCV NS3", "TREATMENT", 0, 11], ["4A protease inhibitors boceprevir", "TREATMENT", 12, 45], ["narlaprevir", "TREATMENT", 55, 66], ["simeprevir", "TREATMENT", 201, 211]]], ["Despite their potent inhibition against the HCV NS3-4A serine protease and the SARS-CoV-2 cysteine M pro , boceprevir (28) and narlaprevir (29) did not inhibit the EV-A71 2A and 3C proteases (IC 50 > 20 \u00b5M), suggesting that they are not nonspecific cysteine protease inhibitors.", [["boceprevir", "CHEMICAL", 107, 117], ["narlaprevir", "CHEMICAL", 127, 138], ["serine", "CHEMICAL", 55, 61], ["cysteine", "CHEMICAL", 90, 98], ["boceprevir", "CHEMICAL", 107, 117], ["narlaprevir", "CHEMICAL", 127, 138], ["cysteine", "CHEMICAL", 249, 257], ["HCV NS3", "ORGANISM", 44, 51], ["boceprevir", "SIMPLE_CHEMICAL", 107, 117], ["narlaprevir", "SIMPLE_CHEMICAL", 127, 138], ["EV-A71 2A", "GENE_OR_GENE_PRODUCT", 164, 173], ["HCV NS3-4A serine protease", "PROTEIN", 44, 70], ["EV-A71 2A and 3C proteases", "PROTEIN", 164, 190], ["HCV", "SPECIES", 44, 47], ["EV-A71 2A", "SPECIES", 164, 173], ["the HCV NS3", "TREATMENT", 40, 51], ["4A serine protease", "TREATMENT", 52, 70], ["the SARS", "TEST", 75, 83], ["CoV-2 cysteine M pro", "TREATMENT", 84, 104], ["boceprevir", "TREATMENT", 107, 117], ["narlaprevir", "TREATMENT", 127, 138], ["the EV", "TEST", 160, 166], ["3C proteases", "TEST", 178, 190], ["IC", "TEST", 192, 194], ["nonspecific cysteine protease inhibitors", "TREATMENT", 237, 277]]], ["The calpain inhibitor MG-132 (43) had an IC 50 value of 3.90 \u00b5M against M pro , and was not active Table 1 .", [["MG-132", "CHEMICAL", 22, 28], ["MG-132", "CHEMICAL", 22, 28], ["calpain", "GENE_OR_GENE_PRODUCT", 4, 11], ["MG-132", "SIMPLE_CHEMICAL", 22, 28], ["calpain", "PROTEIN", 4, 11], ["The calpain inhibitor MG", "TEST", 0, 24]]], ["List of protease inhibitors tested against SARS-CoV-2 M pro in the primary FRET assay.Proteosome inhibitorsHIV protease (aspartic protease) inhibitors -secretase (aspartic protease) inhibitors HCV protease (serine protease) inhibitorsDPP-4 (serine protease) inhibitorsArticle against the EV-A71 2A and 3C proteases (IC 50 > 20 \u00b5M).", [["serine", "CHEMICAL", 207, 213], ["serine", "CHEMICAL", 241, 247], ["serine", "AMINO_ACID", 207, 213], ["inhibitorsDPP-4", "GENE_OR_GENE_PRODUCT", 224, 239], ["serine", "AMINO_ACID", 241, 247], ["EV-A71 2A", "ORGANISM", 288, 297], ["Proteosome inhibitors", "PROTEIN", 86, 107], ["HIV protease", "PROTEIN", 107, 119], ["aspartic protease) inhibitors -secretase (aspartic protease) inhibitors HCV protease", "PROTEIN", 121, 205], ["serine protease) inhibitorsDPP-4", "PROTEIN", 207, 239], ["EV-A71 2A and 3C proteases", "PROTEIN", 288, 314], ["HIV", "SPECIES", 107, 110], ["SARS-CoV", "SPECIES", 43, 51], ["HIV", "SPECIES", 107, 110], ["HCV", "SPECIES", 193, 196], ["EV-A71 2A", "SPECIES", 288, 297], ["protease inhibitors", "TREATMENT", 8, 27], ["SARS", "PROBLEM", 43, 47], ["Proteosome inhibitors", "TREATMENT", 86, 107], ["HIV protease (aspartic protease) inhibitors", "TREATMENT", 107, 150], ["secretase (aspartic protease) inhibitors", "TREATMENT", 152, 192], ["HCV protease (serine protease) inhibitorsDPP", "TREATMENT", 193, 237], ["serine protease) inhibitors", "TREATMENT", 241, 268], ["the EV", "TEST", 284, 290], ["3C proteases (IC", "TREATMENT", 302, 318]]], ["The binding of MG-132 (43) to M pro was also confirmed in the TSA assay with a \u0394T m of 4.02\u00b0C.DPP-4 (serine protease) inhibitorsIn light of the promising results of the calpain inhibitor MG-132 (43), we then pursued testing for other calpain and cathepsin inhibitors that are commercially available (56-63) ( Table 2 ).", [["MG-132", "CHEMICAL", 15, 21], ["TSA", "CHEMICAL", 62, 65], ["MG-132", "CHEMICAL", 187, 193], ["MG-132", "CHEMICAL", 15, 21], ["TSA", "CHEMICAL", 62, 65], ["serine", "CHEMICAL", 101, 107], ["MG-132", "CHEMICAL", 187, 193], ["M pro", "GENE_OR_GENE_PRODUCT", 30, 35], ["C.DPP-4", "GENE_OR_GENE_PRODUCT", 92, 99], ["serine protease", "GENE_OR_GENE_PRODUCT", 101, 116], ["calpain", "GENE_OR_GENE_PRODUCT", 169, 176], ["MG-132", "SIMPLE_CHEMICAL", 187, 193], ["calpain", "GENE_OR_GENE_PRODUCT", 234, 241], ["cathepsin", "GENE_OR_GENE_PRODUCT", 246, 255], ["calpain", "PROTEIN", 169, 176], ["calpain", "PROTEIN", 234, 241], ["MG", "TEST", 15, 17], ["the TSA assay", "TEST", 58, 71], ["a \u0394T m", "TEST", 77, 83], ["C.DPP", "TEST", 92, 97], ["serine protease) inhibitors", "TREATMENT", 101, 128], ["the calpain inhibitor MG", "TEST", 165, 189], ["testing", "TEST", 216, 223], ["other calpain", "TREATMENT", 228, 241], ["cathepsin inhibitors", "TREATMENT", 246, 266]]], ["These compounds were not included in the initial library because they have not been advanced to clinical studies.", [["clinical studies", "TEST", 96, 112]]], ["Among this series of analogs, calpain inhibitor II (61) and XII (62) are the most potent M pro inhibitors with IC 50 values of 0.97 and 0.45 \u00b5M, respectively.", [["inhibitor II", "CHEMICAL", 38, 50], ["calpain", "GENE_OR_GENE_PRODUCT", 30, 37], ["XII (62)", "SIMPLE_CHEMICAL", 60, 68], ["analogs", "TREATMENT", 21, 28], ["calpain inhibitor II", "TREATMENT", 30, 50]]], ["Binding of compounds (61 and 62) to M pro shifted the melting curve of the protein by 6.65 and 7.86\u00b0C, respectively.", [["the melting curve", "TEST", 50, 67], ["the protein", "TEST", 71, 82]]], ["Encouragingly, both compounds (61 and 62) did not inhibit the EV-A71 2A and 3C proteases (IC 50 > 20 \u00b5M).", [["EV-A71 2A", "GENE_OR_GENE_PRODUCT", 62, 71], ["EV-A71 2A and 3C proteases", "PROTEIN", 62, 88], ["the EV", "TEST", 58, 64], ["3C proteases", "TREATMENT", 76, 88], ["IC", "TEST", 90, 92]]], ["Calpain inhibitor I (59) and MG-115 (60) also showed potent inhibition against M pro with IC 50 values of 8.60 and 3.14 \u00b5M, respectively.", [["MG-115", "CHEMICAL", 29, 35], ["MG-115", "CHEMICAL", 29, 35], ["Calpain", "GENE_OR_GENE_PRODUCT", 0, 7], ["MG-115", "SIMPLE_CHEMICAL", 29, 35], ["Calpain inhibitor I", "TEST", 0, 19], ["MG", "TEST", 29, 31]]], ["Calpeptin (56) and PSI (63) had moderate activity against M pro with IC 50 values of 10.69 and 10.38 \u00b5M, respectively.", [["Calpeptin", "CHEMICAL", 0, 9], ["Calpeptin", "CHEMICAL", 0, 9], ["PSI", "CHEMICAL", 19, 22], ["Calpeptin", "SIMPLE_CHEMICAL", 0, 9], ["Calpeptin", "TEST", 0, 9], ["PSI", "TEST", 19, 22]]], ["In contrast, calpain inhibitors III (57) and VI (58) were not active (IC 50 > 20 \u00b5M).DPP-4 (serine protease) inhibitorsWe also included two well-known viral 3CL protease inhibitors GC-376 (64) and rupintrivir (65) in the secondary screening.", [["DPP-4", "CHEMICAL", 85, 90], ["GC-376", "CHEMICAL", 181, 187], ["rupintrivir", "CHEMICAL", 197, 208], ["serine", "CHEMICAL", 92, 98], ["GC-376", "CHEMICAL", 181, 187], ["rupintrivir", "CHEMICAL", 197, 208], ["calpain", "GENE_OR_GENE_PRODUCT", 13, 20], ["DPP-4", "GENE_OR_GENE_PRODUCT", 85, 90], ["serine protease", "GENE_OR_GENE_PRODUCT", 92, 107], ["GC-376", "SIMPLE_CHEMICAL", 181, 187], ["rupintrivir", "SIMPLE_CHEMICAL", 197, 208], ["DPP-4 (serine protease", "PROTEIN", 85, 107], ["calpain inhibitors III", "TEST", 13, 35], ["VI", "TEST", 45, 47], ["IC", "TEST", 70, 72], ["DPP", "TEST", 85, 88], ["serine protease) inhibitorsWe", "TEST", 92, 121], ["viral 3CL protease inhibitors", "TREATMENT", 151, 180], ["GC", "TEST", 181, 183], ["rupintrivir", "TEST", 197, 208], ["the secondary screening", "TEST", 217, 240]]], ["GC-376 (64) is an investigational veterinary drug that is being developed for feline infectious peritonitis (FIP).", [["GC-376", "CHEMICAL", 0, 6], ["feline infectious peritonitis", "DISEASE", 78, 107], ["FIP", "DISEASE", 109, 112], ["GC-376", "CHEMICAL", 0, 6], ["GC-376", "SIMPLE_CHEMICAL", 0, 6], ["feline", "ORGANISM", 78, 84], ["feline", "SPECIES", 78, 84], ["GC", "TEST", 0, 2], ["an investigational veterinary drug", "TREATMENT", 15, 49], ["feline infectious peritonitis", "PROBLEM", 78, 107], ["infectious", "OBSERVATION_MODIFIER", 85, 95], ["peritonitis", "OBSERVATION", 96, 107]]], ["13,14 GC-376 (64) was designed to target the viral 3CL protease and had potent antiviral activity against multiple viruses including MERS-CoV, FIPV, and norovirus.", [["GC-376", "CHEMICAL", 6, 12], ["norovirus", "DISEASE", 153, 162], ["MERS-CoV", "ORGANISM", 133, 141], ["FIPV", "GENE_OR_GENE_PRODUCT", 143, 147], ["norovirus", "ORGANISM", 153, 162], ["viral 3CL protease", "PROTEIN", 45, 63], ["MERS-CoV", "SPECIES", 133, 141], ["FIPV", "SPECIES", 143, 147], ["GC", "TEST", 6, 8], ["the viral 3CL protease", "TREATMENT", 41, 63], ["potent antiviral activity", "TREATMENT", 72, 97], ["multiple viruses", "PROBLEM", 106, 122], ["MERS", "PROBLEM", 133, 137], ["FIPV", "PROBLEM", 143, 147], ["norovirus", "PROBLEM", 153, 162], ["viruses", "OBSERVATION", 115, 122], ["norovirus", "OBSERVATION", 153, 162]]], ["13, 15 Rupintrivir (65) was developed as a rhinovirus antiviral by targeting the viral 3CL protease, but it was discontinued in clinical trials due to side effects.", [["Rupintrivir", "CHEMICAL", 7, 18], ["rhinovirus", "ORGANISM", 43, 53], ["viral 3CL protease", "PROTEIN", 81, 99], ["a rhinovirus antiviral", "TREATMENT", 41, 63], ["the viral 3CL protease", "TREATMENT", 77, 99], ["side effects", "PROBLEM", 151, 163]]], ["16 In our study, we found that GC-376 (64) was the most potent M pro inhibitor with an IC 50 value of 0.03 \u00b5M.", [["GC-376", "CHEMICAL", 31, 37], ["GC-376", "CHEMICAL", 31, 37], ["GC-376", "SIMPLE_CHEMICAL", 31, 37], ["our study", "TEST", 6, 15], ["GC", "TEST", 31, 33], ["an IC", "TEST", 84, 89]]], ["In contrast, rupintrivir (65) was not active against M pro (IC 50 > 20 \u00b5M).", [["rupintrivir", "CHEMICAL", 13, 24], ["rupintrivir", "CHEMICAL", 13, 24]]], ["Previous report also showed that rupintrivir was not active against the SARS-CoV 3CL pro (M pro ) (IC 50 > 100 \u00b5M).", [["rupintrivir", "CHEMICAL", 33, 44], ["SARS", "DISEASE", 72, 76], ["rupintrivir", "CHEMICAL", 33, 44], ["rupintrivir", "SIMPLE_CHEMICAL", 33, 44], ["SARS-CoV", "SPECIES", 72, 80], ["the SARS", "PROBLEM", 68, 76], ["CoV 3CL pro", "TREATMENT", 77, 88], ["IC", "TEST", 99, 101]]], ["17 Both compounds (64 and 65) were inactive against the EV-A71 2A protease, but showed potent inhibition against the EV-A71 3C protease, which is consistent with previously reported results.", [["EV-A71 2A", "ORGANISM", 56, 65], ["EV-A71 3C", "ORGANISM", 117, 126], ["EV-A71 2A protease", "PROTEIN", 56, 74], ["EV-A71 3C protease", "PROTEIN", 117, 135], ["EV-A71 2A", "SPECIES", 56, 65], ["EV-A71 3C", "SPECIES", 117, 126], ["the EV", "TEST", 52, 58], ["the EV", "TEST", 113, 119], ["consistent with", "UNCERTAINTY", 146, 161]]], ["15, 18, 19 When plotting the IC 50 values (log scale) of the inhibitors against M pro from the FRET enzymatic assay with the melting temperature shifts (\u0394T m ) from TSA (Fig. 3a) , a linear correlation was observed, and the r 2 of the linear regression fitting is 0.94.", [["TSA", "CHEMICAL", 165, 168], ["M pro", "PROTEIN", 80, 85], ["the inhibitors", "TREATMENT", 57, 71], ["the FRET enzymatic assay", "TEST", 91, 115], ["the melting temperature shifts", "PROBLEM", 121, 151], ["a linear correlation", "TEST", 181, 201]]], ["This suggests that there is a direct correlation between the enzymatic inhibition and protein binding: a more potent enzyme inhibitor also binds to the protein with higher affinity.", [["the enzymatic inhibition and protein binding", "PROBLEM", 57, 101], ["a more potent enzyme inhibitor", "TREATMENT", 103, 133]]], ["TheMiscellaneous serine protease inhibitorsCathepsin and calpain protease (cysteine protease) inhibitorsMiscellaneous protease inhibitorsArticle stabilization of the M pro against thermal denaturation was also compound concentration dependent (Fig. 3b) .Miscellaneous protease inhibitorsThe binding of the four most potent inhibitors boceprevir (28), calpain inhibitors II (61), XII (62), and GC-376 (64) to SARS-CoV-2 M pro was further characterized by native mass spectrometry (MS) (Fig. 3c-f ).", [["boceprevir", "CHEMICAL", 334, 344], ["GC-376", "CHEMICAL", 393, 399], ["serine", "CHEMICAL", 17, 23], ["cysteine", "CHEMICAL", 75, 83], ["boceprevir", "CHEMICAL", 334, 344], ["Cathepsin", "GENE_OR_GENE_PRODUCT", 43, 52], ["calpain protease", "GENE_OR_GENE_PRODUCT", 57, 73], ["cysteine", "AMINO_ACID", 75, 83], ["boceprevir", "SIMPLE_CHEMICAL", 334, 344], ["calpain", "GENE_OR_GENE_PRODUCT", 351, 358], ["XII", "GENE_OR_GENE_PRODUCT", 379, 382], ["GC-376", "SIMPLE_CHEMICAL", 393, 399], ["TheMiscellaneous serine protease inhibitors", "PROTEIN", 0, 43], ["Cathepsin", "PROTEIN", 43, 52], ["calpain protease", "PROTEIN", 57, 73], ["cysteine protease", "PROTEIN", 75, 92], ["TheMiscellaneous serine protease inhibitors", "TREATMENT", 0, 43], ["Cathepsin", "TREATMENT", 43, 52], ["calpain protease (cysteine protease) inhibitors", "TREATMENT", 57, 104], ["Miscellaneous protease inhibitors", "TREATMENT", 104, 137], ["the M pro", "TREATMENT", 162, 171], ["thermal denaturation", "PROBLEM", 180, 200], ["Miscellaneous protease inhibitors", "TREATMENT", 254, 287], ["potent inhibitors boceprevir", "TREATMENT", 316, 344], ["calpain inhibitors II", "TEST", 351, 372], ["XII", "TEST", 379, 382], ["GC", "TEST", 393, 395], ["SARS", "TEST", 408, 412], ["CoV", "TEST", 413, 416], ["native mass spectrometry", "PROBLEM", 454, 478], ["mass", "OBSERVATION", 461, 465]]], ["Native MS analysis showed that M pro formed a dimer complex with a mass of 69,722 Da, indicating that the extra Nterminal methionine in our M pro construct was cleaved, yielding the native M pro N-terminus with a serine residue (Supplementary information, Fig. S1 ).", [["methionine", "CHEMICAL", 122, 132], ["methionine", "CHEMICAL", 122, 132], ["N", "CHEMICAL", 195, 196], ["serine", "CHEMICAL", 213, 219], ["serine", "AMINO_ACID", 213, 219], ["S1", "GENE_OR_GENE_PRODUCT", 261, 263], ["M pro", "PROTEIN", 31, 36], ["dimer complex", "PROTEIN", 46, 59], ["M pro N-terminus", "PROTEIN", 189, 205], ["S1", "PROTEIN", 261, 263], ["Native MS analysis", "TEST", 0, 18], ["a mass", "PROBLEM", 65, 71], ["the extra Nterminal methionine", "TREATMENT", 102, 132], ["a serine residue", "PROBLEM", 211, 227], ["mass", "OBSERVATION", 67, 71]]], ["A small amount of protomer and dimer with a single C-terminal truncation of the His-tag was also observed, but the intact dimer was the predominant signal (Supplementary information, Fig. S1 ).", [["C", "CHEMICAL", 51, 52], ["His", "CHEMICAL", 80, 83], ["S1", "GENE_OR_GENE_PRODUCT", 188, 190], ["dimer", "PROTEIN", 31, 36], ["C-terminal truncation", "PROTEIN", 51, 72], ["His-tag", "PROTEIN", 80, 87], ["S1", "PROTEIN", 188, 190], ["A small amount of protomer and dimer", "PROBLEM", 0, 36], ["a single C-terminal truncation", "PROBLEM", 42, 72], ["small", "OBSERVATION_MODIFIER", 2, 7], ["amount", "OBSERVATION_MODIFIER", 8, 14], ["dimer", "OBSERVATION_MODIFIER", 31, 36], ["terminal", "OBSERVATION_MODIFIER", 53, 61], ["truncation", "OBSERVATION", 62, 72]]], ["Addition of all four ligands tested, boceprevir (28) , calpain inhibitors II (61), XII (62), and GC-376 (64), showed binding of up to two ligands per dimer ( Fig. 3c-f ), suggesting a binding stoichiometry of one drug per protomer.Mechanism of action of hitsTo elucidate the mechanism of action of hits against SARS-CoV-2 M pro , we focus on five most potent compounds prioritized from the primary and secondary screenings including boceprevir (28), MG-132 (43), calpain inhibitor II (61), calpain inhibitor XII (62), and GC-376 (64).", [["boceprevir", "CHEMICAL", 37, 47], ["GC-376", "CHEMICAL", 97, 103], ["boceprevir", "CHEMICAL", 433, 443], ["MG-132", "CHEMICAL", 450, 456], ["GC-376", "CHEMICAL", 522, 528], ["boceprevir", "CHEMICAL", 37, 47], ["boceprevir", "CHEMICAL", 433, 443], ["MG-132", "CHEMICAL", 450, 456], ["boceprevir", "SIMPLE_CHEMICAL", 37, 47], ["calpain inhibitors II", "SIMPLE_CHEMICAL", 55, 76], ["XII", "GENE_OR_GENE_PRODUCT", 83, 86], ["GC-376", "SIMPLE_CHEMICAL", 97, 103], ["boceprevir", "SIMPLE_CHEMICAL", 433, 443], ["MG-132", "SIMPLE_CHEMICAL", 450, 456], ["calpain inhibitor II", "SIMPLE_CHEMICAL", 463, 483], ["calpain", "GENE_OR_GENE_PRODUCT", 490, 497], ["XII", "GENE_OR_GENE_PRODUCT", 508, 511], ["GC-376", "SIMPLE_CHEMICAL", 522, 528], ["calpain", "PROTEIN", 463, 470], ["calpain", "PROTEIN", 490, 497], ["SARS-CoV", "SPECIES", 311, 319], ["all four ligands", "TEST", 12, 28], ["boceprevir", "TREATMENT", 37, 47], ["calpain inhibitors II", "TEST", 55, 76], ["XII", "TEST", 83, 86], ["GC", "TEST", 97, 99], ["SARS", "PROBLEM", 311, 315], ["boceprevir", "TREATMENT", 433, 443], ["MG", "TEST", 450, 452], ["calpain inhibitor II", "TREATMENT", 463, 483], ["calpain inhibitor XII", "TEST", 490, 511], ["GC", "TEST", 522, 524]]], ["For this, we performed enzyme kinetic studies with different concentrations of inhibitors (Fig. 4) .", [["enzyme kinetic studies", "TEST", 23, 45], ["different concentrations of inhibitors", "TREATMENT", 51, 89]]], ["A biphasic enzymatic progression curve in the presence but not absence of inhibitor is typically a hallmark for a slow covalent binding inhibitor.", [["A biphasic enzymatic progression curve", "PROBLEM", 0, 38], ["a slow covalent binding inhibitor", "TREATMENT", 112, 145], ["biphasic", "OBSERVATION_MODIFIER", 2, 10], ["enzymatic", "OBSERVATION_MODIFIER", 11, 20], ["progression", "OBSERVATION_MODIFIER", 21, 32], ["curve", "OBSERVATION_MODIFIER", 33, 38]]], ["In Fig. 4 , the left column shows the progression curves up to 4 h.", [["left column", "ANATOMY", 16, 27], ["the progression curves", "PROBLEM", 34, 56], ["left", "ANATOMY_MODIFIER", 16, 20], ["column", "ANATOMY", 21, 27], ["progression", "OBSERVATION_MODIFIER", 38, 49], ["curves", "OBSERVATION_MODIFIER", 50, 56]]], ["Biphasic progression curves were observed for all 5 inhibitors at high drug concentrations.", [["Biphasic progression curves", "PROBLEM", 0, 27], ["all 5 inhibitors", "TREATMENT", 46, 62]]], ["Significant substrate depletion was observed when the proteolytic reaction proceeded beyond 90 min.", [["Significant substrate depletion", "PROBLEM", 0, 31], ["the proteolytic reaction", "PROBLEM", 50, 74], ["substrate depletion", "OBSERVATION", 12, 31]]], ["We therefore chose the first 90 min of the progression curves for curve fitting (Fig. 4 , middle column).", [["the progression curves", "TEST", 39, 61], ["curve fitting (Fig. 4 , middle column)", "TREATMENT", 66, 104], ["middle column", "ANATOMY", 90, 103]]], ["We fit the progression curves in the presence of different concentrations of GC-376 (64) with the two-step Morrison equation (Eq.", [["GC-376", "CHEMICAL", 77, 83], ["GC-376", "CHEMICAL", 77, 83], ["the progression curves", "TEST", 7, 29], ["GC", "TEST", 77, 79], ["progression", "OBSERVATION_MODIFIER", 11, 22], ["curves", "OBSERVATION_MODIFIER", 23, 29]]], ["GC-376 (64) binds to SARS-CoV-2 M pro with an equilibrium dissociation constant for the inhibitor (K I ) of 59.9 \u00b1 21.7 nM in the first step.", [["GC-376", "CHEMICAL", 0, 6], ["K", "CHEMICAL", 99, 100], ["GC-376", "CHEMICAL", 0, 6], ["GC", "TEST", 0, 2], ["SARS", "TEST", 21, 25], ["CoV", "TEST", 26, 29], ["an equilibrium dissociation", "PROBLEM", 43, 70], ["the inhibitor", "TEST", 84, 97], ["K I", "TEST", 99, 102]]], ["After initial binding, a covalent bond is formed at a slower velocity between GC-376 (64) and M pro with the second reaction rate constant (k 2 ) being 0.00245 \u00b1 0.00047 s \u22121 , resulting in an overall k 2 /K I value of 4.08 \u00d7 10 4 M \u22121 s \u22121 (Fig. 4a) .", [["GC-376", "CHEMICAL", 78, 84], ["GC", "TEST", 78, 80], ["M pro", "TEST", 94, 99], ["the second reaction rate", "TEST", 105, 129], ["k", "TEST", 140, 141], ["an overall k", "TEST", 190, 202], ["K I value", "TEST", 206, 215], ["covalent bond", "OBSERVATION", 25, 38], ["slower", "OBSERVATION_MODIFIER", 54, 60], ["velocity", "OBSERVATION_MODIFIER", 61, 69]]], ["However, when we tried to fit the proteolytic progression curves for boceprevir (28) , MG-132 (43), calpain inhibitors II (61) and XII (62) using the same two-step reaction mechanism, we could not obtain accurate values for the second rate constant k 2 .", [["boceprevir", "CHEMICAL", 69, 79], ["MG-132", "CHEMICAL", 87, 93], ["boceprevir", "CHEMICAL", 69, 79], ["MG-132", "CHEMICAL", 87, 93], ["boceprevir", "SIMPLE_CHEMICAL", 69, 79], ["MG-132 (43)", "SIMPLE_CHEMICAL", 87, 98], ["calpain", "GENE_OR_GENE_PRODUCT", 100, 107], ["boceprevir", "TREATMENT", 69, 79], ["MG", "TEST", 87, 89], ["calpain inhibitors II", "TREATMENT", 100, 121]]], ["This is presumably due to significant substrate depletion before the equilibrium between EI and EI.", [["significant substrate depletion", "PROBLEM", 26, 57], ["presumably due to", "UNCERTAINTY", 8, 25], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["substrate depletion", "OBSERVATION", 38, 57]]], ["42 k 2 /K I is commonly used to evaluate the efficacy for covalent inhibitor.", [["covalent inhibitor", "TREATMENT", 58, 76]]], ["We observed substrate depletion when proteolytic reactions progress longer than 90 min; therefore only first 90 min of the progress curves were used in the curve fitting (Fig. 6, middle column) .", [["substrate depletion", "PROBLEM", 12, 31], ["proteolytic reactions", "PROBLEM", 37, 58], ["substrate depletion", "OBSERVATION", 12, 31], ["middle column", "ANATOMY", 179, 192]]], ["In this study, we could not accurately determine the k 2 for the protease inhibitors: calpain inhibitor II, MG132, boceprevir, and calpain inhibitor XII, due to the very slow k 2 in these cases: significant substrate depletion before the establishment of the equilibrium between EI and EI*.", [["inhibitor II", "CHEMICAL", 94, 106], ["MG132", "CHEMICAL", 108, 113], ["boceprevir", "CHEMICAL", 115, 125], ["MG132", "CHEMICAL", 108, 113], ["boceprevir", "CHEMICAL", 115, 125], ["calpain inhibitor II", "GENE_OR_GENE_PRODUCT", 86, 106], ["MG132", "SIMPLE_CHEMICAL", 108, 113], ["boceprevir", "SIMPLE_CHEMICAL", 115, 125], ["calpain", "GENE_OR_GENE_PRODUCT", 131, 138], ["XII", "GENE_OR_GENE_PRODUCT", 149, 152], ["calpain inhibitor XII", "PROTEIN", 131, 152], ["this study", "TEST", 3, 13], ["the protease inhibitors", "TREATMENT", 61, 84], ["calpain inhibitor II", "TREATMENT", 86, 106], ["MG132", "TREATMENT", 108, 113], ["boceprevir", "TREATMENT", 115, 125], ["calpain inhibitor XII", "TREATMENT", 131, 152], ["significant substrate depletion", "PROBLEM", 195, 226], ["significant", "OBSERVATION_MODIFIER", 195, 206], ["substrate depletion", "OBSERVATION", 207, 226]]], ["In these cases, K I was determined with Morrison equation in Prism 5.Differential scanning fluorimetryThe binding of protease inhibitors to M pro was monitored by differential scanning fluorimetry (DSF) using a Thermo Fisher QuantStudio TM 5 Real-Time PCR System.", [["K I", "GENE_OR_GENE_PRODUCT", 16, 19], ["K I", "PROTEIN", 16, 19], ["K I", "TEST", 16, 19], ["Differential scanning fluorimetry", "TEST", 69, 102], ["protease inhibitors", "TREATMENT", 117, 136], ["a Thermo Fisher QuantStudio TM", "TREATMENT", 209, 239]]], ["TSA plates were prepared by mixing M pro protein (final concentration of 3 \u03bcM) with inhibitors, and incubated at 30\u00b0C for 30 min.", [["TSA", "CHEMICAL", 0, 3], ["TSA", "CHEMICAL", 0, 3], ["TSA", "SIMPLE_CHEMICAL", 0, 3], ["TSA plates", "TREATMENT", 0, 10], ["mixing M pro protein", "TREATMENT", 28, 48], ["inhibitors", "TREATMENT", 84, 94]]], ["1\u00d7 SYPRO orange (Thermo Fisher Scientific) were added and the fluorescence of the plates were taken under a temperature gradient ranging from 20 to 90\u00b0C (incremental steps of 0.05\u00b0C/s).", [["the fluorescence of the plates", "TREATMENT", 58, 88], ["a temperature gradient", "TEST", 106, 128]]], ["The melting temperature (T m ) was calculated as the mid-log of the transition phase from the native to the denatured protein using a Boltzmann model (Protein Thermal Shift Software v1.3).", [["denatured protein", "PROTEIN", 108, 125], ["The melting temperature", "TEST", 0, 23], ["a Boltzmann model", "TREATMENT", 132, 149]]], ["Thermal shift that was represented as \u0394T m was calculated by subtracting reference melting temperature of proteins in DMSO from the T m in the presence of compound.Differential scanning fluorimetryCytotoxicity measurement A549, MDCK, HCT-8, Caco-2, Vero, and BEAS2B cells for cytotoxicity CPE assays were seeded and grown overnight at 37\u00b0C in a 5% CO 2 atmosphere to \u223c90% confluence on the next day.", [["A549", "ANATOMY", 222, 226], ["MDCK", "ANATOMY", 228, 232], ["HCT-8", "ANATOMY", 234, 239], ["Caco-2", "ANATOMY", 241, 247], ["Vero", "ANATOMY", 249, 253], ["BEAS2B cells", "ANATOMY", 259, 271], ["DMSO", "CHEMICAL", 118, 122], ["DMSO", "CHEMICAL", 118, 122], ["CO", "CHEMICAL", 348, 350], ["DMSO", "SIMPLE_CHEMICAL", 118, 122], ["T m", "GENE_OR_GENE_PRODUCT", 132, 135], ["A549", "CELL", 222, 226], ["MDCK", "CELL", 228, 232], ["HCT-8", "CELL", 234, 239], ["Caco-2", "CELL", 241, 247], ["Vero", "CELL", 249, 253], ["BEAS2B cells", "CELL", 259, 271], ["A549", "CELL_LINE", 222, 226], ["MDCK", "CELL_LINE", 228, 232], ["HCT-8", "CELL_LINE", 234, 239], ["Caco-2", "CELL_LINE", 241, 247], ["Vero", "CELL_LINE", 249, 253], ["BEAS2B cells", "CELL_LINE", 259, 271], ["Thermal shift", "PROBLEM", 0, 13], ["Differential scanning fluorimetry", "TEST", 164, 197], ["Cytotoxicity", "TEST", 197, 209], ["A549", "TEST", 222, 226], ["MDCK", "TEST", 228, 232], ["HCT", "TEST", 234, 237], ["Caco", "TEST", 241, 245], ["Vero", "TEST", 249, 253], ["BEAS2B cells", "PROBLEM", 259, 271], ["cytotoxicity CPE assays", "PROBLEM", 276, 299]]], ["Cells were washed with phosphate-buffered saline (PBS) and 200 \u00b5L DMEM containing 2% FBS and 1% penicillin-streptomycin, and various concentrations of protease inhibitors were added to each well.", [["Cells", "ANATOMY", 0, 5], ["FBS", "ANATOMY", 85, 88], ["phosphate", "CHEMICAL", 23, 32], ["FBS", "CHEMICAL", 85, 88], ["penicillin", "CHEMICAL", 96, 106], ["streptomycin", "CHEMICAL", 107, 119], ["phosphate", "CHEMICAL", 23, 32], ["penicillin", "CHEMICAL", 96, 106], ["streptomycin", "CHEMICAL", 107, 119], ["Cells", "CELL", 0, 5], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 23, 48], ["FBS", "ORGANISM_SUBSTANCE", 85, 88], ["penicillin-streptomycin", "SIMPLE_CHEMICAL", 96, 119], ["Cells", "TEST", 0, 5], ["phosphate-buffered saline (PBS", "TREATMENT", 23, 53], ["200 \u00b5L DMEM", "TREATMENT", 59, 70], ["2% FBS", "TREATMENT", 82, 88], ["penicillin", "TREATMENT", 96, 106], ["streptomycin", "TREATMENT", 107, 119], ["various concentrations of protease inhibitors", "TREATMENT", 125, 170]]], ["48 h after addition of the protease inhibitors, cells were stained with 66 \u03bcg/mL neutral red for 2 h, and neutral red uptake was measured at an absorbance at 540 nm using a Multiskan FC microplate photometer (Thermo Fisher Scientific).", [["cells", "ANATOMY", 48, 53], ["cells", "CELL", 48, 53], ["the protease inhibitors", "TREATMENT", 23, 46], ["cells", "TREATMENT", 48, 53], ["neutral red uptake", "PROBLEM", 106, 124], ["a Multiskan FC microplate photometer", "TREATMENT", 171, 207]]], ["The CC 50 values were calculated from best-fit dose-response curves using Graph-Pad Prism 5 software.Differential scanning fluorimetrySARS-CoV-2 CPE assay Antiviral activities of test compounds were determined in nearly confluent cultures of Vero 76 cells.", [["cultures", "ANATOMY", 230, 238], ["Vero 76 cells", "ANATOMY", 242, 255], ["CC", "CHEMICAL", 4, 6], ["Vero 76 cells", "CELL", 242, 255], ["Vero 76 cells", "CELL_LINE", 242, 255], ["Vero 76", "SPECIES", 242, 249], ["The CC 50 values", "TEST", 0, 16], ["response curves", "TEST", 52, 67], ["Graph", "TEST", 74, 79], ["Differential scanning fluorimetrySARS-CoV", "TEST", 101, 142], ["CPE assay", "TEST", 145, 154], ["Antiviral activities of test compounds", "TEST", 155, 193], ["confluent cultures", "TEST", 220, 238]]], ["The assays were performed in 96-well Corning microplates.", [["The assays", "TEST", 0, 10]]], ["Cells were infected with approximately 60-fold of 50% cell culture infectious doses (CCID 50 ) of SARS-CoV-2 and 50% effective concentrations (EC 50 ) were calculated based on virus-induced CPE quantified by neutral red dye uptake after 5 days of incubation.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 54, 58], ["SARS", "DISEASE", 98, 102], ["Cells", "CELL", 0, 5], ["cell", "CELL", 54, 58], ["red dye", "SIMPLE_CHEMICAL", 216, 223], ["SARS-CoV", "SPECIES", 98, 106], ["Cells", "TEST", 0, 5], ["CCID", "TEST", 85, 89], ["SARS", "TEST", 98, 102], ["CoV", "TEST", 103, 106], ["EC", "TEST", 143, 145], ["virus", "PROBLEM", 176, 181], ["neutral red dye uptake", "PROBLEM", 208, 230], ["incubation", "TREATMENT", 247, 257]]], ["USA-WA1/2020 strain of SARS-CoV-2 obtained from the WRCEVA was used for both CPE and VYR assays.", [["SARS", "DISEASE", 23, 27], ["USA", "GENE_OR_GENE_PRODUCT", 0, 3], ["SARS-CoV-2", "ORGANISM", 23, 33], ["WRCEVA", "DNA", 52, 58], ["SARS-CoV", "SPECIES", 23, 31], ["USA", "TEST", 0, 3], ["SARS", "PROBLEM", 23, 27], ["CoV", "TEST", 28, 31], ["the WRCEVA", "TREATMENT", 48, 58], ["VYR assays", "TEST", 85, 95]]], ["Three microwells at each concentration of compound were infected.", [["infected", "PROBLEM", 56, 64], ["microwells", "OBSERVATION_MODIFIER", 6, 16], ["compound", "OBSERVATION_MODIFIER", 42, 50], ["infected", "OBSERVATION", 56, 64]]], ["Two uninfected microwells served as toxicity controls.", [["toxicity", "DISEASE", 36, 44], ["Two uninfected microwells", "TREATMENT", 0, 25], ["toxicity controls", "TREATMENT", 36, 53], ["uninfected microwells", "OBSERVATION", 4, 25]]], ["Cells were stained for viability with neutral red (0.11% final concentration) for 2 h.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["neutral red", "TREATMENT", 38, 49]]], ["Excess dye was rinsed from the cells with PBS.", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36], ["Excess dye", "PROBLEM", 0, 10], ["PBS", "TREATMENT", 42, 45]]], ["The absorbed dye was eluted from the cells with 0.1 mL of 50% S\u00f6rensen's citrate buffer (pH 4.2)-50% ethanol.", [["cells", "ANATOMY", 37, 42], ["S\u00f6rensen's citrate", "CHEMICAL", 62, 80], ["ethanol", "CHEMICAL", 101, 108], ["citrate", "CHEMICAL", 73, 80], ["ethanol", "CHEMICAL", 101, 108], ["cells", "CELL", 37, 42], ["S\u00f6rensen", "SIMPLE_CHEMICAL", 62, 70], ["citrate", "SIMPLE_CHEMICAL", 73, 80], ["ethanol", "SIMPLE_CHEMICAL", 101, 108], ["The absorbed dye", "PROBLEM", 0, 16], ["50% S\u00f6rensen's citrate buffer", "TREATMENT", 58, 87], ["pH", "TEST", 89, 91]]], ["Plates were read for optical density determination at 540 nm.", [["density", "OBSERVATION", 29, 36]]], ["Readings were converted to the percentage of the results for the uninfected control using an Excel spreadsheet developed for this purpose.", [["the uninfected control", "TREATMENT", 61, 83], ["an Excel spreadsheet", "TEST", 90, 110]]], ["EC 50 values were determined by plotting percent CPE versus log 10 inhibitor concentration.", [["EC", "ANATOMY", 0, 2], ["EC", "CELL", 0, 2], ["plotting percent CPE", "TREATMENT", 32, 52], ["log 10 inhibitor concentration", "TREATMENT", 60, 90]]], ["Toxicity at each concentration was determined in uninfected wells in the same microplates by measuring dye uptake.Differential scanning fluorimetrySARS-CoV-2 VYR assay VYR assays were conducted by first replicating the viruses in the presence of test compound.", [["Toxicity", "DISEASE", 0, 8], ["dye", "SIMPLE_CHEMICAL", 103, 106], ["Toxicity at each concentration", "PROBLEM", 0, 30], ["Differential scanning fluorimetrySARS-CoV", "TEST", 114, 155], ["VYR assay VYR assays", "TEST", 158, 178], ["uninfected wells", "OBSERVATION", 49, 65], ["dye uptake", "OBSERVATION", 103, 113], ["viruses", "OBSERVATION", 219, 226]]], ["Supernatant was harvested 3 days post infection from each concentration of test compound and the virus yield was determined by endpoint dilution method.", [["Supernatant", "ANATOMY", 0, 11], ["infection", "DISEASE", 38, 47], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["infection", "PROBLEM", 38, 47], ["test compound", "PROBLEM", 75, 88], ["the virus yield", "PROBLEM", 93, 108], ["harvested", "OBSERVATION", 16, 25], ["infection", "OBSERVATION", 38, 47]]], ["Briefly, supernatant virus was serially diluted in log 10 increments and then plated onto quadruplicate wells of 96-well plates seeded with Vero 76 cells.", [["supernatant", "ANATOMY", 9, 20], ["Vero 76 cells", "ANATOMY", 140, 153], ["Vero 76 cells", "CELL", 140, 153], ["Vero 76 cells", "CELL_LINE", 140, 153], ["supernatant virus", "PROBLEM", 9, 26]]], ["The presence or absence of CPE for determining a viral endpoint was evaluated by microscopic examination of cells 6 days post infection.", [["cells", "ANATOMY", 108, 113], ["CPE", "CHEMICAL", 27, 30], ["infection", "DISEASE", 126, 135], ["cells", "CELL", 108, 113], ["CPE", "PROBLEM", 27, 30], ["a viral endpoint", "PROBLEM", 47, 63], ["microscopic examination", "TEST", 81, 104], ["infection", "PROBLEM", 126, 135], ["CPE", "OBSERVATION", 27, 30], ["infection", "OBSERVATION", 126, 135]]], ["From these data, 90% virus inhibitory concentrations (EC 90 ) were determined by regression analysis.Differential scanning fluorimetryInfluenza A virus A/California/07/2009 (H1N1) plaque reduction assay The plaque assay was performed according to previously published procedures.", [["plaque", "ANATOMY", 180, 186], ["plaque", "ANATOMY", 207, 213], ["plaque reduction", "DISEASE", 180, 196], ["Influenza A virus A", "ORGANISM", 134, 153], ["California/07/2009", "ORGANISM", 154, 172], ["plaque", "PATHOLOGICAL_FORMATION", 180, 186], ["Influenza A virus", "SPECIES", 134, 151], ["Influenza A virus A/California/07/2009 (H1N1)", "SPECIES", 134, 179], ["these data", "TEST", 5, 15], ["90% virus inhibitory concentrations", "TREATMENT", 17, 52], ["EC", "TEST", 54, 56], ["regression analysis", "TEST", 81, 100], ["Differential scanning fluorimetry", "TEST", 101, 134], ["Influenza", "PROBLEM", 134, 143], ["plaque reduction assay", "TREATMENT", 180, 202], ["The plaque assay", "TEST", 203, 219], ["plaque", "OBSERVATION", 207, 213]]], ["43 M pro crystallization and structure determination 10 mg/mL of SARS-CoV-2 M pro was incubated with 2 mM GC376 at 4\u00b0C overnight.", [["GC376", "CHEMICAL", 106, 111], ["GC376", "CHEMICAL", 106, 111], ["structure determination", "TREATMENT", 29, 52], ["SARS", "PROBLEM", 65, 69]]], ["The protein was diluted to 2.5 mg/mL the following day in protein buffer (50 mM Tris, pH 7.0, 150 mM NaCl, 4 mM DTT).", [["NaCl", "CHEMICAL", 101, 105], ["Tris", "CHEMICAL", 80, 84], ["NaCl", "CHEMICAL", 101, 105], ["DTT", "CHEMICAL", 112, 115], ["The protein", "TREATMENT", 0, 11], ["protein buffer", "TREATMENT", 58, 72], ["Tris", "TEST", 80, 84], ["pH", "TEST", 86, 88], ["NaCl", "TEST", 101, 105]]], ["Since GC3760 is water soluble, no precipitation was observed, and centrifugation was not necessary.", [["GC3760", "CHEMICAL", 6, 12], ["GC3760", "CHEMICAL", 6, 12], ["GC3760", "SIMPLE_CHEMICAL", 6, 12], ["precipitation", "PROBLEM", 34, 47], ["centrifugation", "TREATMENT", 66, 80], ["water soluble", "OBSERVATION_MODIFIER", 16, 29]]], ["Crystals were grown by mixing 2 \u03bcL of the protein solution with 1 \u03bcL of the precipitant solution (15% PEG 2 K, 10% 1,6-hexanediol, and 0.2 M NaCl) in a hanging-drop vapor-diffusion apparatus.", [["Crystals", "ANATOMY", 0, 8], ["PEG 2 K", "CHEMICAL", 102, 109], ["1,6-hexanediol", "CHEMICAL", 115, 129], ["NaCl", "CHEMICAL", 141, 145], ["PEG", "CHEMICAL", 102, 105], ["1,6-hexanediol", "CHEMICAL", 115, 129], ["NaCl", "CHEMICAL", 141, 145], ["Crystals", "ORGANISM_SUBSTANCE", 0, 8], ["1,6-hexanediol", "SIMPLE_CHEMICAL", 115, 129], ["Crystals", "TEST", 0, 8], ["the protein solution", "TREATMENT", 38, 58], ["the precipitant solution", "TREATMENT", 72, 96], ["hexanediol", "TREATMENT", 119, 129], ["a hanging-drop vapor-diffusion apparatus", "TREATMENT", 150, 190]]], ["Crystals were cryoprotected by transferring to a cryoprotectant solution (20% PEG 2 K, 10% 1,6-hexanediol, 20% glycerol) and flash-frozen in liquid nitrogen.", [["PEG 2 K", "CHEMICAL", 78, 85], ["1,6-hexanediol", "CHEMICAL", 91, 105], ["glycerol", "CHEMICAL", 111, 119], ["PEG", "CHEMICAL", 78, 81], ["1,6-hexanediol", "CHEMICAL", 91, 105], ["glycerol", "CHEMICAL", 111, 119], ["nitrogen", "CHEMICAL", 148, 156], ["Crystals", "ORGANISM_SUBSTANCE", 0, 8], ["1,6-hexanediol", "SIMPLE_CHEMICAL", 91, 105], ["glycerol", "SIMPLE_CHEMICAL", 111, 119], ["Crystals", "TEST", 0, 8], ["a cryoprotectant solution", "TREATMENT", 47, 72], ["hexanediol", "TREATMENT", 95, 105], ["20% glycerol", "TREATMENT", 107, 119], ["flash-frozen in liquid nitrogen", "TREATMENT", 125, 156]]], ["X-ray diffraction data for the SARS-CoV-2 M pro -GC376 complex structure was collected on the SBC 19-ID beamline at the Advanced Photon Source (APS) in Argonne, IL, and processed with the HKL3000 software suite.", [["SARS-CoV-2 M pro -GC376 complex structure", "PROTEIN", 31, 72], ["X-ray diffraction data", "TEST", 0, 22], ["the SARS", "TEST", 27, 35], ["CoV", "TEST", 36, 39], ["the SBC", "TEST", 90, 97]]], ["44 The CCP4 versions of MOLREP was used for molecular replacement using a previously solved SARS-CoV-2 M pro structure (PDB ID: 5RGG) as a reference model.", [["MOLREP", "PROTEIN", 24, 30], ["SARS-CoV-2 M pro structure", "PROTEIN", 92, 118], ["RGG", "PROTEIN", 129, 132], ["MOLREP", "TREATMENT", 24, 30], ["molecular replacement", "TREATMENT", 44, 65], ["a previously solved SARS", "PROBLEM", 72, 96]]], ["45 Rigid and restrained refinements were performed using REFMAC and model building was performed with COOT.", [["Rigid and restrained refinements", "TREATMENT", 3, 35], ["REFMAC and model building", "TREATMENT", 57, 82]]], ["46, 47 Protein structure figures were made using PyMOL (Schr\u00f6dinger, LLC).DATA AVAILABILITYThe structure for SARS-CoV-2 M pro has been deposited in the Protein Data Bank with accession number 6WTT.", [["SARS-CoV-2 M pro", "PROTEIN", 109, 125], ["PyMOL (Schr\u00f6dinger, LLC", "TREATMENT", 49, 72], ["SARS", "PROBLEM", 109, 113], ["CoV", "TEST", 114, 117], ["LLC", "ANATOMY", 69, 72]]]], "PMC7267642": [], "a0200c5d4f5317ae6099afc98db93349cd5b2cb3": [["children with disabilities.", [["children", "ORGANISM", 0, 8], ["children", "SPECIES", 0, 8]]], ["The work we were doing was based on previous SCD research conducted in schools in Britain (See X et al., 2010) , while also learning from experiences of local sickle cell school clubs that had been created with varying success.", [["sickle cell", "ANATOMY", 159, 170], ["sickle cell", "CELL", 159, 170], ["sickle cell", "OBSERVATION", 159, 170]]], ["They supported prioritisation of SCD as neglected public health issue (Ware, 2013) with a strong focus on understanding prevalence, improving medical care and ensuring prevention (Roberts et al., 2015) .", [["SCD", "DISEASE", 33, 36], ["SCD", "PROBLEM", 33, 36], ["improving medical care", "TREATMENT", 132, 154]]]], "c7545ebe2b23370a0c9564a64ad5ae32c43f7b79": [["IntroductionSAT solvers have been successfully applied in many practical domains, including cryptanalysis, hardware and software verification but also with increasing interest have been used to solve hard mathematical problems [17, 21, 26] .", [["IntroductionSAT solvers", "TREATMENT", 0, 23], ["cryptanalysis", "TREATMENT", 92, 105], ["hardware", "TREATMENT", 107, 115], ["software verification", "TEST", 120, 141], ["hardware", "OBSERVATION", 107, 115]]], ["Sequential state-of-the-art SAT solving combines the well-known conflict-drivenclause-learning procedure (CDCL) [33, 34] with sophisticated preprocessing techniques [10, 23] and other efficient heuristics for variable selection [6, 28, 30] , restarts [2, 7, 32] , and clause database reduction [32] .", [["Sequential state", "TEST", 0, 16], ["the-art SAT solving", "TREATMENT", 20, 39], ["learning procedure", "TREATMENT", 86, 104], ["sophisticated preprocessing techniques", "TREATMENT", 126, 164]]], ["While some authors argue that there was \"no major performance breakthrough in close to two decades\" [29] , at the same time computers have become more and more powerful thanks to the ubiquitous availability of multi-core processors and the increasing usage of computers in the cloud.", [["multi-core processors", "TREATMENT", 210, 231]]], ["Thus improving the efficiency of parallel SAT solving remains an important topic.", [["SAT", "TISSUE", 42, 45], ["parallel SAT solving", "TREATMENT", 33, 53], ["efficiency", "OBSERVATION_MODIFIER", 19, 29]]], ["Accordingly, beside the traditional parallel track, the SAT Competition 2020 [19] features for the first time also a cloud track.IntroductionOne approach to solve large problems in parallel consists in splitting the problem into smaller, more manageable instances, for example, using cube and conquer [16, 20] .", [["large problems", "PROBLEM", 163, 177], ["cloud track", "OBSERVATION", 117, 128], ["large", "OBSERVATION_MODIFIER", 163, 168], ["problems", "OBSERVATION", 169, 177], ["smaller", "OBSERVATION_MODIFIER", 229, 236]]], ["All these sub-problems are subsequently solved independently in parallel.", [["sub", "OBSERVATION_MODIFIER", 10, 13]]], ["This method was used by Heule to settle some long-standing mathematical conjectures [17, 21] .", [["This method", "TREATMENT", 0, 11]]], ["Splitting the problems was done automatically by a tool, but then required to manually distribute instances for parallel solving.IntroductionIn this paper, we present Paracooba [15] .", [["Splitting the problems", "PROBLEM", 0, 22], ["parallel solving", "TREATMENT", 112, 128]]], ["After splitting a problem with the look-ahead solver March, Paracooba transfers the sub-problems in an efficient way to many nodes (including over network).", [["nodes", "OBSERVATION", 125, 130]]], ["It detects when new instances become online and balances the work across all available nodes.IntroductionOther attempts for automatic and efficient distribution of problems exist, but use divide and conquer: Problems are dynamically split when nodes are underused (Sect.", [["nodes", "ANATOMY", 244, 249], ["nodes", "MULTI-TISSUE_STRUCTURE", 87, 92], ["nodes", "MULTI-TISSUE_STRUCTURE", 244, 249], ["nodes", "OBSERVATION", 87, 92], ["nodes", "OBSERVATION", 244, 249]]], ["In contrast, Paracooba assumes the problem is already split.", [["split", "OBSERVATION", 54, 59]]], ["Each node runs at least one instance of the SAT solver CaDiCaL [5] .", [["node", "ANATOMY", 5, 9], ["node", "MULTI-TISSUE_STRUCTURE", 5, 9], ["node", "OBSERVATION", 5, 9]]], ["The sub-problems are solved incrementally to reuse information from the previous solving.", [["sub", "OBSERVATION_MODIFIER", 4, 7]]], ["Paracooba relies on a custom protocol to automatically detect nodes that are underused and balances work across all nodes, including newly joining ones.", [["a custom protocol", "TREATMENT", 20, 37], ["nodes", "PROBLEM", 62, 67], ["nodes", "OBSERVATION", 62, 67], ["nodes", "OBSERVATION", 116, 121]]], ["It also supports disconnecting nodes by rebalancing the jobs (Sect.", [["nodes", "ANATOMY", 31, 36], ["disconnecting nodes", "MULTI-TISSUE_STRUCTURE", 17, 36], ["disconnecting nodes", "PROBLEM", 17, 36], ["disconnecting nodes", "OBSERVATION", 17, 36]]], ["3).IntroductionIn the experiments, we focus on a single CNF cruxmiter, a miter for 32-bit adder trees [25] , which is considered a challenge for resolution-based solvers and exemplary for the difficulties that arise in the verification of arithmetic circuits (see also [24] ).", [["a single CNF cruxmiter", "TREATMENT", 47, 69], ["the difficulties", "PROBLEM", 188, 204]]], ["4 show that we get linear scaling with respect to the number of threads.Preliminaries and Related WorkWe use standard notations and refer the reader to the Handbook of Satisfiability for an introduction to SAT [8] as well as to the chapter on parallel SAT solving [4] in the Handbook of Parallel Constraint Reasoning [14] .Preliminaries and Related WorkOne idea to improve solving of large instances is to distribute the work across different machines, via either a diversification of the search or splitting of the search space.", [["parallel SAT solving", "TREATMENT", 243, 263], ["large", "OBSERVATION_MODIFIER", 384, 389], ["instances", "OBSERVATION", 390, 399], ["search space", "OBSERVATION", 516, 528]]], ["ManySAT [13] pioneered the approach, which is now used in various tools like CryptoMiniSat [35] , HordeSat [3] , Plingeling [5] , and Syrup [1] .", [["ManySAT", "CHEMICAL", 0, 7], ["HordeSat", "TREATMENT", 98, 106]]], ["As soon as any instance derives SAT or UNSAT, then the problem is solved.Preliminaries and Related WorkWe use another approach that divides the search space explicitly as pioneered in [9, 22, 36] and refined in [16, 20] .", [["SAT", "TISSUE", 32, 35], ["another approach", "TREATMENT", 110, 126]]], ["Solving the formula \u03d5 is equivalent to splitting it into the two formulas \u03d5\u2227x and \u03d5\u2227\u00acx and solving them.", [["\u03d5\u2227\u00acx", "CELL_LINE", 82, 86]]], ["Unlike diversification, the overall problem is only considered to be UNSAT if all sub-problems are.", [["diversification", "OBSERVATION", 7, 22]]], ["Still, if any sub-problem is SAT, the overall problem is SAT, too.", [["SAT", "TISSUE", 29, 32], ["SAT", "TISSUE", 57, 60]]], ["By splitting the formula recursively, we obtain a formula of the form \u03d5 \u2227 c 1 , ..., \u03d5 \u2227 c n where the conjunctions c i are called cubes.", [["c 1", "PROTEIN", 74, 77], ["\u03d5", "PROTEIN", 85, 86]]], ["We use March [18] to split the problem: It produces cubes, e.g., of the form L 1 L 2 L 3 , L 1 L 2 \u00acL 3 , ..., \u00acL 1 \u00acL 2 \u00acL 3 .", [["\u00acL", "TEST", 111, 113], ["cubes", "OBSERVATION", 52, 57]]], ["The cubes can be represented as a binary tree, the cube tree, where cubes are a path to a leaf: At each node, either the left (positive) or the right path (negative) is taken.ArchitectureParacooba distinguishes between the masters that initiated work and workers that do the actual solving.", [["leaf", "ANATOMY", 90, 94], ["node", "ANATOMY", 104, 108], ["right path", "ANATOMY", 144, 154], ["node", "MULTI-TISSUE_STRUCTURE", 104, 108], ["binary tree", "OBSERVATION", 34, 45], ["leaf", "ANATOMY", 90, 94], ["node", "OBSERVATION", 104, 108], ["left", "ANATOMY_MODIFIER", 121, 125], ["right", "ANATOMY_MODIFIER", 144, 149]]], ["Each node can either explore the cube tree deeper by sending work further (see Sect.", [["node", "ANATOMY", 5, 9], ["node", "MULTI-TISSUE_STRUCTURE", 5, 9], ["node", "OBSERVATION", 5, 9]]], ["3.1) or solve the problem itself if a leaf node of the cube tree has been reached (Sect.", [["leaf node", "ANATOMY", 38, 47], ["leaf node", "MULTI-TISSUE_STRUCTURE", 38, 47], ["cube tree", "MULTI-TISSUE_STRUCTURE", 55, 64], ["a leaf node of the cube tree", "TREATMENT", 36, 64], ["leaf node", "OBSERVATION", 38, 47]]], ["Nodes are also responsible for sending the result SAT or UNSAT back.", [["SAT", "TISSUE", 50, 53], ["the result SAT", "TEST", 39, 53]]], ["Paracooba supports joining of new nodes dynamically, and the leaf nodes are able to wait for new tasks without consuming resources or shut down automatically, which is important if Paracooba is run in the cloud (Sect.", [["nodes", "ANATOMY", 34, 39], ["leaf nodes", "ANATOMY", 61, 71], ["nodes", "MULTI-TISSUE_STRUCTURE", 34, 39], ["leaf nodes", "MULTI-TISSUE_STRUCTURE", 61, 71], ["new nodes dynamically", "PROBLEM", 30, 51], ["the leaf nodes", "PROBLEM", 57, 71], ["new", "OBSERVATION_MODIFIER", 30, 33], ["nodes", "OBSERVATION", 34, 39], ["leaf nodes", "OBSERVATION", 61, 71]]], ["Figure 1 gives an overview of the solving process.Static OrganizationTo combine fast local solving with automatic distribution to networked compute nodes, Paracooba sees tasks as paths in the cube tree.", [["cube tree", "MULTI-TISSUE_STRUCTURE", 192, 201], ["networked compute nodes", "PROBLEM", 130, 153], ["compute nodes", "OBSERVATION", 140, 153]]], ["Only unassigned tasks are distributed further.", [["tasks", "OBSERVATION", 16, 21], ["distributed", "OBSERVATION_MODIFIER", 26, 37]]], ["A compute node is mapped to one Paracooba process which contains a fixed-size thread pool of local workers.", [["node", "ANATOMY", 10, 14], ["node", "MULTI-TISSUE_STRUCTURE", 10, 14], ["A compute node", "PROBLEM", 0, 14], ["node", "OBSERVATION", 10, 14], ["fixed", "OBSERVATION_MODIFIER", 67, 72], ["size", "OBSERVATION_MODIFIER", 73, 77], ["thread", "OBSERVATION_MODIFIER", 78, 84], ["local workers", "OBSERVATION", 93, 106]]], ["Beside maintaining information on available nodes, every compute node has a unique 64-bit ID.Static OrganizationConnections between compute nodes are established at any time either by an integrated auto-discovery protocol or by providing a known peer at startup.", [["node", "ANATOMY", 65, 69], ["nodes", "MULTI-TISSUE_STRUCTURE", 44, 49], ["node", "MULTI-TISSUE_STRUCTURE", 65, 69], ["nodes", "MULTI-TISSUE_STRUCTURE", 140, 145], ["an integrated auto-discovery protocol", "TREATMENT", 184, 221], ["nodes", "OBSERVATION", 44, 49], ["node", "ANATOMY", 65, 69], ["nodes", "OBSERVATION", 140, 145]]], ["Once connected, each compute node receives the full formula sent by the master.", [["node", "ANATOMY", 29, 33], ["node", "OBSERVATION", 29, 33]]], ["Each compute node has a solving context for every master with the problem and the cubes to solve, a queue for unassigned tasks, and one for assigned tasks.", [["node", "ANATOMY", 13, 17], ["node", "MULTI-TISSUE_STRUCTURE", 13, 17], ["node", "OBSERVATION", 13, 17]]], ["Only paths in cube trees are exchanged during solving and similar assigned tasks are solved by the same solver.", [["paths", "OBSERVATION_MODIFIER", 5, 10], ["cube trees", "OBSERVATION", 14, 24]]], ["By using low-level socket functionality (UDP/TCP), Paracooba can be run without setting up a specialized environment (as needed for MPI [12] ).Static OrganizationNew (unassigned) tasks received by a compute node are inserted into the queue.", [["node", "ANATOMY", 207, 211], ["UDP", "CHEMICAL", 41, 44], ["node", "MULTI-TISSUE_STRUCTURE", 207, 211], ["low-level socket functionality (UDP/TCP", "TREATMENT", 9, 48], ["a compute node", "TREATMENT", 197, 211], ["New", "OBSERVATION_MODIFIER", 162, 165], ["node", "OBSERVATION", 207, 211]]], ["When a compute node becomes idle, tasks with paths to leafs are instantiated into assigned tasks to be solved locally, whereas shorter paths are split (by going deeper in the cube tree) into unassigned tasks that are distributed further.", [["node", "ANATOMY", 15, 19], ["node", "MULTI-TISSUE_STRUCTURE", 15, 19], ["node", "OBSERVATION", 15, 19]]], ["The overall strategy is to solve tasks with longer paths locally (as we are closer to leafs), while other tasks are distributed to further known compute nodes.Static OrganizationThe SAT solver CaDiCaL [5] solves the assigned tasks incrementally [11] .", [["further known compute nodes", "PROBLEM", 131, 158], ["nodes", "OBSERVATION", 153, 158]]], ["It makes use of efficient preprocessing, including variable elimination and relying on efficiently restoring preprocessing steps if necessary [11] .", [["efficient preprocessing", "TREATMENT", 16, 39]]], ["This also provides a motivation for solving long paths locally: the cubes after a long shared path will be similar, making it possible to reuse more information compared to solving diverse cubes, where most of the preprocessing will have to be undone.", [["solving long paths locally", "TREATMENT", 36, 62], ["the cubes", "TREATMENT", 64, 73]]], ["If hard sub-problems are clustered on a single compute node, some can be offloaded.SolvingWe use the look-ahead solver March [18] to generate cubes.", [["node", "ANATOMY", 55, 59], ["node", "MULTI-TISSUE_STRUCTURE", 55, 59], ["hard sub-problems", "PROBLEM", 3, 20], ["a single compute node", "TREATMENT", 38, 59], ["hard sub", "OBSERVATION_MODIFIER", 3, 11], ["node", "OBSERVATION", 55, 59]]], ["Paracooba takes the output file containing the formula and the cubes as argument.", [["the formula", "TREATMENT", 43, 54], ["output", "OBSERVATION_MODIFIER", 20, 26]]], ["This Paracooba instance is the master node.", [["node", "ANATOMY", 38, 42], ["master node", "MULTI-TISSUE_STRUCTURE", 31, 42], ["master node", "OBSERVATION", 31, 42]]], ["All compute nodes parse both formula and cubes (reusing CaDiCaL's parser).", [["CaDiCaL's parser", "TREATMENT", 56, 72], ["nodes", "OBSERVATION", 12, 17]]], ["After parsing, the initial task consisting of the empty path is created on the master compute node which will then branch on the first variable of the cube tree and create new unassigned tasks.", [["node", "OBSERVATION", 94, 98], ["new", "OBSERVATION_MODIFIER", 172, 175]]], ["These are either solved directly on the master or distributed to other compute nodes.SolvingPaths in the cube tree are often transmitted across the network and should, therefore, have a compact representation.", [["cube tree", "MULTI-TISSUE_STRUCTURE", 105, 114], ["solved", "OBSERVATION", 17, 23], ["nodes", "OBSERVATION", 79, 84]]], ["We represent them as 64-bit unsigned integers, where the first 58 bits describe the path in the binary tree and the last 6 bits specify the length of the path.", [["binary", "ANATOMY", 96, 102], ["tree", "ANATOMY_MODIFIER", 103, 107]]], ["This representation entails a maximum tree height of 58, which limits the number of different tasks to 2 58 .", [["a maximum tree height", "TEST", 28, 49], ["maximum", "OBSERVATION_MODIFIER", 30, 37], ["tree", "OBSERVATION_MODIFIER", 38, 42], ["height", "OBSERVATION_MODIFIER", 43, 49]]], ["This constraint is not an issue, since it is 11 orders of magnitude larger than the one million cubes used for Heule's proof for Pythagorean Triples [21] that already created a 200TB proof.", [["Pythagorean Triples", "TREATMENT", 129, 148], ["not an", "UNCERTAINTY", 19, 25], ["issue", "OBSERVATION", 26, 31]]], ["Communication between compute nodes is done using a custom protocol, which defines messages sent over UDP and TCP.", [["UDP", "CHEMICAL", 102, 105], ["TCP", "CHEMICAL", 110, 113], ["UDP", "CHEMICAL", 102, 105], ["TCP", "CHEMICAL", 110, 113], ["UDP", "SIMPLE_CHEMICAL", 102, 105], ["a custom protocol", "TREATMENT", 50, 67], ["nodes", "OBSERVATION", 30, 35]]], ["Once a new compute node becomes known, all other nodes establish a TCP connection to it, which is used for all remaining transfers in order to circumvent UDP reliability issues in larger environments.SolvingA sample interaction between a master and two daemon compute nodes is given in Fig. 2 .", [["node", "ANATOMY", 19, 23], ["UDP", "CHEMICAL", 154, 157], ["UDP", "CHEMICAL", 154, 157], ["node", "MULTI-TISSUE_STRUCTURE", 19, 23], ["UDP", "SIMPLE_CHEMICAL", 154, 157], ["a new compute node", "PROBLEM", 5, 23], ["all other nodes", "PROBLEM", 39, 54], ["two daemon compute nodes", "TREATMENT", 249, 273], ["node", "OBSERVATION", 19, 23], ["nodes", "OBSERVATION", 49, 54], ["nodes", "OBSERVATION", 268, 273]]], ["Work is rebalanced from daemon 1 to daemon 2.", [["daemon 2", "CHEMICAL", 36, 44], ["daemon 2", "GENE_OR_GENE_PRODUCT", 36, 44]]], ["Once the problem is solved, the status is bubbled up to master and each node is responsible for collecting the results of offloaded jobs.", [["node", "ANATOMY", 72, 76], ["node", "MULTI-TISSUE_STRUCTURE", 72, 76], ["node", "OBSERVATION", 72, 76]]], ["Finally, master can conclude (UN)SAT.SolvingEvery daemon and every master sends a status message at every \"tick\", i.e., in configurable intervals with default 100 ms, to all compute nodes it knows.Fig.", [["nodes", "OBSERVATION", 182, 187]]], ["Interaction between master and two daemons, without status messagesWhen distributing tasks to other compute nodes, the ID of the original master, of the distribution target, and of the sender are always referenced, making all Paracooba instances aware of senders and receivers of each task.", [["other compute nodes", "PROBLEM", 94, 113], ["nodes", "OBSERVATION", 108, 113]]], ["For the same reason, status messages of daemon compute nodes also contain a list of all current contexts to announce the formulas for which they can solve tasks.System ManagementBy automatically discovering compute nodes in the same network, Paracooba can manage its overall resources automatically.", [["daemon compute nodes", "PROBLEM", 40, 60], ["compute nodes", "PROBLEM", 207, 220], ["nodes", "OBSERVATION", 55, 60], ["nodes", "OBSERVATION", 215, 220]]], ["Every daemon that is newly discovered by a master gets the formula and the cubes and, once ready, can receive tasks from all other connected compute nodes.", [["compute nodes", "MULTI-TISSUE_STRUCTURE", 141, 154], ["nodes", "OBSERVATION", 149, 154]]], ["Whenever a master node goes offline, it sends an offline announcement, which removes its solving context from all connected daemons, including all results and solver instances.System ManagementCompute nodes maintain a moving average of time between status messages for all other connected nodes.", [["node", "ANATOMY", 18, 22], ["nodes", "ANATOMY", 289, 294], ["node", "MULTI-TISSUE_STRUCTURE", 18, 22], ["nodes", "MULTI-TISSUE_STRUCTURE", 289, 294], ["all other connected nodes", "PROBLEM", 269, 294], ["node", "OBSERVATION", 18, 22], ["nodes", "OBSERVATION", 201, 206], ["nodes", "OBSERVATION", 289, 294]]], ["If a remote compute node does not send a status update early enough, it gets removed from the list of known nodes and all tasks sent to that node get re-added to the local unassigned-task queue (and can, for example, be offloaded again).System ManagementTo save compute resources, an auto-shutdown timer can be enabled to measure the time a compute node has been idle without active tasks to shut down the compute node, if no new tasks are added before the timer runs out.", [["node", "ANATOMY", 20, 24], ["node", "ANATOMY", 141, 145], ["node", "ANATOMY", 414, 418], ["nodes", "MULTI-TISSUE_STRUCTURE", 108, 113], ["node", "MULTI-TISSUE_STRUCTURE", 141, 145], ["node", "MULTI-TISSUE_STRUCTURE", 349, 353], ["node", "MULTI-TISSUE_STRUCTURE", 414, 418], ["known nodes", "PROBLEM", 102, 113], ["all tasks", "TEST", 118, 127], ["System Management", "TREATMENT", 237, 254], ["a compute node", "PROBLEM", 339, 353], ["node", "OBSERVATION", 20, 24], ["nodes", "OBSERVATION", 108, 113], ["node", "ANATOMY", 141, 145], ["node", "OBSERVATION", 349, 353], ["node", "OBSERVATION", 414, 418]]], ["Because tasks get distributed to inactive nodes quickly, the timeout can be set to low values (e.g., 3 s) to reduce cost, making Paracooba suited for cloud scenarios.ExperimentsAs motivated in the introduction, we tested our tool Paracooba on a 32-bit cruxmiter problem [25] , for which March takes less than 10 s to split the initial problem into 52 520 cubes.", [["nodes", "MULTI-TISSUE_STRUCTURE", 42, 47], ["inactive nodes", "PROBLEM", 33, 47], ["cloud scenarios", "PROBLEM", 150, 165], ["a 32-bit cruxmiter problem", "TREATMENT", 243, 269], ["inactive", "OBSERVATION_MODIFIER", 33, 41], ["nodes", "OBSERVATION", 42, 47]]], ["We then run Paracooba on our compute cluster of 32 nodes connected through cheap commodity 1 Gbit ethernet cards.", [["nodes", "ANATOMY", 51, 56], ["nodes", "OBSERVATION", 51, 56]]], ["Each node contains two 8-core Intel Xeon E5-2620 v4 CPUs running at 2.10 GHz (turbo-mode disabled) and 128 GB main memory.", [["node", "ANATOMY", 5, 9], ["node", "MULTI-TISSUE_STRUCTURE", 5, 9], ["Intel Xeon E5-2620 v4 CPUs", "DNA", 30, 56], ["turbo", "TEST", 78, 83], ["node", "OBSERVATION", 5, 9]]], ["Thus every node has 16 cores.", [["node", "ANATOMY", 11, 15], ["node", "MULTI-TISSUE_STRUCTURE", 11, 15], ["node", "OBSERVATION", 11, 15], ["16 cores", "OBSERVATION_MODIFIER", 20, 28]]], ["Table 1 shows the performance with respect to the number of threads.The run-time distribution for solving cubes is heavily skewed.", [["solving cubes", "TREATMENT", 98, 111]]], ["After 2 min, 5 instances of CaDiCaL are still running and it takes another minute to solve those.", [["CaDiCaL", "CHEMICAL", 28, 35], ["CaDiCaL", "CHEMICAL", 28, 35], ["CaDiCaL", "SIMPLE_CHEMICAL", 28, 35], ["CaDiCaL", "TREATMENT", 28, 35]]], ["Paracooba outperforms static scheduling done by splitting the cubes upfront over 512 threads and solving each resulting iCNF for each group of cubes incrementally by CaDiCaL (4 min 17 s wall-clock time).", [["iCNF", "PROTEIN", 120, 124], ["the cubes upfront", "TREATMENT", 58, 75], ["each group of cubes", "TREATMENT", 129, 148]]], ["We experimented with resplitting cubes, but could not improve solving time.ConclusionParacooba is the first distributed cube-and-conquer solver.", [["resplitting cubes", "TREATMENT", 21, 38]]], ["It relies on the state-of-the-art look-ahead solver March to split the problem and then efficiently distributes the cubes over as many nodes as available.", [["nodes", "OBSERVATION", 135, 140]]], ["Our experiments reveal that the speedup is larger than the number of cores until saturation is reached.ConclusionAs future work, it would be interesting to support proof generation in the nodes and store them in the master node.", [["nodes", "ANATOMY", 188, 193], ["node", "ANATOMY", 223, 227], ["nodes", "MULTI-TISSUE_STRUCTURE", 188, 193], ["master node", "MULTI-TISSUE_STRUCTURE", 216, 227], ["Our experiments", "TEST", 0, 15], ["proof generation in the nodes", "PROBLEM", 164, 193], ["larger", "OBSERVATION_MODIFIER", 43, 49], ["nodes", "OBSERVATION", 188, 193], ["node", "OBSERVATION", 223, 227]]]]}